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“During the Middle Ages there were all kinds of crazy ideas, such as that a piece of rhinoceros 
horn would increase potency. Then a method was discovered for separating the ideas--which 
was to try one to see if it worked, and if it didn't work, to eliminate it. 
This method became organized, of course, into science.” 
 
Richard Feynman – Cargo Cult Science (Caltech Commencement) 
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Synthesis of N-Heterocyclic Carbene Gold(I) Complexes: 
Towards the Development of new Organometallic Drugs 
 
Biomedical applications of gold complexes based on N-heterocyclic carbenes (NHCs) are 
beginning to unfold. Some cationic gold(I) NHCs complexes show antimitochondrial activities, a 
very promising action mode in the fight against cancer; due to their positive charge these 
complexes target preferentially tumor cells, leading to cell death. 
In this work of thesis, three groups of new NHC-based gold and heterobimetallic complexes 
involving aliphatic or aromatic amino-functionalized NHCs with interesting potential in 
biomedical research have been synthesized and characterized.  
The first group is formed by three luminescent heterobimetallic gold(I)-ruthenium(II) 
complexes containing heteroditopic bipyridine-NHC ligands. These compounds have been 
biologically investigated by in vitro tests for their antitumoral, antileishmanial and antimalarial 
activities. Finally, imaging studies in cancer cells have been performed exploiting the 
luminescent properties of the most active compound. 
The second group of molecules is concerned by cationic gold(I) complexes containing two 1-
[2-(diethylamino)ethyl]imidazolydene ligands. First the complexes have been tested for their 
antiproliferative activity in prostate cancer cell line PC-3. Lipophilicity (Log P) has been 
determined for these complexes. The most active complex has been tested for the cytotoxic 
activities in five human cancer cell lines and primary endothelial cells demonstrating a potent 
action and selectivity for cancer cells. In addition, antileishmanial and antimalarial activities of 
these compounds have been investigated showing interesting results. 
The third group is formed by a hetero-dinuclear gold(I)-silver(I) and a trinuclear gold(I)-
copper(II) complexes containing phenanthroline-NHC ligands. The compounds are formed by 
two different organometallic units potentially able to act as multi-targeting anticancer drug. 
 
[Résumé] Luca Boselli, thèse PhD 
 
 
 
Synthèse de complexes carbènes N-hétérocycliques d’or(I): 
vers le développement de nouveaux médicaments 
organométalliques 
 
Les applications biomédicales des complexes d'or à base de carbènes N-hétérocycliques 
(NHC) commencent à se développer. Certains complexes NHCs d'or(I) cationiques montrent 
une activité antimitochondriale, un mode d'action très prometteur dans la lutte contre le 
cancer; grâce à leur charge positive ces complexes ciblent préférentiellement les cellules 
tumorales, conduisant à la mort cellulaire.  
Dans ces travaux de thèse, trois familles de nouveaux complexes d’or à ligands NHCs et 
montrant un potentiel intéressant dans le domaine de la recherche biomédicale ont été 
synthétisés et caractérisés. 
Le premier groupe est formé par trois composés hétérobimétalliques luminescents or(I)-
ruthenium(II) contenant des ligands hétéroditopiques de type bipyridine-NHC. Ces composés 
ont été étudiés biologiquement par des tests in vitro pour leurs activités antitumorale, 
antileishmaniale et antipaludique. Enfin, des études d'imagerie par microscopie confocale 
dans les cellules cancéreuses ont été réalisées en exploitant les propriétés de luminescence  de 
ces composés. 
Le deuxième groupe est constitué par des complexes d'or(I) contenant deux ligands 1-[2 
(diéthylamino)éthyle]imidazolydène. Tout d'abord, ces complexes ont été testés pour leur 
activité antiproliférative sur une lignée cellulaire du cancer de la prostate PC-3. La lipophilie 
(Log P) des composés a été déterminée. Le complexe le plus actif a été testé pour son activité 
cytotoxique sur cinq lignées de cellules tumorales humaines et des cellules endothéliales 
primaires. Le complexe le plus actif démontré une sélectivité pour les cellules cancéreuses. En 
outre, les activités anti-leishmaniose et antipaludique des composés ont été étudiées montrant 
des résultats intéressants.  
Le troisième groupe concerne un composé hétéro-dinucléaire d’or(I)-argent(I) et un 
complexe hétéro-trinucléaire or(I)-cuivre(II) contenant des ligands phénantroline-NHC. Ces 
composés sont formés par deux unités organométalliques différentes, pour une application 
potentielle en anticancer.  
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 Introduction: NHCs 1.
 N-Heterocyclic carbenes  1.1 
Although known for many decades, it is only in the last ten years that N-heterocyclic carbenes 
(NHCs) have come to occupy a central position in the armory of organometallic chemists.
1
 For a 
long time, carbenes, were considered to be very reactive and short lived molecules that could not 
be isolated.
2
 Thus, the first unequivocal isolation of an NHC and its crystal structure analysis by 
Arduengo et al. in 1991 caused a lot of excitement.
3
 Chemists have been fascinated by the 
surprising versatility of NHCs that play an important role in all fields of chemistry today, 
especially in organometallic you can explore the enormous possibility of obtaining different 
metal complexes. The unusual stability of NHC is in part a result of shielding by sterically 
demanding substituents on the ring. However, much more important is the electronic 
stabilization by mesomeric interaction of the lone pairs of electrons on the nitrogen atoms with 
the empty p orbital of the sp
2
 hybridized carbenic carbon atom. This latter feature, the 
importance of resonance structures (Figure 1-1), also nicely explains why NHCs are electron-
rich nucleophilic species, whereas other carbenes, like Fisher carbenes, are generally found to be 
electrophilic being strong π-acceptors.2,4 The sp2-hybrid orbital is normally described as  orbital 
and NHC in fact behave like typical -donor ligands that can substitute classical 2e- donor 
ligands such as amines, ethers, and phosphines in metal coordination chemistry. 
 
Figure 1-1.  General representation of an NHC with relative resonance structures. 
NHCs form the largest and most important group of stable aminocarbenes. Here, the divalent 
carbon atom is part of a ring and is flanked by at least one nitrogen atom. The readily accessible 
imidazole-2-ylidenes and dihydro-imidazole-2-ylidenes are particularly studied at the moment, 
NHCs with six- and seven-membered rings are also known, but are still in their infancy.
5
 The 
carbenic carbon atom of NHC is stabilized by the pπ–pπ electron donation of the two adjacent 
nitrogen atoms accounting for a stabilization energy of approximately 70 kcal/mol. For 
unsaturated systems aromaticity can contribute an additional 25 kcal/mol of stabilization.
6,7
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Although NHCs are stable, they are still carbenes and highly reactive, and since a strong base 
was needed in their making, they themselves are easily protonated.
8,9
 
 N-Heterocyclic carbene ligands 1.2 
We will focus our attention exclusively on functionalized imidazole-2-ylidenes that are the 
most widely used NHC ligands. NHCs are usually prepared by the deprotonation of imidazolium 
salts, therefore first of all it is necessary to synthesize the appropriate substituted pro-ligands. An 
NHC precursor can be prepared using several methods, but there are two most common routes to 
generate it: (1) the direct quaternization of  the nitrogen atoms of the imidazole ring by reaction 
with primary alkyl- (or aryl-) halides in presence of a strong base or (2) assembling an imidazole 
ring with the substituents already in place by reactions of primary amines, glyoxal and 
formaldehyde in the presence of an acid (Scheme 1-1). 
 
Scheme 1-1. Different ways to synthesis an imidazolium salt. 
With (1) it is possible to introduce two different substituents by reacting an alkyl-imidazole 
with a different primary alkyl- (or aryl-) halide giving an unsymmetrically substituted NHC 
(Scheme 1-1b). The disadvantage is that this method is mainly limited to primary alkyl halides 
because secondary and tertiary alkyl halides are subject to unwanted elimination reactions. 
The second method (2) is particularly useful for the synthesis of imidazolium salts bearing 
aromatic, very bulky or functionalized N,N’-substituents (c, Scheme 1-1). For the synthesis of 
unsymmetrically N,N’-disubstituted imidazolium salts, method (2) has to be modified. This is 
achieved by using 1 equiv. of ammonium chloride and 1 equiv. of the primary amine resulting in 
the formation of N-substituted imidazole (d, Scheme 1-1). Subsequent reaction with a primary 
alkyl halide, as showed in method (1), yields the desired unsymmetrically N,N’-disubstituted 
imidazolium salt. Obviously this method is limited in its substitution pattern regarding the 
 | Introduction: NHCs 3 
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second substitution by the same disadvantage as method (1), namely that just primary alkyl 
halides can be used.10 
 N-Heterocyclic carbene complexes 1.3 
Today, transition metal complexes of NHCs are mainly formed using four methods (see 
Scheme 1-2):  
(a) reaction of a transition metal complex with a free carbene (preformed or generated in situ);  
(b) reaction of an imidazolium salt with a transition metal complex possessing a basic anion or 
entity; 
(c) by using a carbene transfer agent (transmetalation);  
(d) by reacting an imidazolium salt with a transition metal salt in the presence of a weak base.  
 
Scheme 1-2.  Four general methods to synthesize NHC-M complexes. 
The synthesis a) (Scheme 1-2) of an M(NHC) complex by employing the free NHC by 
deprotonation of the corresponding imidazolium salt with a strong base, is a reliable method that 
allow the largest choice of transition metal complexes as starting material. However, the 
isolation of the desired NHC is not always trivial and the use of strong bases could be 
incompatible with the carbene’s functional groups or with the desired target complex.  
In the synthesis b) (Scheme 1-2), the base is “replaced” by the anion of the transition metal 
compound. This method works best if a coordinating anion, such as chloride or bromide, is 
supplied with the imidazolium salt. This is a mild method to prepare metal complexes, but it is 
not the best way if the pro-ligand does not contain a coordinating anion, because this anion 
should be provided by additional inorganic salts that could lead to unwanted anion exchange.  
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Method c) (Scheme 1-2) is another convenient synthetic strategy to access to NHC transition 
metal complexes consists in the use of the corresponding Ag(I)-NHC complexes as NHC transfer 
reagents, which avoids the cumbersome synthesis of free carbenes. Generally, these silver 
complexes are readily synthesized, by reaction of the corresponding imidazolium salts with 
silver(I) oxide, without the need to work under inert atmosphere.
11–13
 
The method d) (Scheme 1-2) consists in the reaction of an imidazolium salt with a transition 
metal salt in presence of a weak base. An equilibrium between the imidazolium salt and its 
deprotonated form, the carbene, is established because of the reaction with the mild base. The 
equilibrium is shifted towards the carbene by strong coordination of the NHC ligand to the 
transition metal. 
 Applications of M-NHC complexes 1.4 
Complexes with N-heterocyclic carbene ligands are principally investigated for their catalytic 
properties. The second and third generation of Grubbs catalysts (for instance 1 and 2 in Figure 1-
2)  are the corner stones of today’s extensive use of olefin metathesis in organic and polymer 
chemistry.
14,15
 The initiation rate of the Grubbs' catalyst 1 can be altered by replacing the 
phosphine ligand with more labile ones like pyridine: in the example reported in Figure 1-2, the 
initiation rate is increased more than a million fold from the second to the third generation 
catalyst.
15
  
 
Figure 1-2.  Example of second and third generation of Grubbs catalyst (on the left); Examples 
of liquid crystals reported by Liu et al. (on the right). 
Beyond catalysis, NHCs are going to gain relevance in materials science. For example, Liu et 
al. reported the first thermally stable liquid crystals based on long chain NHC-palladium 
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complexes such as 3 (Figure 1-2). The new liquid crystalline phases are thermally stable up to 
the isotropic temperatures without decomposition.
16
 Promising results have been also obtained in 
studies dealing with photophysical and photochemical properties.
17
 The presence of a high field 
strength ligand such as an NHC in the complexes gives rise to high energy emissions, and 
consequently, to the desired blue color needed for organic light emitting diode (OLED) 
applications.
17
  For example, NHC-Iridium complex 4 (Figure 1-3), reported by Wu and co-
workers, presents a high quantum yield  (0.73) and was used as a dopant for the fabrication of a 
blue phosphorescent OLED, showing unprecedented light coordinates (0.16, 0.13).
18
  
                
Figure 1-3.  NHC-Ir(III) compound (4) as highly phosphorescent blue OLED reported by Wu et 
al.; on the right is reported an image of blue OLED as example. 
Furthermore, the great versatility of NHC ligands for structural modifications, together with 
the use of other ancillary ligands in the complex, provides numerous possibilities for the 
synthesis of phosphorescent materials, with emission colors over the entire visible spectra and 
potential future applications in fields such as photochemical water-splitting, chemosensors and 
dye-sensitized solar cell.
17
 
An increasing number of studies are opening fascinating frontiers for NHC complexes with 
possible application even in the biomedical field that will be focused in this thesis. 
 M-NHC complexes in medicine 1.5 
Over the last few years NHCs have entered the field as “new” ligands for bioactive 
coordination compounds. Although most of these results are preliminary, metal NHC species 
have certainly shown to be good candidates as potential drugs for treating a wide of biological 
afflictions. Probably the first reports on biological activity of metal NHC complexes were 
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published between 1996 and 1999 by Cetinkaya et al., who described the antibacterial properties 
of ruthenium(II) and rhodium(I) NHC complexes.
19,20
 Afterwards the number of literature 
reports on metal NHC slowly rose until the end of 2005, after started to increase drastically and 
nowadays research on the biological potential of metal NHC complexes is one of the most active 
areas within the emerging field of bio-organometallic chemistry.
21
 A good candidate as 
organometallic drug should have some prerequisites: 
 molecule accessible in few steps synthesis 
 easy modulation of the physicochemical properties (lipophilicity, basicity, etc.) 
 simple derivatization of the ligand 
 high stability in biological environment 
 remarkable biological activities. 
Some metal NHC-complexes fit very well with all these properties making them perfect 
candidates for drug development. The growing interest in these metallotherapeutic drugs is 
mostly focused on antimicrobial and anticancer activities, but recently also some results 
concerning antimalaria activities have been published. The most important results reported in the 
literature for bioactive NHC compounds are mainly related to Au, Ag, Pt, Pd, and Cu 
complexes.
21,22
 
 Silver complexes: in general, silver complexes were used as antimicrobial agents 
for many years and they currently found applications as antiseptics.
23
 Young’s group is 
one of the first to introduce the possible use of Ag(I)-NHCs in medicine demonstrating 
their exceptional antimicrobial efficacy, complex 5 (Figure 1-4) for example, is strongly 
active against a broad spectrum of both gram-positive and gram-negative bacteria 
including B. dolosa strains AU4459, Bcc organisms for which there is no effective 
therapy, with MIC (Minimum Inhibitory Concentration) values between 1-10 μg/mL.7,24 
The potential use of this complex as a useful nebulized therapy for cystic fibrosis 
oriented lung infections is under exploration.
7
 
 
Figure 1-4.  NHC-Ag(I) silver complexes as antimicrobial (5) and anticancer (6a-c) 
agents reported by Young et al.. 
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Silver in the elemental form is inactive, but in oxidation states 1+, it acquires its 
biomedical properties though the mechanism of action is not yet completely understood. 
It seems that silver(I) is able to bind to bacteria cell surfaces, and interact with enzymes 
and proteins important for cell wall synthesis.
7
 Furthermore, a more recent study from the 
same group, showed Ag(I)-NHCs complexes derived from 4,5-dichloro-1H-imidazole 
stable to light and water, exhibiting antitumor activity against ovarian (OVCAR-3) and 
breast (MB157) cancer cells in vitro.
25
 However, they had not significant effects on 
cervical (HeLa) cancer cells. In paricular, 6c showed best activity with IC50 = 20 µM 
against OVCAR-3 cancer cells and  IC50 = 20 µM against MB157 cancer cells.
25
  
 Platinum complexes: platinum-based organometallic complexes play the leading 
role as anticancer agents. The discovery of the antitumor properties of cisplatin was 
followed by one of the most impressive drug success stories ever and by a significant 
improvement of cancer chemotherapy.
23,26
 Beside cisplatin (7 in Figure 1-5), several 
other platinum complexes have been approved for current tumor therapy.
27,28
 Not 
unexpectedly, also platinum NHC complexes were investigated and showed a very 
interesting biological profile especially involving Pt(II).
29,30
 Platination of DNA is widely 
believed to account for the anticancer effect of cisplatin as well as various platinum(II) 
complexes.
29,30
 
 
Figure 1-5.  Structure of Cisplatin and NHC-Pt(II) complex reported by Che et al.. 
Che et al. reported, for example, a series of cyclometalated platinum(II) complexes 
containing NHC ligands; 8 (Figure 1-5) was the most potent anticancer agent (1.4 µM > 
IC50 > 0.6 µM) with cytotoxic activity towards human cancer cell lines of cervical 
epithelioid carcinoma (HeLa), hepatocellular carcinoma (HepG2), and nasopharyngeal 
carcinoma (SUNE1), and showing tumor-selectivity with respect to a normal derived 
human lung fibroblast cell line (CCD-19Lu, IC50 = 11.6 µM) under in vitro conditions. 
The found efficacy was higher than that of the clinically-used cisplatin. Furthermore, in 
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vivo tests show significant inhibition of tumor growth in the nude mice model.
30
 
However, Che and co-workers found that complex 8 preferentially accumulates in the 
cytoplasmic structure of the cells instead of covalently binding to nuclear DNA.
30   
 Palladium complexes: considering the structural and thermodynamic analogy 
between Pt(II) and Pd(II) complexes, there is also much interest in the study of less 
expensive Pd(II) derivatives as potential anticancer drugs.
24,31,32
 Similar to platinum 
agents, DNA is also their major target in the cell. The Pd(II) ions are capable of 
interacting with DNA, thus enabling cross bindings and inhibiting its synthesis as well as 
inducing apoptosis.
22,32
 The most important example is probably the one reported by 
Panda and Gosh concerning two biologically active Pd(II)–NHC complexes: one bis-
NHC complex 9a (Figure 1-6) and one mixed complex 9b (Figure 1-6), with NHC and 
pyridine ligands.
22,33
  
 
Figure 1-6.  Structures of NHC-Pd complexes reported by Panda and co-workers. 
Specifically, 9a showed more cytotoxicity (from 2- to 20-fold) than cisplatin against 
cervical cancer (HeLa, IC50 = 4 µM), breast cancer (MCF-7, IC50 = 1 µM), and colon 
carcinoma (HCT116, IC50 = 0.8 µM) cell lines. Further studies showed that 9a inhibited 
tumor cell proliferation by arresting the cell cycle progression at the G2 phase, preventing 
the mitotic entry of the cell as known for the cisplatin mode of action.
21,33
 
 Copper complexes: copper has multifaceted role in human biology, it is important 
for the function of several enzymes and proteins and is involved in a lot of physiological 
and  pathological processes.
34,35
 However, copper can also be toxic due to its redox 
activity and affinity for binding sites that should be occupied by other metals. The copper 
concentration in the human body is tightly regulated at the levels of cells, organs, and 
body, since copper free ions are potentially harmful.
34,35
 Copper deficiency in humans 
can lead to contract the Menkes disease and an excess can lead to contract the 
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Alzheimer’s disease.34,35 Moreover, the copper concentration seems to be connected also 
to the cancer progression. By the way, exploiting the coordination capacity of NHC 
ligands to stabilize Cu(I), recently, a great variety of copper complexes has been screened 
for cytotoxicity and some complexes showed good antitumor activity in vitro and in 
vivo.
21,22,36,37
 Cu(I)–NHC complex 10a (Figure 1-7) showed high cytotoxicity against 
human cancer cells and was developed by the groups of Gautier and Morel.
38
 An increase 
of cytotoxicity up to 150-fold compared with cisplatin in the HL60 (Human 
promyelocytic leukemia cell line, IC50 = 0.04 µM) was observed. 
 
Figure 1-7.  Structures of NHC-Cu complexes reported by Gautier and co-workers.  
The same group reported also another series of NHC copper compounds with higher 
cytotoxicities than cisplatin in MCF-7 cells.
39
 One of these complexes is 10b (IC50 = 0.25 
µM), a fluorescent compound that could permit elucidation of the intracellular position. 
Copper compounds could act by different mode of action, but common mechanism 
suggested concern DNA cleavage, induction of ROS (reactive oxygen species) formation 
leading to cell homeostasis misregulation and apoptosis. 
21,22,36,37
  
 Gold complexes: Gold has been exploited for its healing properties for several 
thousand years and gold complexes have been evaluated for a large range of 
pharmaceutical applications (antitumor, antimicrobial, anti-arthritis, etc…).40 While the 
possible application of metal NHC complexes as anti-infectives is mainly dominated by 
silver derivatives, for the use as anticancer agents NHC-gold complexes play the most 
important role.
21,22,41
  
The anticancer activities of NHC-gold complexes will be discussed in detail in 
Chapter 2. 
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 NHC-gold complexes 1.6 
Gold has long time played a marginal role in coordination chemistry involving NHC ligands, 
but in the last years, gold−NHC complexes started to have a substantial increasing interest. As a 
matter of fact, a growing number of new applications have appeared for Au–NHC complexes, 
which constitutes a formidable challenge in utility-oriented research. Marion et al. reported in 
2007 the first catalyzed isomerization of allylic acetates using the NHC-gold complex 11 (now 
commercially available), that represented also the first gold catalyzed allylic rearrangement. 
Subsequently a range of transformations, mediated by mononuclear gold–NHC catalysts (Figure 
1-8) have been reported.
42–46
 
 
 
Figure 1-8.  Scheme of possible reactions catalyzed by NHC-gold complexes (right) and 
structure of commercial available NHC-Au(I)  catalyst (complex 11 on the left). 
Another development in gold chemistry has been stimulated by the photophysical properties 
of mononuclear, polynuclear gold or gold-heterometallic complexes. Gimeno and co-workers for 
example, recently reported a series of strongly luminescent three-coordinate NHC-gold(I) 
compounds (Figure 1-9).
17
 These cationic derivatives display a modulation of the luminescence 
depending on the substituent and the electronic properties of the ligands. The lifetime 
measurements, the high quantum yields (from 59 to 99%), especially in the solid state, and the 
ease of their preparation make them good candidates for future application as OLEDs.
47
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Figure 1-9. Complexes 12a-12d under UV light at 354 nm and related structure.17 
Polynuclear NHCs complexes could be obtained involving multi-NHC ligands or involving 
the donor properties of functional groups (Figure 1-10). Exploiting the simple derivatization of 
the carbenes, a huge variety of hybrid systems are possible. Numerous heterobidentate NHCs 
have been synthesized and coordinated through both donor functions, which include not only 
neutral groups, such as heterocycles, phosphines, amines, amides, or imines but also anionic 
donors, the latter being increasingly studied because of their stronger interaction with the metal 
center depending on the nature of the metal and the nature of the ligand.
48
 This kind of 
complexes can have some additional properties in respect to the mono-NHC compounds. 
Polynuclear gold(I) complexes for example can exhibit an intriguing phenomenum called  
“aurophilic” interaction, related to the study of the attractive interactions between closed-shell 
(d
10
) gold(I) centers, that in some case can give rise to unexpected luminescent properties of the 
compounds.
13,49–52
 Briefly, the aurophilic binding presents the following characteristics: (a) at 
two-coordinate gold(I) centers, the interactions appear to occur perpendicularly to the molecular 
axis independent of the radial direction; (b) in absence of steric hindrance, the metal-metal 
distances are clearly shorter than the sum of two van der Waals radii (3.7 Å), in favorable cases 
as short as 2.7 Å, but generally around 3 Å; (c) several gold atoms can gather at a given gold 
center in a polynuclear species, to form triangles, squares or lozenges of gold atoms etc…; (d) 
the bond energy associated with the interaction is generally in the range of 20-50 kJ/mol, higher 
than the energy of standard van der Waals contacts; (e) when dissolved in a donor solvent, 
solvation of the monomers predominates in most cases over the intermolecular interactions of a 
species which is an oligomer in the crystal - intramolecular Au-Au contacts are generally not 
affected by solvation.
49
 These interactions, by means of relativistic effects, lead to a mixing of 
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the gold 5d and 6s orbitals, lowering the energy gap between the ground and excited states and 
enhancing the probability of electronic transitions.
53
 Armaroli and collaborators reported in 2012 
a blue-emitting dinuclear NHC gold(I) complex featuring a nearly unit quantum yield (96%) in 
the solid state (13, Figure 1-10).
51
 The NHCs involved presents a simple structure without 
specifically functionalization with any chromophore and the luminescence have been attributed 
to the relatively short Au···Au distance (3.2722(5) Å) in the range of distance for aurophilic 
interactions.  
 
Figure 1-10. Bis-NHC gold complexes reported by Armaroli et al. (complex 13) and by 
Hemmert et al. (complexes 14a and 14b). 
There are just few reports of gold complexes with short metal–metal contacts which are 
luminescent in solution. Hemmert et al. succeeded in this goal by reporting in 2009 the synthesis 
of dimeric dinuclear gold(I) complexes bearing different alcohol-functionalized NHC ligands (14 
in Figure 1-10). All complexes displayed absorption bands between 216 and 282 nm in 
acetonitrile, characteristic of π-π* LC transitions, while the corresponding emission bands were 
found in the high-energy range of 328-446 nm, with another low-energy band (except 14a) 
centered at 526 nm, which were assigned to IL and MC transitions, respectively.
52
 In addition to 
aurophilic interactions, other kind of M-M interaction as Ag-Ag, Au-Ag, Cu-Cu, Au-Cu have 
been observed.
54–60
 Catalano et al. reported some examples of luminescent NHC heterobimetallic 
complexes by exploiting the coordination of functional groups; recently a particular study on the 
Cu-Au interactions has been performed (Scheme 3-4).
58,59
 Interestingly, the complex 15, which 
displayed an intense blue-emission at 462 nm in the solid state, could react with MeOH vapors to 
afford the green-emissive species 16, which emitted at 520 nm. This process was completely 
reversible and consisted of the modulation of the Au···Cu separation depending on the solvent 
molecule coordinated to the copper centre.
58
 
13 -PF6
-
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Scheme 1-3. Vapochromic heterobimetallic complexes involving pyridyl NHC-ligands 
reported by Catalano et al. . 
Besides catalytic and photophysical properties, the great potential of NHC-gold complexes 
begin to unfold as bioactive molecules by exploiting the versatility of NHC ligands with the 
relatively simple derivatization of the imidazolium salt (pro-ligand) and the known biomedical 
properties of gold metal.
40,61–63
 The bioactivity of gold complexes in different field of medicine 
will be focused in the next chapter. 
  
 
14 ................................    Introduction: NHCs | 
 
 Synthesis of N-Heterocyclic Carbene Gold(I) Complexes: Towards the Development of new Organometallic Drugs 
  
| Introduction: gold in medicine 15 
 
 
 Introduction: gold in medicine 2.
The earliest medical use of gold seems to be mostly attributed to Chinese, in 2500 BC. But 
already from prehistory, gold was considered to have magical power of healing. In the middle 
ages the alchemists made many potions containing some gold powders to drink as medicinal 
treatment. In 17th century a gold based medicine was considered a panacea against melancholy. 
Currently, no significant curative properties of the elemental state have been established. The 
begin of gold compounds application in modern medicine is in 1890 when Robert Koch 
discovered that K[Au(CN)2] exhibited bacteriostatic activity.
61
 Originally, gold compounds were 
used as a therapy against pulmonary tuberculosis, the suggestion that the tubercle bacillus was a 
causative agent for rheumatoid arthritis led to the use of gold therapy for this disease. However, 
it was then proved that these therapies do not provide an effective treatment against tuberculosis 
but on the other hand clinical studies against rheumatoid arthritis led years later to confirm the 
efficacy of gold componds.
61
 At the moment, just one gold compound has found a current 
clinical use, Auranofin (triethylphosphine(2,3,4,6-tetra-O-
acetyl-β-D-thiopyranosato-S)gold(I) (Figure 2-1), as anti-
arthritis oral drug since 1985. Nevertheless, current 
researches show encouraging results regarding the activity of 
gold compounds also against bacteria, fungi, HIV, bronchial 
asthma, malaria, leishmaniasis and cancer.
40,61–63
 
 Gold complexes as antibacterial and antifungal 2.1 
Many gold(I) and gold(III) complexes have been evaluated for their antibacterial and 
antifungal activities.
64
 Currently gold(I) complexes have attracted much more attention 
especially involving phosphine and N-heterocyclic carbene ligands.
64
 Auranofin, for example, 
was found to be particularly active in vitro against different strains of Gram-positive 
Staphylococcus aureus, with low MIC values (ranging from 0.125 to 0.5 mg/L).
64–67
 
Antibacterial and antifungal activity of gold(I) complexes having coordinated NHC ligands 
(complexes 19a–19c, Fig. 2-2) has been reported by Özdemir et al.. It was found that the activity 
of the investigated gold(I) complexes against bacteria and fungi was strongly dependent on the 
nature of the substituents on the nitrogen atoms of the corresponding NHC ligand.
68
  
Figure 2-1.  Auranofin. 
structure. 
18 
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Figure 2-2. Molecular structure of NHC-gold complexes reported by Özdemir et al. 
Thus, complexes 19a and 19b were found to inhibit growth of Gram-positive bacteria Staph. 
aureus and Enterococcus faecalis (MIC = 12.5 μg/mL), while having no effect toward Gram-
negative bacteria Escherichia coli and Pseudomonas aeruginosa and fungi Candida albicans and 
Candida tropicalis. On the other hand, the incorporation of a pentamethylbenzyl group as a 
substituent on nitrogen atoms (complex 19b), resulted only in good antifungal activity (MIC = 
12.5 μg/mL). At the moment, in general, gold complexes with +1 oxidation state of gold have 
showed much more activity than Au(III) compounds as antibacteria agents.
64
 The mechanism of 
action is not completely understood. Anyway for the instance, NHC-gold complexes meanly 
appear to be less active then the corresponding silver complexes.
21,22
  
 Gold complexes as anti-HIV/AIDS 2.2 
Gold compounds have been investigated against human immunodeficiency virus (HIV) 
showing promising activity obtained from both clinical and laboratory studies.
62
  
HIV is the virus that can lead to acquired immunodeficiency syndrome, or AIDS. Unlike 
some other viruses, the human body cannot get rid of HIV. That means that once you have HIV, 
you have it for life. No safe and effective cure currently exists. HIV affects specific cells of the 
immune system, called CD4+ T cells (white blood cells). Over time, HIV can destroy so many of 
these cells that the body can’t fight off infections and disease. When this happens, HIV infection 
leads to AIDS.
69
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❶ Fusion of HIV to the host cell surface. 
❷ HIV RNA reverse transcriptase 
integrase and others virals proteins enter 
the host cell. ❸ Viral DNA is formed by 
reverse transcription. ❹ Viral DNA is 
transported across the nucleus and 
integrates into the host DNA. ❺ New 
viral RNA is used as genomic RNA and to 
make viral proteins. ❻ New viral RNA 
and proteins move to the cell surface and a 
new, immature, HIV forms. ❼ The virus 
matures by protease releasing individual 
HIV proteins. 
 
Figure 2-3. The HIV replication cycle: the virus that causes AIDS is shown budding out of a 
human immune cell, which the virus infects and uses to replicate.  
The interest in gold containing compounds as agent against AIDS has been stimulated by a 
clinical report that an AIDS patient not accepting anti-HIV drugs but treated with Auranofin (8, 
Figure 2-1) for psoriatic arthritis experienced increasing CD4+ T cell counts, in contrast to the 
usually irreversible decline of these cells.
70
 These findings suggest that gold complexes should 
be systematically investigated for anti-HIV activity. Further possible mode of actions for gold 
complexes are the inhibition of reverse transcriptase (RT), protease (PR) and viral entry of host 
cells.
62
 Other important compounds are Aurothioglucose (AuTG) (Figure 2-4) and 
Aurothiomalate (AuTM) (Figure 2-4), both are anti-arthtitic agents that have been shown to 
possess anti-HIV properties.
71
 The majority of the gold-based compounds reported as anti-HIV 
candidate, have gold in its +1 oxidation state.
62
 Although gold(III) compounds have long time 
been anticipated as promising candidates for drug development, limited success has been 
achieved due to their poor solution stability under physiological conditions considering that 
gold(III) as strong oxidizing agent can be easily reduced.
40,62,72
 
However, Che and co-workers reported a series of physiologically stable gold(III) porphyrins 
which possess significant in vitro inhibition of human immunodeficiency virus type-1 (HIV-1) 
reverse transcriptase. 22 (Figure 2-4)  was the most potent inhibitor of HIV-1 with an IC50 value 
= 0.31 μM.73  
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Figure 2-4. Structure of gold containing anti-HIV compounds. 
At the moment no NHC-gold complexes have been reported as experimental anti-HIV/AIDS 
agent. 
 Gold complexes as antimalaria 2.3 
Malaria is an infectious disease caused by protozoan parasites of the genus Plasmodium and is 
still a major cause of illness and death in tropical countries. Of the five species that cause malaria 
(P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi), the most serious form of the 
disease is caused by P. falciparum. Malaria parasites are transmitted by the bite of an infected 
female mosquito of the Anopheles genus. The natural ecology of malaria involves malaria 
parasites infecting successively two types of hosts: humans and female Anopheles mosquitoes. In 
humans (Figure 2-5), the parasites grow and multiply first in the liver cells and then in the red 
cells of the blood. In the blood, successive broods of parasites grow inside the red cells and 
destroy them, releasing daughter parasites ("merozoites") that continue the cycle by invading 
other red cells. The blood stage parasites are those that cause the symptoms of malaria. When 
certain forms of blood stage parasites ("gametocytes") are picked up by a female Anopheles 
mosquito during a blood meal, they start another, different cycle of growth and multiplication in 
the mosquito (not showed). After 10-18 days, the parasites are found (as "sporozoites") in the 
mosquito's salivary glands. When the Anopheles mosquito takes a blood meal on another human, 
the sporozoites are injected with the mosquito's saliva and start another human infection when 
they parasitize the liver cells. Thus the mosquito carries the disease from one human to another 
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(acting as a "vector"), perpetuating the malaria life cycle. Differently from the human host, the 
mosquito vector does not suffer from the presence of the parasites.
69
  
After replication in the liver , the parasites 
undergo asexual multiplication in the 
erythrocytes (red blood cells) . Some 
parasites differentiate into sexual 
erythrocytic stages (gametocytes) ❼. Blood 
stage parasites are responsible for the clinical 
manifestations of the disease. The 
gametocytes, male and female, are ingested 
by an Anopheles mosquito during a blood 
meal ❽. The parasites’ multiplication in the 
mosquito leads to motile and elongated 
zygotes (ookinetes) which invade the midgut 
wall of the mosquito where they develop into 
oocysts. The oocysts grow, rupture, and 
release sporozoites.  Inoculation of the 
sporozoites ❶ into a new human host 
perpetuates the malaria life cycle.  
Figure 2-5. Schema of the Life Cycle of Plasmodium (Source: CDC, modified). 
The World Health Organization estimates that 3.3 billion people were at risk of malaria in 
2011, with approximately 80% of malarial cases and 90% of deaths occurring in the African 
region. The major antimalarial drug namely chloroquine (CQ) (Figure 2-6) is today almost 
completely ineffective, due to parasite resistance. Also Artemisinin and its derivatives are a 
group of current drugs that possess very rapid action against Plasmodium falciparum malaria.
74
 
Artemisinin is isolated from the plant Artemisia annua, sweet wormwood, herb employed in 
Chinese traditional medicine. However, a growing resistance of the parasite to Artemisinin, have 
also been noted in several countries. Several antimalarial drugs which are useful for treating 
rheumatoid arthritis exhibit pharmacological profiles similar to gold drugs, which suggests that 
there might be common features in the mechanisms of antiarthritic and antimalarial action.
62
 
Thus, the role of gold as a potential enhancer of antimalarial activity is under investigation.
75–79
 
Navarro reviewed many gold complexes showing potential anti-parasitic properties.
78,80
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Figure 2-6. Structures of gold(I) containing antimalarial compounds. 
The CQ complex of triphenylphosphine gold(I) (24, Figure 2-6), for example was found to be 
more active in vitro than CQ against two CQ-resistant strains of Plasmodium falciparum (IC50 = 
5.1 - 23 nM) and also in vivo against Plasmodium berghei.
78,80
 Few NHC-Au complexes as 
antimalarial agents have been investigated. Recently our group reported two mononuclear 
gold(I) complexes containing nitrogen heterocyclic functionalized arms, namely quinoline 
(complex 25a) and methylbipyridine (complex 25b) moieties (Figure 2-6) showing good 
antiplasmodial activity against P. falciparum (strain FcM29-Cameroon) with IC50 values of 1.1 
and 0.33 μM, respectively. The 25b efficacy on P. falciparum was found to be better than the 
one showed by the reference drug CQ (IC50 = 0.445 μM) and no hemolysis has been observed 
(for both compounds 25a and 25b).
76
 In the same report dinuclear gold(I) and gold(III) bis-NHC 
complexes have been also investigated. 
 
Figure 2-7. Structures of gold(I) and gold(III) containing antimalarial compounds. 
The gold(I) complex 26 (Figure 2-7) and gold(III) complexes 27a and 27b showed moderate 
activity against P. falciparum strain FcM29 with IC50 values of 15 μM, 9 μM and 13 μM, 
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respectively, but considerably lower than mononuclear complexes 25a, 25b and CQ. 
Furthermore, hemolysis has been observed on parasite cultures. Currently, no other NHC-gold 
compounds with antimalarial activity have been reported in literature. 
 Gold complexes as antileishamaniasis 2.4 
Leishmaniasis is one of the most important parasitic diseases worldwide as regards of its 
critical impact on human health and also because of the rapid emergence and spreading of 
resistant parasites. It is encountered in 97 countries, mainly in tropical and sub-tropical regions, 
but also in southern Europe, especially around the Mediterranean area.
81
 These parasitic 
infections are caused by a protozoan of the Leishmania genus transmitted to its mammal hosts 
(humans, dogs, monkeys, rodents) by the bite of an infected sandfly (Phlebotominae). 
Leishmania parasites present two major morphological stages: extracellular flagellated 
promastigotes in the digestive tract of their sandfly vector and non-motile amastigotes inside the 
cells of their hosts’ mononuclear phagocytic system.81 The life cycle of leishmaniasis is 
descripted in more detail in Figure 2-8. 
 
Figure 2-8.  .  Scheme of the life cycle of Leishmaniasis. 69 
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Life Cycle of Leishmaniasis: Leishmaniasis is transmitted by the bite of infected female 
phlebotomine sandflies. The sandflies inject the infective stage (i.e., promastigotes) from their 
proboscis during blood meals . Promastigotes that reach the puncture wound are phagocytized 
by macrophages and other types of mononuclear phagocytic cells. Progmastigotes transform in 
these cells into the tissue stage of the parasite (i.e., amastigotes) , which multiply by simple 
division and proceed to infect other mononuclear phagocytic cells . Parasite, host, and other 
factors affect whether the infection becomes symptomatic and whether cutaneous or visceral 
leishmaniasis results. Sandflies become infected by ingesting infected cells during blood meals ( , 
). In sandflies, amastigotes transform into promastigotes, develop in the gut (in the hindgut for 
leishmanial organisms in the Viannia subgenus; in the midgut for organisms in the Leishmania 
subgenus), and migrate to the proboscis . 69 
 
There are three main forms of the disease caused by different organisms, namely cutaneous 
leishmaniasis (Oriental sore), mucocutaneous leishmaniasis (Espundia) and the most severe 
visceral leishmaniasis (Kala-azar). There are an estimated 14 million people infected worldwide 
with an annual incidence of 2 million and about 50.000 estimated deaths due to its visceral form, 
considering that the number of cases is certainly under-evaluated as leishmaniases are reportable 
disease in only 40 countries.
82
 
 
 
Figure 2-9. Commercial drugs currently used against Leishmaniasis disease. 
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Currently the most common drugs used for the treatment of this disease are pentavalent 
antimonials (sodium stibogluconate named “Pentostam” and meglumine antimoniate named 
Glucantime), amphotericin B, pentamidine, paromomycin and miltefosine (Figure 2-9).
83
  
However, these drugs present several problems including non-oral routes of administration 
(except for miltefosine), expensive cost of liposomal amphotericin B, high toxicity of 
antimonials, pentamidine, paromomycin and amphotericin B and adverse events of most 
clinically used molecules, leading to patients withdrawing from treatment and emergence of 
resistant strains.
81,84,85
 
Different metal-complexes of rhodium, iridium, platinum and copper have been tested until 
now showing good antileishmanial activity.
83,86
 However, there are just few gold based 
compounds studied for this medical application.
64,83,86,87
 Colotti and co-workers evaluated 
Auranofin (complex 18 in Figure 2-1) and [AuCl(PEt3)] (complex 34 in Figure 2-10) as 
antileishmanial agents.
88
 Tests in vitro showed strong inhibition of trypanothione reductase (an 
important target of Leishmania parasites), with both Auranofin and 34 with a Ki (inhibitory 
constant) of 0.155 and 0.018 μM, respectively.88  
 
Figure 2-10. Structures of antileishmanial gold complexes. 
Navarro et al. reported a dinuclear gold(I) (complex 35 in Figure 2-10) with the bioactive 
pyridine-2-thiol N-oxide as coligand, active in vitro against promastigotes of two different 
species of the genus Leishmania, namely L. mexicana and L. braziliensis. The complex 35 
induced a potent dose dependent antiproliferative effect on both species of Leishmania studied. 
After 30 min a 1 μM dose of the complex induced a potent leishmanicidal effect (LD50, lethal 
dose for half of the parasite population). Moreover the gold(I) complex showed low unspecific 
cytotoxicity on mammalian macrophages, being highly selective to parasites.
89
 This suggests that 
the antiproliferative effect is probably related to the inhibition of NADH (nicotinamide adenine 
dinucleotide) fumarate reductase, an enzyme that is present in the parasite but not in mammalian 
cells.
89
 The same group reported also an example of gold(III) complex (36 in Figure 2-10), 
containing a DNA intercalating dppz ligand (dppz is dipyrido-phenazine) able to induced potent 
dose-dependent antiproliferative activities against L. mexicana with a MIC value of 3.4 nM and a 
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lethal dose (LD26) of 17 nM after 48 h. Mechanistic studies showed the interaction of the 
molecule with the DNA helix of the parasite. 
No NHC-gold complexes as antileishamanial agents have been reported in literature until 
now. 
 Gold complexes as anticancer 2.5 
 With regard to medical applications, apart as antiarthritic, gold complexes are especially 
studied for their anticancer activities. The design and testing of gold complexes for antitumor 
activities over the past several decades has been based on three rationales:
62
 (1) analogies 
between square planar complexes of Pt(II) and Au(III), both of which are d
8 
ions; (2) analogy to 
the immunomodulatory effects of gold(I) antiarthritic agents; (3) complexation of gold(I) and 
gold(III) with known antitumor agents to form new compounds with enhanced activity. The 
discovery that Auranofin had activity against HeLa cells in vitro and P388 leukemia cells in vivo 
led to the screening of many Auranofin analogues, but their spectrum of activity was limited.
90
 
However these results encouraged research on other gold complexes as anticancer agents and 
recently several promising classes of gold-based drug candidates have been described: 
bischelating phosphines, dithiocarbamates, porphyrines, or NHCs are important examples of 
ligands used for coordination of the gold central atoms in new biologically active gold 
metallodrugs.
21,41,91,92
 
 
The action of gold(III) compounds is mainly associated to the interaction with DNA, in  
particular with guanine, interfering with transcription and replication processes and consequently 
causing the apoptosis of cells. Unlike Au(III) complexes so considered as DNA targeting, Au(I) 
complexes are considered as mitochondria targeting.  
Mitochondria play a key role in the regulation of apoptosis (cell death) and in diseases 
characterized by abnormal apoptotic responses such as cancer. Actually, the development of new 
chemotherapeutic mitochondria targeting is considered as a “hot issue” because potentially we 
could overcome the two main problems in cancer chemotherapy: i) the treatment of tumour cells 
that shows drug-resistance versus the currently used drugs and ii) the absence of selectivity of 
the drugs normally used in distinguishing healthy cells from diseased cells.
41
 Carcinoma cells 
have an elevated mitochondrial membrane potential (ψm) compared to normal human epithelial 
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cells. It is possible to exploit this phenomenum as driving force to deliver the complex just inside 
the cancer cell.
93
 
 
Figure 2-11. NHC-gold complex mitochondria targeting inside a general cancer cell. 
Mitochondria targeting mode of action: Mitochondria are membrane-bound organelles 
considered as the “power plant” of the cell, because they generate over 80% of ATP, used as a 
source of chemical energy. In addition to supplying cellular energy, mitochondria are involved in 
other tasks such as signaling, cellular differentiation, cell death, as well as the control of the cell 
cycle and cell growth.
94
 Apoptosis is a process of programmed cell death characterized by the 
activation of caspases (cysteine-aspartic proteases). Caspases activation is an essential decision 
point that cleaves multiple targets in cells. In vertebrate cells the mitochondrial (intrinsic) 
pathway is the major form of apoptosis, and the critical event responsible for caspase activation 
is mitochondrial membrane permeabilization (MMP) referred as the “point of no return” of cell 
death.
41,95
 Numerous pro-apoptotic signal-transducing molecules and pathological stimuli 
converge on mitochondria to induce MMP, which leads to the release of cytochrome c and other 
pro-apoptotic proteins from the inter-membrane space.
41,95
 MMP can derive from two distinct, 
but partially overlapping, molecular mechanisms. On the one hand, large channels formed by 
pro-apoptotic proteins from the Bcl-2 family (apoptosis regulating proteins as Bcl-2-associated 
protein X (BAX) or Bcl-2 antagonist/killer (BAK)) might selectively promote mitochondrial 
outer membrane permeabilization (MOMP). On the other hand, cell death inducers such as Ca
2+
 
overload and oxidative stress trigger MMP at the inner mitochondrial membrane (IM), by 
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favouring the opening of the permeability transition pore complex (PTPC). This process is 
known as mitochondrial permeability transition (MPT).
96
 
 
Figure 2-12. A cartoon depicting reported by Berners-Price et al.41 concerning apoptosis 
induction via the mitochondrial pathway, illustrating the two proposed mechanisms that 
lead to release of cytochrome c and other pro-apoptotic proteins from the inter-membrane 
space, triggering the activation of caspases (see Ref.95 for a more detailed pictorial 
representation). 
Furthermore, MOMP can also occur as a consequence of MPT. Formation of the PTPC pore 
allows water and molecules up to ∼1.5 kDa to pass through, causing swelling of the matrix 
which is sufficient to break the outer membrane to produce MOMP.
97,98
 The composition of the 
transition pore is not clear, but recent studies showed a fundamental role of the adenine 
nucleotide translocator (ANT) and the voltage dependent anion channel (VDAC) as structural 
component of PTPC.
97
  
Chen and co-workers observed that the potential of the mitochondrial membrane (ψm ) is 
much higher in cancer cells than in normal cells.
93
 One approach to the selective targeting of 
mitochondria in cancer cells involves the classes of compounds named DLCs, delocalized 
lipophilic cations. DLCs can pass through the lipid bilayer and enter selectively in the 
mitochondria of cancer cells driven by the abnormally high membrane potential. 
Most of the anticancer drugs have an indirect activity against mitochondria, provoking a 
cytotoxic action by inducing apoptosis through signaling pathways that just finally involve 
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MOMP. However, the intrinsic resistance to the indirect induction of MOMP is a characteristic 
of cancer cells because of the overexpression of apoptosis-inhibitory PTPC pore components or 
as a consequence of the overexpression of antiapoptotic proteins from the Bcl-2 family, 
mutations of proapoptotic Bcl-2 antagonists and p53. By the way, an action directs on 
mitochondrial membrane, interfering directly with the operation of Bcl-2 family member could 
overcome the drug resistance, solving the problem at its source. 
Another molecular target is the thioredoxin reductase (TrxR), an enzyme overexpressed in 
cancer cells and responsible of growth promoting effects that support tumor cell drug resistance.  
Thioredoxin reductases targeting mode of action: Many cellular processes including 
antioxidant defence, redox and cell growth regulation as well as selenium metabolism are related 
to the action of thioredoxin reductase (TrxR). The TrxRs are a class of ubiquitous selenoenzymes 
that have a central role in the regulation of the cellular redox state (see Scheme 2-1). TrxR is a 
NADPH-dependent flavoprotein (as glutathione reductase) responsible for cell homeostasis 
regulation and closely linked to many disease conditions including rheumatoid arthritis or 
cancer.
99
 This kind of homodimeric proteins contains for each monomer a FAD prosthetic group, 
a NADPH binding domain, and an active site containing a redox-active disulfide bond.
100
 
Electrons are taken from NADPH via TrxR and are transferred to the active site of TrxR, which 
goes on to reduce protein disulfides or other substrates.
99
 
 
Scheme 2-1. The thioredoxin reductase/thioredoxin system.  
On the molecular level, the selenocysteine (Sec) residue in the C-terminal active site of TrxR 
is considered as the ultimate target for gold species, forming a covalent bond between gold and 
selenium atoms. The interaction of Au(I) with Se-free enzyme glutathione reductase (GR) is also 
well known, due to the Au-S affinity.
101
 
When the mitochondrial TrxR is inhibited, the rapid formation of H2O2 that is continuously 
formed by the respiratory chain, does not permit to the peroxyredoxin (Prx) to be restored. In 
turn, oxidized thioredoxin can act on several different targets, leading to the opening of the pore 
or increasing the permeability of outer membrane and, therefore, causing the release of 
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apoptogenic factors (mechanism proposed for Auranofin).
102
 Humans express three thioredoxin 
reductase isozymes: TrxR1 (cytosolic), TrxR2 (mitochondrial), TrxR3 (testis specific).
103
 
Metallodrugs based on Au(I), could combine the two target (mitochondria and TrxR) acting 
against TrxR2 in tumoral cell.  
 
Scheme 2-2. Scheme depicting the mechanism of Auranofin alteration of the thiol redox 
balance in mitochondria leading to apoptosis, as proposed by Bindoli et al.;102 Prx, per- 
oxiredoxin (thioredoxin peroxidase); TrxR, thioredoxin reductase; Trx-(SH)2, reduced 
thioredoxin; Trx-S2, oxidised thioredoxin. 
Auranofin (18, Figure 2-1 and Scheme 2-2) has been shown to 
have anticancer activity by targeting mitochondria, particularly as 
inhibitors of mammalian thioredoxin reductases.
101
 Consequently a 
variety of Au(I) compounds involving phosphine ligands have been 
screened showing good anticancer activities. Berners-Price et al. 
reported for example a bis[1,2-bis(diphenylphosphino)ethane]gold(I) 
chloride ([Au(dppe)2Cl] 37, Figure 2-13) showing a broader spectrum 
of antitumour activity and it is considered to act by an 
antimitochondrial mechanism via interacting with thioredoxin reductase.
104
 
[Au(dppe)2Cl] was also selected for pre-clinical trials, but was abandoned when severe 
hepatotoxicity was observed in dogs.
105
 The note similarities between NHC and phosphine 
ligands has made interesting to test the biological activities of NHC-gold complexes. 
 
Figure 2-13. Gold(I) 
complex reported by 
Berners-Price et al.. 
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 NHC-gold complexes as anticancer agents 2.6 
Extensive investigations are currently focused on the synthesis of metal complexes with a 
better chemotherapeutic index in terms of increased bioavailability, more antiproliferative 
activity, higher selectivity and fewer side effects than the platinum drugs.  
Gold(I)-NHC complexes have been reported to be really interesting anticancer agents. These 
complexes are more stable and easier to synthetize than phosphine complexes. Moreover, NHCs 
are very versatile ligands and the relatively simple derivatization of the imidazolium salt (pro-
ligand) gives the possibility to obtain a large series of different wingtip groups modifying and 
tuning the stability and the lipophilic character of the complexes. 
Au(III)-NHC complexes are known to be unstable, in biological 
environment; Au(III) is usually rapidly reduced to Au(I) or even 
Au(0) by cellular thiol-containing compounds.
40,62,72
 Anyway there 
are some stable Au(III) that have shown strong anticancer 
properties. Good examples have been reported by the group of Che 
et al., where a strong chelating ligand scaffold stabilize the Au(III) 
avoiding the demetalation of complexes.
106,107  
Among them [Au(2,6-diphenylpyridine)(NHC)] 
trifluoromethanesulfonate (38, Figure 2-14) showed high antiproliferative effects in vitro against 
a panel of human cancer cell lines including hepatocellular carcinoma (HepG2), cervical 
epithelioid carcinoma (KB and its camptothecin-resistant cell line KB-CPT-100), non-small cell 
lung carcinoma (NCI-H460) and nasopharyngeal carcinoma (SUNE1) with IC50 values of 0.17 to 
28 μM. The activity of 38 is attributed to induced DNA strand breaks that lead to subsequent cell 
death. Furthermore, this is a singular case because the gold(III) compound shows higher in vitro 
cytotoxicity to carcinoma cells, than to the normal lung fibroblast cells CCD-19Lu (IC50 = 25 
μM).106 
Normally, the problem of DNA targeting agents as Au(III) complexes and cisplatin analogues 
is the undifferentiated killing of normal and cancer cells. The consequences are important side 
effects in case of chemotherapy. Really interesting are the properties carried out from the studies 
on Au(I)-NHCs, that showed a different mode of action. These compounds could combine both 
selective mitochondria targeting and selective thioredoxin reductase inhibition properties within 
a single molecule. This means, as introduced in the precedent section, that it should be possible 
to get antiproliferative effects on cisplatin-resistant (and general drug resistant) cancer cells and 
Figure 2-14. NHC-
Au(III) complex 
reported by Che et al.. 
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to gain selectivity in cytotoxicity against diseased cells. The state of art concerning this kind of 
complexes will be exhaustively discussed in the next section. 
2.6.1 Mono-NHC Gold(I) complexes as anticancer agents 
As analogues of Auranofin (18) and [(Et3P)AuCl] (34), Berners-Price et al. reported a series 
of neutral (NHC)-Au(I)-X complexes having X = Cl and 2’,3’,4’,6’-tetra-O-acetyl-β-D-
glucopyrano-syl-1-thiolato (Figure 2-15). The alkyl substituents of the NHC ligands were varied 
to allow modulation of the lipophilic properties of the resultant complexes. 
 
Figure 2-15. NHC-Au(I) complexes reported by Berners-Price et al.. 
Mitochondria targeting of these complexes was observed and the biological  activities 
suggested a relation with the lipophilicity of the molecules.
108
 Nolan and co-workers investigated 
the biological properties of Au–NHC complexes against breast cancer (MDA-MB 231), prostate 
cancer (LNCaP), and bladder tumor (MGH-U1) cell lines.
109
 Among these complexes, 41a and 
41b (Figure 2-16) showed most efficient cytotoxicity with IC50 values between 0.9 and 1.9 μM 
against MDA-MB 231 and LNCaP and 0.18 μM against MGH-U1.  
 
Figure 2-16. NHC-Au(I) complexes reported by Nolan et al. (41a and 41b) and reported by Ott 
et al. (complex 42). 
However, the comparison of the cytotoxicity using a human breast carcinoma cell line (B42 
CL16) and normal breast epithelial cell line B42 shows unselective toxicity of 41a and 41b (IC50 
< 0.5 μM in both cell lines). The same result was found using a human prostate epithelial cell 
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line P21TZ and a prostate carcinoma cell line P21PZ derived from the same patient (IC50 < 0.5 
μM in both cell lines).109 
Gold(I) compounds involving 1,3-benzimidazol-2-ylidene ligands type were biologically 
investigated by Ott et al., showing an interaction between complexes and the active site of GR 
(glutathione reductase) and TrxR.
110
 The chlorido derivative NHC-Au(I)-Cl  (42 in Figure 2-16), 
for example, showed  antiproliferative effects against  MCF-7 (breast cancer cell line) with IC50 
= 4.6 μM and HT-293 (colon cancer cell line) with IC50 = 6.4 μM but also against human 
embryonic kidney  (HEK-293)  non tumorigenic cells (IC50 = 10 μM), not showing significant 
bioselectivity. The found inactivity of the free ligand confirmed that the growth inhibition of 
cancer cells is due to the gold core. In this study, some details have also been reported about the 
biological behavior of the complex that reveal a pharmacodynamic pattern that is mainly the 
consequence of several pathways related to the inhibition of TrxR, showing an intensive binding 
of 42 to albumin (similar to Auranofin behavior), but also due to distinct effects against 
mitochondrial biochemistry not necessarily related to TrxR inhibition.
110
   
Dinda et al. synthetized two complexes with similar structures (43a and 43b in Figure 2-17) 
that showed modest in vitro cytotoxic properties tested against various cancer cell lines, B16F10 
(mouse melanoma), HepG2 (human hepatocarcinoma) and HeLa (human cervical carcinoma) 
with IC50 values between 27.0 and 33.8 μM. However, a certain interest is given by the value 
reported for the test on normal human peripheral blood mono nuclear cells that did not show any 
significant cytotoxic effect at 100 µM of concentration, whereas 10 µM of cisplatin showed 75% 
cytotoxicity.
29
 
 
Figure 2-17. NHC-Au(I) complexes reported by Dinda et al. (43a and 43b) and reported by 
Tacke et al. (complexes 44a, 44b and 44c). 
Tacke et al. reported a series of neutral cyanobenzyl and benzyl substituted gold complexes 
(44a-44c in Figure 2-17).
111
 The complexes were synthetized via silver transmetalation. All these 
compounds were biologically investigated against the human cancerous renal cell line Caki-1 
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and the gold complexes 44a, 44b and 44c showed IC50 values of 12, 12, and 10 µM, 
respectively. Silver correspondents (not showed) were also tested, resulting two or three times 
less efficacy than the gold one, with IC50 > 27 µM. These differences were attributed to the fact 
that silver complexes were less stable and less soluble compared to the related gold complexes 
(44a-44c).
111
  
Gust et al. reported a family of thirteen neutral diarylimidazol-2-ylidene gold(I) complexes 
and among these compounds, 45a-f  (Figure 2-18) showed high growth inhibitory properties 
against MCF-7 ( 0.8 < IC50 < 1.2 µM), MDA-MB 231( 1.7 < IC50 < 2.4 µM), and HT-29 ( 2.3 < 
IC50 < 4.2 µM). Complex 46 (Figure 2-18), without C4,C5-standing aromatic rings, was tested 
against the same cancer lines showing 3.0 < IC50 < 7.7 µM. The mode of action, for these 
complexes, is still unclear, but TrxR has been excluded as main target.
112,113
 
 
Figure 2-18. NHC-Au(I) complexes reported by Gust et al.. 
The inhibition of TrxR cannot be considered as the universal mode of action always involved 
in the anticancer action of Au(I)-NHC compounds. Another target that can be involved, for 
example, is the protein tyrosine phosphatases (PTP) present in many key steps of cancer 
metabolism. The inhibition of this group of enzymes by interaction with a NHC-gold(I) complex 
was shown via in vitro tests by Barrios and co-workers reporting the activity of 47 (IC50 = 7 µM) 
against PEST (peptide sequence that is rich in proline (P), glutamic acid (E), serine (S), and 
threonine (T)).114  
Biological studies on the compound 48 (Figure 2-19) and its silver analogue (not showed) 
were reported by Panda et al., but low antiproliferative effects against HeLa cells were found for 
both complexes (1.7% of growth inhibition using drug solutions at 10 μM of concentration).33 
Conversely, the study on the molecule 49 (Figure 2-19), reported by Gautier and Morel, 
displayed a significant activity against five cancerous cell lines showing IC50 values of 4.3 µM 
against KB (oral carcinoma), 4.3 µM against HL60 (promyelocytic leukaemia), 0.29 µM against 
HL60, 5.1 µM against HL60R (resistant HL60), 1.29 µM against MCF-7 (breast cancer) and 4.5 
µM against MCF-7R (resistant MCF-7). 
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Figure 2-19. NHC-Au(I) complexes reported by Barrios et al. (47), Panda et al. (48), 
Gautier et al. (49) and Li et al. (50). 
Although, in this particular case, the silver analogue of 49 (not showed) was more cytotoxic 
(IC50 = 0.08 µM) than the corresponding Au(I) complex  against the MCF-7 cell line.
39
 
Li and collaborators reported a gold(I) complex bearing an amino linked NHC (50 in Figure 
2-19) which showed good antiproliferative activity in the human U-87 cancer cells 
(glioblastoma) with IC50 = 1.26 µM and modest against MCF-7 (IC50 = 16.28 µM) and MDA-
MB-231 (IC50 = 14.22 µM). The activity in U-87 cells involves S-phase arrest, blocking DNA 
replication. In addition, observations indicate that 50 induces apoptosis through externalization 
of phosphatidylserine, DNA fragmentation, poly(ADP-ribose)polymerase cleavage, and 
activation of caspase-3. 50 does not inhibit human TrxR and does not trigger apoptosis through a 
DNA independent mechanism, but at the same time the DNA binding mode of the complex is 
significantly different from that of cisplatin. This neutral Au species interacts with DNA in a pre- 
carious manner, which in turn initiates operation of a mitochondrial-mediated apoptosis 
pathway.
115
 
The group of Metzler-Nolte has reported the synthesis of NHC gold(I) halide, amino acid and 
peptide complexes (51a-51c in Figure 2-20). This example of bioconjugate systems has had the 
objective of improving the effectiveness of these coumpounds, nevertheless, the introduction of 
an amino acid to the imidazole moiety of the gold complexes led to a decrease in biological 
activity. In vitro tests against Hela, HepG2 and HT29 cells, showed for 51a IC50 values between 
2.8 and 4.7 µM and for 51b-51c IC50 values between 8.3 and 28.1 µM with exception of 51b 
against HeLa cells (IC50 = 3.4 µM).
116
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Figure 2-21. Visualization of the complex 52 
in HEK-293T, A2780S and A2780R cells  
using confocal microscopy. Column: (a) 
fluorescence of the compounds; (b) 
propidium iodide (nuclear marker 
localization; (c) merge. 
 
 
Figure 2-20. NHC-Au(I) complexes reported by Metzler-Nolte et al. (51a-51c) and by Casini et 
al. (complex 52). 
On the other hand, amino acid transporters are over-expressed in some tumor cell lines. By 
hijacking such amino acid transporters, these amino acid derivatives could be specific for tumor 
cells over normal, healthy cells. 
116,117
  
Casini et al. reported a fluorescent gold(I)-NHC complex functionalized with a fluorescent 
anthracenyl ligand (52 in Figure 2-20) that was examined for cytotoxicity in normal and tumor 
cells.
118
 Preliminary fluorescence microscopy experiments showed that the compound enter in 
cells, and is particularly efficient in penetrating tumor cells where it reach the nuclear 
compartment Figure 2-21. Cytotoxic effects of the compound 52 were confirmed with in vitro 
testing against human ovarian cancer cell lines cisplatin sensitive (A2780S) and resistant 
(A2780R), with IC50 values ranging from 3 to 
7 μM after 24 h incubations. However, the 
same activity was also found on the non-
tumorigenic human embryonic kidney cell 
line (HEK-293T), showing aspecific toxicity. 
Moreover, further obtained results indicate a 
correlation between the cytotoxicity of 
compound 52 and Trx/Prx3 (mitochondrial 
peroxiredoxins) oxidation via TrxR inhibition 
in cells.
118
 Peroxiredoxins (Prxs) are enzymes 
decomposing peroxides using a highly 
reactive cysteine thiolate in their active site. 
Prx3 is kept reduced by the mitochondrial 
thioredoxin system, thus playing a role in 
protecting mitochondria from H2O2 produced 
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by the respiratory chain complexes.
119,120
 
The same group reported a series of gold(I) complexes with a 2-pyrimidinethiolato ligand 
(53a-53d in Figure 2-22), with antiproliferative effects against A2780S, A2780R with IC50 
values ranging from 3.2 to 16.2 μM but also against non tumoral HEK-293T cells in the same 
range of concentration. These complexes were found to be potent inhibitors of both the cytosolic 
and mitochondrial isoforms of the TrxR enzymes (TrxR1 and TrxR2) but showing more effects 
against TrxR1 than TrxR2. Interestingly, unlike Auranofin, TrxR inhibition by Au(I) NHC 
appears to be relevant in cancerous cells, while the enzyme was almost unaffected in the non 
tumorigenic HEK-293T cell line.
121
 
 
Figure 2-22. NHC-Au(I) complexes reported by Casini et al. (53a-53d). 
The complex 53a was found to be the best TrxR inhibitor and also the best anticancer agent 
among the other complexes; interestingly this kind of correlation was found also for the other 
less active molecules (53b-53d).
121
 
Huynh and co-workers have reported the synthesis and characterization of a series of neutral 
and cationic NHC-gold(I) with anticancer activities. Among these complexes the cationic 
heteroleptic biscarbene 54a (Figure 2-23) showed strong antiproliferative effects against NCI-
H1666 non-small cell lung cancer cell line with IC50 = 0.241 μM while the neutral correspondent 
54b showed IC50 > 10 μM.
22,122,123
  
 
Figure 2-23. NHC-Au(I) complexes reported by Huynh et al. (54a and 54b) and by Cronje et al. 
(complex 55). 
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This finding might be related to effects of delocalized lipophilic cations.
41
 The cationic 
complexes have the ability to readily pass through the lipid membrane of mitochondria and 
accumulate within the mitochondria as result of the large mitochondrial membrane potential, 
eventually leading to mitochondria-induced apoptosis.
23,122,123
   
A rare example of ylideneamine gold(I) complex (55 in Figure 2-23) has been biologically 
investigated and reported by Cronje et al.; the complex 55 exhibited modest anticancer activity 
against HeLa cells with IC50 = 19.2 μM.
124
  
2.6.2 Bis-NHC Gold(I) complexes as anticancer agents 
The first important contribution about bis-NHC gold compounds as anticancer agents 
targeting mitochondrial function has been presented by Berners-Price et al. reporting synthesis 
and biological investigations of a family of six linear, two-coordinate homoleptic cationic Au(I) 
complexes. The two five-membered imidazole-2-ylidenes ligands were functionalized with 
different alkyl substituents (56a-56e in Figure 2-24) in order to vary the ratio 
hydrophilic/lipophilic properties leaving unchanged the structural core of the complex. The 
leaning of complexes to induce mitochondrial membrane permeabilization was assessed by a 
standard assay that measures increases in mitochondrial volume (swelling) based on a decrease 
in the apparent absorbance (540 nm) of a mitochondrial suspension in presence of the compound. 
The triggering of Ca
2+ 
sensitive mitochondrial swelling has been observed and the activity was 
clearly dependent on the lipophilicity (the most lipophilic compounds induced the most rapid 
onset of swelling).
125
 
 
Figure 2-24. Bis-NHC Au(I) complexes reported by Berners-Price et al. and by Young et al.. 
The same group reported another study based on the previous one where they found a fine 
tuning of lipophilicity in the Et-derivative compound 57 that showed selective toxicity against 
breast cancer cell lines (MDA-MB-231 and MDA-MB-468) in respect to normal human 
mammary epithelial cells (HMEC). Besides, the activity in cancer cells was selective in the 
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inhibition of mitochondrial TrxR and was not interfering with glutathione reductase (GR). 
Furthermore, it was found that 57 could selectively induce apoptosis via the activation of 
caspase 9 and caspase 3 in cancer cells, but not in normal cells.  
Young’s group also developed two bis-NHC gold(I) complexes; 58a and 58b (Figure 2-24) 
were tested on the H460 lung cancer cell line showing antiproliferative activities with IC50 
values of 7 and 18 μM, respectively. The mode of action and selectivity were not investigate in 
this case.
126
 
Nolan and co-workers, next to the neutral complexes described in the previous paragraph (41a 
and 41b in Figure 2-16), reported a second series of cationic bis-NHC gold(I) complexes (59-63 
in Figure 2-25) with the aim to induce selectively apoptosis in cancer cell lines.
109
  
 
Figure 2-25. Bis-NHC Au(I) complexes reported by Nolan et al.. 
The cationic complexes were more effective than the neutral complexes 41a and 41b, 
showing high antiproliferative effects against LNCaP with IC50 values from 0.37 to 0.75 μM and 
against MDA MB231 with IC50 values from 1.70 to 3.00 μM. However, no selectivity was found 
using a human urothelial cell line (SV-HUC-1) and a bladder carcinoma cell line (MGH-U1) 
with IC50 < 0.3 μM for all the tested compounds.
109
 
A congruent example was reported by Ott and co-workers. They enhanced the 
antiproliferative effects of the chlorido derivative NHC-Au(I)-Cl (complex 42), increasing the 
lipophilicity/surface of the compound by replacing the halogen by a second NHC or a PPh3 
ligand (64a and 64b in Figure 2-26) to the formation of cationic complexes.
110
  
The introduction of a positive charge turned out to be a key feature to increase the cellular 
uptake, induce mitochondrial accumulation, and improve general cytotoxic properties. This 
could be related to effects commonly known for DLCs.
41
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Figure 2-26. NHC-Au(I) complexes reported by Ott et al.. 
The bis-NHC complex 64a showed high activity against MCF-7 (IC50 = 0.81 μΜ) and against 
HT-29 (IC50 = 0.44 μΜ). To investigate the drug selectivity, compound 64a was also tested in 
non tumoral cells (HEK-293) showing IC50 = 3.13 μΜ.
110
   
Gust et al. reported a series of different linear NHC-Au-L systems with a 4,5-diarylimidazole 
ligand. Also in this case, compared to mono NHC gold complexes (45a-45f in Figure 2-18), the 
growth inhibitory effects of the bis-NHC complexes (65a-65d in Figure 2-27) against breast 
(MCF-7 and MDA-MB 231) and colon (HT-29) cancer cells are strongly increased with IC50 
values from 0.10 to 0.72 μΜ.112 
 
Figure 2-27. Bis-NHC Au(I) complexes reported by Gust et al. and by Kunz et al..  
An original stable bis-protic homoleptic gold-bis(imidazol-2-ylidene) complex (66 in Figure 
2-27) was reported by Kunz et al..
127
 A preliminary cytotoxicity screening against K562 (human 
myelogenous leukemia) and A2780sens (ovarian carcinoma) cancer cell lines showed no 
cytotoxicity up to 10
-5 
M.
127
 This experimental evidence could be interpreted as a further proof 
that the presence of lipophilic functional groups is fundamental.  
A recent report by Casini et al. showed the antiproliferative effects of caffeine based NHC-
Au(I) complexes.
128
 Complexes 67a-67g (Figure 2-28) were tested in vitro in the human ovarian 
cancer A2780 cell line, its cisplatin resistant variant (A2780/R), in human ovarian cancer 
SKOV3 cells, as well as in the human lung cancer A549 cell line. In addition, in order to 
evaluate the compounds’ selectivity for cancerous compared to healthy cells, the gold complexes 
were also tested in human embryonic kidney HEK-293T cells. The found activities for all 
compounds (67a-67g) showed IC50 values from 13 to 90 μΜ in all cell lines. However, in the 
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specific case, complex 67a showed interesting anticancer properties in vitro against the human 
ovarian cancer cell line A2780 and its cisplatin resistant variant A2780/R (IC50 around 16 μΜ). 
Moreover, it appeared to be poorly toxic in non cancerous HEK-293T cells in vitro (IC50 > 100 
μΜ), as in healthy tissues ex vivo where 67a shows some toxicity mainly at 100 μM and 24 h 
incubation in liver (as well as in kidney slices).
128
   
 
Figure 2-28. Bis-NHC Au(I) complexes reported by Casini et al.. 
In this case the mode of action represents an exception because the complex 67a appears to be 
able to interact selectively thanks to its ability to recognize and link just the tumoral G-
quadruplexes. However further studies are necessary to confirm direct DNA binding in cells.
128
 
Mao et al. reported two cationic Au(I)–NHC complexes derived from cyclophanes (68a and 68b 
in Figure 2-29) and the two silver(I) correspondents (not showed).
129
 The four complexes were 
tested for their antiproliferative activity against human cervical carcinoma (HeLa), human lung 
adenocarcinoma epithelial (A549), cisplatin-resistant A549 (A549R), human breast carcinoma 
(MDA-MB-231) and human normal liver (LO2) cell lines. The bis-NHC Au(I) complexes 68a 
and 68b displayed higher antiproliferative activity and selectivity in comparison with the 
corresponding bis-NHC Ag(I) compounds. 
 
Figure 2-29. Bis-NHC Au(I) complexes reported by Mao et al.. 
In details 68a showed IC50 values = 3.3 μM against Hela, 10.2 μM against A549, 4.5 μM 
against MDA-MB-231 and 16 μM against A549R. Finally, in normal LO2 cells IC50 = 65.1 μM. 
Very similar values were found for 68b. For the corresponding silver complexes, IC50 values 
from 12.4 to 22 μM were found in all cell lines, including LO2. These gold and silver complexes 
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are very similar in structure confirming that different metals are involved in different modes of 
action. In this specific case both complexes can significantly reduce the mitochondrial membrane 
potential, indicating that they can induce apoptosis through the mitochondrial pathway. Gold and 
silver complexes can both trigger apoptosis stimulating the activation of caspase but just gold 
complexes (68a and 68b) were found, in addition, able to increase the intracellular ROS to 
cytotoxic levels.
129
 
Moreover, determination of intercellular localization of compounds by confocal microscopy 
was performed, showing accumulation of complexes (68a and 68b and also silver analogues) 
mainly in the cytoplasm. It was found that the gold complex 68b was localized in the 
mitochondria, but not in the lysosomes.
129
  
2.6.3 Polynuclear NHC complexes 
Berners-Price et al. reported a family of anticancer dinuclear gold(I) complexes having bidentate 
NHC ligands connected by various linkers (as 69a and 69b in Figure 2-30) and showing 
aurophilic interactions.
130,131
 Normally, the activity of this kind of molecular systems is quite a 
rare exception because often the aurophilic interaction entails an increase in the stability that can 
deactivate biochemical interactions. Compound 69b exhibited modest cytotoxicity in RAW264.7 
(mouse leukemic monocyte-macrophage) cells cell line (IC50 = 52 μM, 48 h) but other 
preliminary studies indicated greater potency in other cell lines, such as the human 
promyelocytic leukaemia cell line, HL60 (IC50 = 10 μM, 48 h incubation). Complex 69b was 
also found to be able to induce, at concentrations of 10 µM, Ca
2+
 sensitive MPT evidenced by 
mitochondrial swelling.
130,131
 Furthermore, the luminescence associated to the aurophilic 
interaction gave the possibility to control the cellular distribution via fluorescence microscopy. 
In RAW264.7 cells (where the complex 69b was less active) 69b was not localized in 
mitochondria.
130
 
The compound 70 (Figure 2-30) reported by Raubenheimer et al. is probably the only 
example of heterobimetallic complexes published exhibiting high growth inhibition potency at 
lower concentrations against three different tumoral cells. 
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Figure 2-30. Polynuclear NHC-Au(I) complexes reported by Berners-Price et al. (69a and 69b) 
and by Raubenheimer et al. (complex 70). 
Complex 70 was screened against the human HeLa cervix epithelioid carcinoma cell lines 
(IC50 = 0.572 μM), the human CoLo 320 DM colon adenocarcinoma line (IC50 = 1.007 μM) and 
the Jurkat leukaemia cell line (IC50 = 0.253 μM). Moreover, selectivity of cytotoxicity have been 
investigated testing the compound in human lymphocytes (primary cell cultures); normal cells 
were less sensitive to the experimental drug 70 than the cancer cells (tumor specificity = 6.976), 
indicating selectivity for cancer cells. However, it is still unclear if the presence of the 
ferrocene fragment can enhance the biological properties or not.132 
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 NHC-Au(I) complexes containing a 3.
Ru(bpy)3-side arm  
To facilitate the comprehension of the discussion, in chapters 3, 4, 5 and in the conclusion, the 
molecules reported as literature examples will be numbered with roman numbers ([I], [II], [III], 
etc.) and the synthesized complexes will have a different special bold numbering as 1Ru or 
1RuAu. The bold number indicates the ligand, and the metal symbol corresponds to the related 
metal complex. 
 Introduction 3.1 
In this chapter, we will discuss our researches on heterobimetallic gold(I)-ruthenium(II) 
complexes containing heteroditopic bipyridine-N-heterocyclic carbene (NHC) ligands. In the 
literature, only a limited number of heterobimetallic transition-metal complexes with NHC 
ligands have been reported. In some cases, an NHC binding site is mixed with an ancillary 
ligand, e.g. a sulfur, a phosphine, a phenanthroline, a cyclopentadienyl, or a salen-type ligand, to 
achieve binding of two different metal centers, in others multi-NHCs ligands are employed.
133
 
Peris et al. used a dicarbene ligand to connect two different metal centers by stepwise 
deprotonation of the 1,2,4-trimethyl-1,2,4-triazolium precursor salt. In this way, it was possible 
to bind at first iridium to one binding site of the ligand and then rhodium, palladium or 
ruthenium to the other site of the triazolediylidene ([Ia], Figure 3-1). These mixed-metal 
complexes were tested in different tandem reactions including the dehalogenation/transfer 
hydrogenation, Suzuki-coupling/transfer hydrogenation and Suzuki-coupling/R-alkylation of 
haloacetophenone.
81,83,137
 The best results were obtained from the employment of the Pd-Ir 
system, that was proved to be active in these three tandem processes. Moreover, in these 
processes each metal carries out one different catalytic transformation in a one-pot procedure. 
For example, in the case of the dehalogenation/transfer hydrogenation reaction, the Ir complex 
produced only the hydrogenation transfer whereas the Pd compound gave only the 
dehalogenation process. Furthermore, this mixed system is more efficient than the related 
homodimetallic complexes suggesting a catalytic cooperation. 
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Figure 3-1. Schematic representation of dinuclear NHC complexes reported by Peris et al.. 
Following these interesting results, the same group afterwards reported other examples of 
dinuclear complexes involving a Y-shaped tris-NHC ([Ib] and [Ic] in Figure 3-1).
135
 The ligand 
can bind to two different metals by a stepwise procedure in which the first step invariably 
implies coordination via the chelating side of the ligand. As in the precedent example (see [Ia] in 
Figure 3-1) they showed an Ir-Pd system active in different catalytic tandem reactions obtaining 
similar results to those previously reported.
135
  The use of a bis- or poly-NHC as ligand, in which 
two NHC groups are linked by a variable spacer, is not common in the synthesis of mixed metal  
systems. The difficulties are in prohibiting a chelating coordination mode and to introduce 
selectively stepwise the desired metals.  
 
Scheme 3-1. Schematic representation of a stepwise coordination reaction to obtain 
dinuclear bis-NHC bridged mixed-metal complexes reported by Braunstein et al.. 
Braunstein et al. prepared a stable free dicarbene by deprotonation of the bis(imidazolium) 
precursor salt, which was reacted with [IrCl(cod)]2 in ethanol to obtain a mixture of the dinuclear 
Ir(I) complex and the mononuclear Ir(I) complex with its second NHC unit reprotonated 
(Scheme 3-1). After isolation of the monometalated species, it was reacted with [RhCl(cod)]2 in 
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the presence of Cs2CO3 to generate a heterodinuclear Ir(I)−Rh(I) complex ([IIe] in Scheme 3-
1).
138
  
Cowie et al. also used mono-NHC metal complexes with a pendant imidazolium unit as 
precursors for bis-NHC bridged mixed-metal complexes of Ir(I)−Rh(I), Pd(II)−Ir(I), and 
Pd(II)−Rh(I) (Scheme 3-2).139  
 
Scheme 3-2. Schematic representation of a two steps coordination reaction to obtain 
dinuclear bis-NHC bridged mixed-metal complexes proposed by Cowie et al.. 
Hahn and co-workers designed tris-NHC type ligands which could be metalated step by step, 
giving rise to Pd(II)-Rh(III), Pd(II)-Ir(III), Rh(III)-Rh(III)-Ir(III) and Rh(III)-Rh(III)-Au(I) 
complexes (Figure 3-2).
140,141
 
 
Figure 3-2. Schematic representation of dinuclear tris-NHC complexes reported by Hahn et 
al.. 
Another approach to prepare heterobimetallic NHC containing complexes is based on the 
combination of NHCs with an ancillary ligand. This strategy was applied by Straub and co-
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workers who synthesized Pd-Au and Pd-Cu complexes using a thiol-functionalized asymmetrical 
bis(triazolium) precursor.
142
  
 
Figure 3-3 Schematic representation of dinuclear tris-NHC complexes reported by Straub et 
al.. 
Peters presented in 2013 a salen-bridged bis-NHC system permitting the preparation of Pd-
Ag, Pd-Ni and Ag-Ni complexes (Figure 4-6). A preliminary investigation in catalysis showed 
that the complexes are capable of catalyzing the 1,4-addition of oxindoles to 2-nitrostyrene, but 
the products were racemic mixtures of diastereomers.
143
   
 
Figure 3-4 General modular design of dinuclear salen bis-NHC complexes reported by Peters 
et al. (left). A bimetallic complex containing a cyclopentadienyl-annulated imidazol-2-
ylidene by Arduengo et al. (right). 
In 2005 Arduengo reported a Ru-Pd complex that incorporates a cyclopentadienyl-annulated 
imidazol-2-ylidene moiety (Figure 3-4). The complex [VII] showed activity as catalyst in the 
[VII]      Peters
sss 
Arduengo      
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Suzuki reaction in aqueous media. Fusion of the ruthenocene moiety to the imidazole ring does 
not impair the catalytic activity of the metal bound to the carbene center but may offer some 
advantages for aqueous-based systems.
144
  
Catalano and collaborators used pyridyl- and quinolyl-containing substituents on an NHC for 
the synthesis of Ag-Au, Ag-Cu and Cu-Au compounds.
145,55,56,58,146
 Some of these complexes 
showed luminescent properties promoted by metallophilic interactions.
56,58,146,147,145
 For example, 
complexes [VIIIa] reacted with copper(I) halides (X= Cl, Br, I) in dichloromethane to form 
luminescent gold(I)-NHC complexes containing Cu(I)–X dimers (Scheme 3-3).56 
 
Scheme 3-3. Synthesis of gold(I)–NHC complexes containing copper(I) halide butterfly dimers 
reported by Catalano et al. . 
The same group reported another particular study on the Cu-Au interactions (Scheme 3-4).
58
 
Interestingly, the complex [IXa], which displayed an intense blue-emission at 462 nm in the 
solid state, could react with MeOH vapors to afford the green-emissive species [IXb], which 
emitted at 520 nm. This process was completely reversible and consisted in the modulation of 
the Au···Cu separation depending on the solvent molecule coordinated to the copper centre.58 
 
Scheme 3-4 Vapochromic heterobimetallic complexes involving  pyridyl NHC-ligands 
reported by Catalano et al. . 
Chen achieved binding of two different metal centers (Pd-Cu and Pd-Ag) using an 
asymmetrical 3-(1,10-phenanthrolin-2-yl)-1-pyridin-2-ylmethyl)-imidazolylidene that will be 
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discussed in Chapter 5.
133
 Most targeted applications of these heterobimetallic complexes are 
material research and catalysis. Research on metal-metal interactions plays a marginal role.  
Moreover,  except the example by Raubenheimer et al. of the Au-Fe system discussed in  
Chapter 2, no example on the biological activity of NHC-heterobimetallic gold(I) containing 
complexes has been investigated.
132
  
 Presentation of the first project 3.2 
The objective of this first project was the preparation of luminescent Au-Ru heterobimetallic 
complexes with potential biomedical applications. The Figure 3-5 shows schematically our 
starting ideas of Ru-Au dinuclear systems, basically consisting in a Au(I) complex involving 
NHC ligands with functional side arms able to coordinate the Ru(II) metal center. 
 
Figure 3-5. Schematic illustration of three different  possible gold-ruthenium systems. 
Generally, we considered a nitrogen containing side arm as an ideal candidate for the 
complexation of transition metals as Ru(II). The choice of the NHC ligand is related to a 
previous work carried out within our group. Recently, Hemmert et al. have reported the synthesis 
and the biological investigation of a series of mono- and dinuclear gold(I) and mononuclear 
silver(I) complexes based on NHC ligands.
76
 Among these compounds, two mononuclear Au(I) 
complexes involving NHC ligands functionalized with quinoline and methylbipyridine ([Xa] and 
[Xb] in Figure 3-6) have aroused a particular interest because of their strong antimalarial 
activities (see paragraph 2.3). The presence of nitrogen containing heterocycles in the 
compounds seems to have a great influence on the antiplasmodial activity, probably related to 
the lipophilicity, the basicity and structural features of these compounds.
76
 Moreover, a methyl-
bpy side-arm could be an ideal ligand for the coordination of the ruthenium center and, by 
employing two additional bpy ligands, it is possible to obtain a luminescent Ru(II)(bpy)3 unit 
(known fluorophore). 
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Figure 3-6. NHC-Au(I) complexes reported by Hemmert et al. as antimalarial agents ([Xa] and 
[Xb] correspond to 25a and 25b in Figure 2-6). 
Connecting a gold(I)-NHC drug, by a methyl-bridge, to the ruthenium fluorophore we could 
form a multifunctional molecular system. 
The mono-NHC halogen coordinated system b) (see Figure 3-5) was chosen as final 
molecular model, because the Au-X bond, more labile and less sterically protected, could permit 
a faster reaction of the gold center with biological targets and the cationic character of the 
compounds is still preserved by the double charge present on the ruthenium metal center.  
The choice of the tris(bipyridine)ruthenium(II) unit, as side wing of the gold complex, allows 
to conceive multiple approaches employable, for example, in potential anticancer treatments (see 
Scheme 3-5):  
i) by exploiting the luminescence properties of the ruthenium unit, it could be possible 
to monitor the uptake and the intracellular position of our drug by confocal 
microscopy; this is a way to use the Au-Ru system as a bifunctional bimetallic 
compound for both therapeutic and imaging applications (so called theranostic 
agents);
148–152
  
ii) our drug-fluorophore system could be sensitive to the presence of the gold center;  for 
example the NHC-gold(I) bond cleavage, caused by reactions with biological targets, 
could change the photophysical properties of the compound leading to luminescence 
signal variations and giving, therefore, intracellular mechanistic insights;  
iii) the ruthenium based fluorophore, could also act as photodynamic therapy (PDT) 
agent; the ruthenium unit, after appropriate irradiation, could be light activated 
becoming itself or inducing the formation of reactive cytotoxic species able to kill 
cancer cells.
153
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These three approaches, described in Figure 3-5, are not mutually exclusive, potentially 
providing a really interesting synergic action of the two metal moieties. 
 
Scheme 3-5. Potential roles of the Ru(bpy)3 unit of our Ru-Au system in cancer treatment. 
Since many years Ru(bpy)3
2+
 is holding pride of place in the field of inorganic photochemistry 
and photophysics because of its known peculiarity.
154–158
 The cell uptake concerning the 
ruthenium(II) tris-bipyridine is relatively poor but, as reported by Puckett and Barton, by 
modifying and making the molecule more lipophilic it is possible to improve the membrane 
permeabilization properties.
159
 In our case, the presence of the carbene gold complex should 
increase the lipophilicity of the molecule allowing to the heterobimetallic compound to enter in 
cells and making the imaging by the Ru(bpy)3
2+
 unit possible. Ru(bpy)3
2+
 is also known to be 
able to sensitize the formation of singlet oxygen when irradiated in aerated aqueous solution 
because of its long-lived excited state as energy donor in energy transfer processes. 
 
The singlet oxygen is a reactive oxygen species (ROS) that can react with cellular proteins 
and lipids. Inducing the generation of cytotoxic levels of ROS, by light irradiation of the 
ruthenium complex, it could induce cancer cell death (Scheme 3-6).
160
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Scheme 3-6. Formation of singlet oxygen promoted by a general light-activated 
photosensitizer. 
 Synthesis and characterization of pro-ligands 3.3 
 Three methylbipyridyl substituted NHC pro-ligands having similar structures with three 
different functional groups: methyl (1), butyl (2) and benzyl (3): 
 
Figure 3-7. NHC pro-ligands functionalized with a methyl-bpy unit. 
The carbene precursors 1 to 3 were synthesized as described for 1 in the literature.
76
 Briefly, 
2-acetylpyridine and iodine were heated in pyridine to give the corresponding pyridinium salt, 
which was then reacted with metacrolein in formamide in the presence of ammonium acetate to 
afford 5-methyl-2,2’-bipyridine. The methyl group then converted to the corresponding 
bromomethyl by treatment with N-bromosuccinimide and azoisobutyronitrile. Finally, in the case 
of methyl- and butylimidazole an excess of imidazole was heated with 5-(bromomethyl)-2,2’-
bipyridine in toluene to obtain the wanted pro-ligands. In the case of benzyl only one equivalent 
of imidazole was used (see Scheme 3-8). 
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Scheme 3-7. Synthesis of pro-ligands 1 to 3. 
Compounds 1-3 (Scheme 3-7) have been characterized by 
1
H, 
13
C NMR spectroscopy, and 
high resolution mass spectrometry. The most notable features in the 
1
H and 
13
C spectra of the 
imidazolium salts are the resonances for imidazolium protons (H2) located between 9.37 and 
10.67 ppm and the corresponding imidazolium carbons (C2) in the range of 134.9-139.0 ppm. 
The high resolution mass spectra (HRMS) of the pro-ligands exhibit the classical peaks 
corresponding to [M-Br
-
]
+
 cations: for 2  m/z =  293.1770 and for 3 m/z =  327.1612. 
Furthermore, 2 and 3 have been crystallized from CH2Cl2/pentane and analyzed by X-ray 
diffraction. 
 Synthesis and characterization of complexes 3.4 
 Three imidazolium salts having Ru(bpy)3 as side arms are presented in this chapter as 
1Ru, 2Ru and 3Ru: 
 
Figure 3-8. Ruthenium complexes. 
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In order to obtain the heterobimetallic complexes, two synthetic strategies are possible: a) the 
formation of the carbene-gold unit followed by complexation of Ru(bpy)2 by the functionalized 
gold-NHC complex or b) the complexation of the ruthenium by the substituted imidazolium salt 
before, followed by transformation of the imidazolium into Au(I)-NHC unit (see Scheme 3-8). 
By taking into account that the gold-NHC can be formed under mild conditions via the silver 
transmetalation, the complexation of ruthenium demands relative drastic conditions (EtOH/H2O 
under reflux) and the gold-NHC is less stable than Ru(II)(bpy)3, we decided to start with the 
complexation of ruthenium (strategy b) in Scheme 3-8).  
 
Scheme 3-8. Two possible synthetic approaches to obtain the Au-NHC complex with Ru(bpy)3 
side-arm. 
The Ru(bpy)2Cl2 precursor has been synthesized as describe in the literature by Whitten et 
al.,
161
 reacting commercial RuCl3 and 2,2’-bipyridine at reflux in N,N-dimethylformamide for 
three hours. 1Ru and 3Ru (Figure 3-8) were formed by heating 1 and 3 (Figure 3-7), 
respectively, in EtOH/H2O followed by addition of Ru(bpy)2Cl2. The solutions were 
concentrated and an anion exchange with NH4PF6 led to orange precipitates. In the case of 2Ru 
the complex was obtained without anion exchange directly by partial evaporation of the solvents 
and precipitation at low temperature from acetonitrile. In the 
1
H NMR spectra the presence of all 
expected signals with correct integration ratios and in particular the imidazolium protons on the 
C2 atoms at δ = 8.90 ppm (1Ru), 10.14 ppm (2Ru) and 9.10 ppm (3Ru), respectively, indicate 
the formation of the desired complexes. This has been confirmed by the peaks corresponding to 
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[M-PF6] for 1Ru and 3Ru, and [M-Br-Cl] for 2Ru found by mass spectrometry. From HRMS 
measurements: m/z = 955.1023 for 1Ru, m/z (z = 2) = 353.1058 for 2Ru and m/z = 1117.0977 
for 3Ru. 
Three gold heterobimetallic Ru-Au complexes and the three related silver precursor 
complexes are presented in this chapter as 1RuAg, 2RuAg, 3RuAg, 1RuAu, 2RuAu and 
3RuAu: 
 
 
Figure 3-9. Heterobimetallic complexes (Ru-Ag and Ru-Au). 
The silver complexes 1RuAg and 3RuAg (Figure 3-9) could be obtained by adding one 
equivalent of Ag2O to a solution of the corresponding ruthenium complexes and KCl in 
acetonitrile. The lack of the proton-signal H2 in 
1
H NMR indicated the formation of the carbene 
complexes. All three gold complexes have been synthesized by classical transmetalation 
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reactions. In the case of 1RuAu and 3RuAu by 1:1 reactions between 1RuAg and 3RuAg, 
respectively, and Au(SMe2)Cl and for 2RuAu by in-situ reaction of 2Ru and Ag2O followed by 
addition of Au(SMe2)Cl. All these reactions have been carried out in acetonitrile. NMR 
spectroscopy unequivocally demonstrates the formation of the gold(I) complexes; the 
13
C spectra 
show the resonance for the carbenic carbon atoms at 172.3, 170.2 and 171.1 ppm, for 1RuAu, 
2RuAu and 3RuAu, respectively. These values are in the range of reported values for Au(I)-
NHC complexes having C-Au-X (X = halide) motifs.
46
  
The syntheses of the ruthenium complexes and the heterobimetallic Ru-Ag and Ru-Au 
complexes are summarized in Scheme 3-9.  
 
Scheme 3-9. Syntheses of the ruthenium complexes 1Ru to 3Ru, of the ruthenium-silver 
complexes 1RuAg and 3RuAg and of the ruthenium-gold complexes 1RuAu to 3RuAu. 
 Molecular structures 3.5 
The X-ray structures of two pro-ligands (2 and 3), two ruthenium complexes (1Ru and 3Ru) 
and a heterobimetallic compound (3RuAu) are reported in this section. 
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The n-butyl substituted pro-ligand 2 has been crystallized from a CH2Cl2/pentane solution, the 
colorless crystals have been analyzed by X-ray diffraction. The cationic part of the molecule is 
shown in Figure 3-10. 
 
Figure 3-10. Cationic part of the molecular structure of 2 depicted at a 50% level for the 
ellipsoids. 
Also the pro-ligand 3 was crystallized from a CH2Cl2/pentane solution. The cationic part of 
the molecule is shown in Figure 3-11. 
 
Figure 3-11. Cationic part of the molecular structure of 3 depicted at a 50% level for the 
ellipsoids. 
Both structures confirm the expected molecule showing the cycle of the aromatic imdazole N-
substituted by a methyl bipyridine on one side and by a butyl or a benzyl for 2 and 3 
respectively. 
Very small crystals of complex 1Ru could be obtained by slow evaporation of a methanol 
solution. The data are of low quality, but the analysis shows clearly the complexation of the 
ruthenium cation by three bpy units (Figure 3-12).  
The ruthenium cation is coordinated by three bpy units in a classical distorted octahedral 
geometry. The benzyl substituted complex 3Ru has been crystallized by slow vapor diffusion of 
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diethylether in a saturated solution of the compound in methanol. As in 1Ru the ruthenium atom 
is coordinated by three bpy units in a classical way (Figure 3-13). 
 
 
 
The gold complex 3RuAu was crystallized at low temperature from a concentrated 
acetonitrile solution. To the best of our knowledge, this structure (Figure 3-14) represents the 
first example of a Ru-Au complex involving an NHC ligand. Both coordination geometries are 
classical for each metal: an octahedral geometry for the ruthenium(II) coordinated by three bipy 
units and a nearly linear coordination of the gold(I) by one NHC and one chlorine anion.   
The gold-carbene (1.975(6) Å) and the gold-chlorine (2.272(2) Å) distances are in good 
agreement with values (Au-C between 1.91 and 2.07 Å; Au-Cl between 2.26 and 2.33 Å) found 
for such compounds in the CCDC (Cambridge Crystallographic Data Center) data base. Both 
Figure 3-12. Cationic part of the molecular 
structure of 1Ru depicted at a 30% level 
for the ellipsoids. Hydrogen atoms and 
disordered anions are omitted for clarity. 
Selected bond lengths (Å) and angles (°): 
Ru-N between 2.04 and 2.07, N-Ru-N 
between 78 and 96. 
Figure 3-13. Cationic part of the 
molecular structure of 3Ru depicted 
at a 30% level for the ellipsoids. 
Hydrogen atoms, anions and 
disordered non-coordinating solvent 
molecules are omitted for clarity. 
Selected bond lengths (Å) and angles 
(°): Ru-N between 2.05 and 2.07, N-
Ru-N between 78 and 97. 
 
  
 
58 .......................  NHC-Au(I)  complexes containing a Ru(bpy)3-side arm | 
 
 Synthesis of N-Heterocyclic Carbene Gold(I) Complexes: Towards the Development of new Organometallic Drugs 
parts of the complex, the NHC-Au-Cl unit and the Ru(bipy)3 unit seem to be independent and 
isolated from an electronical point of view.  
 
 
Figure 3-14. Cationic part of the molecular structure of 3RuAu depicted at a 50% level for the 
ellipsoids. Hydrogen atoms and anions are omitted for clarity. Selected bond lengths (Å) and 
angles (°): Ru-N between 2.05 and 2.07, C-Au 1.975(6), Au-Cl 2.282(2), C-Au-Cl 176.1(2), N-
Ru-N between 78 and 97. 
 Photophysical studies 3.6 
All complexes, except silver compounds, have been photophysically investigated at standard 
pressure and room temperature, in solution and in the solid state.  
By changing the substituent (methyl, n-butyl and benzyl) the energy involved in the electronic 
transitions didn’t show significant differences. Figure 3-15 illustrates the photophysical 
characterization in water solution of the complex 2RuAu and the corresponding precursor 2Ru. 
The absorption spectra of the ruthenium complex 2Ru (green curve) and the heterobimetallic 
Ru-Au complex 2RuAu (red curve) exhibit the characteristic bands found in the complex 
Ru(bpy)3 (black curve).  
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Figure 3-15. Absorption and emission spectra of 2Ru (green curve), 2RuAu (red curve) and 
Ru(bpy)3 (black curve). In the onglet the excitation spectra of 2Ru (green curve), 2RuAu (red 
curve). 
The intense band at ≈ 285 nm encompasses the ligand-centered (LC) π→π* transitions, and 
the others two intense bands at ≈ 240 and 450 nm are attributed to metal-to-ligand charge 
transfer (MLCT) d→π* transitions. The shoulders at ≈ 322 and 344 have been assigned metal 
centered transitions (MC) (Figure 3-15).
155
 The emission spectra of complexes display broad and 
structureless emission bands centered around 625 nm that is attributed to 
3
MLCT transitions.
155
 
Figure 3-16. Simplified general molecular orbital diagram for Ru polypyridine complexes in 
octahedral symmetry of Ru(bpy)3 showing the three types of electronic transitions occurring 
at low energies. 
Also if the electronic transitions involved are the same, it is possible to observe some 
differences in the spectra related to 2RuAu and 2Ru. The absorption spectrum of 2RuAu seems 
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to have a slightly more intense MLCT at ≈ 240 nm with respect to 2Ru and Ru(bpy)3. This 
could be due to the light absorption of the Au-NHC unit (absorbance maxima at ca. 250−260 nm 
bands.
65
 Exciting 2RuAu and 2Ru at 450 nm (isoabsorption point) we have obtained a more 
intense emission band for 2RuAu (centered at 615 nm) and a less intense emission for 2Ru 
(centered at 630 nm). The presence of the gold center probably promote a more stable 
arrangement that can avoid the partial quenching observed for the 2Ru phosphorescence. The 
quantum yield, calculated respect to the standard Ru(bpy)3 in water, indeed, showed (Figure 4-
24) that for the ruthenium complex 2Ru (green curve) the luminescence is quenched of about 
33% compared to the complex 2RuAu. The excitation spectra obtained by fixing the emission 
wavelength at 615 nm for 2RuAu and 630 nm for 2Ru are both characterized by a very similar 
profile to the absorption spectra which allow to confirm that these molecules follow the paths of 
deactivation known for Ru(bpy)3. Furthermore, from the characterization in acetonitrile (not 
showed), it is possible to observe significant decreasing of the quantum yields of complexes 
2RuAu and 2Ru respect to those found in water, however in acetonitrile there is no significant 
differences between the quantum yield of 2RuAu and 2Ru (see Table 3-1). These results 
confirm that the quenching observed in water solution should be due to different rearrangements 
of the external coordination sphere. 
 
 
Figure 3-17 Excited-state decay curves measured in water solution at RT for 2RuAu (red 
curve) and 2Ru (black curve) by using single photon counting technique; emission 
wavelength at 615 nm for 2RuAu and 630 nm for 2Ru; excitation wavelength 450 nm. 
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The 
3
MLCT* excited-state decay curves measured for 2RuAu and 2Ru are presented in 
Figure 3-17. The lifetime measured (single photon counting technique) in water solution for the 
complex 2RuAu is 33% longer than the one measured for 2Ru, in agreement with the quantum 
yield difference found.  
The summary of the data obtained by the photophysical characterization of compounds in 
solution are reported in Table 3-1. 
 
Table 3-1. Summary of the photophysical data obtained by the characterization in solution of 
ruthenium compounds. 
 Biological studies 3.7 
 All compounds except silver complexes presented herein have been tested in vitro against 
Plasmodium falciparum FcB1-Colombia strain, Leishmania infantum promastigotes and Hep3B 
cell lines (human hepatocarcinoma).  
3.7.1 Antimalaria investigation 
Whereas the Au(NHC)2 complexes corresponding to 1 (complex [Xb] in Figure 3-6 and 
previously introduced in paragraph 2.3 and reported in Figure 2-6) showed interesting 
antimalarial activities, we decided to investigate the activities of this new family of 
heterobimetallic compounds. The antiplasmodial screening was performed inside the group by 
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Dr. Françoise Benoit Vical. Compounds were tested in vitro against the CQ-resistant 
Plasmodium falciparum strain FcB1-Colombia (IC50 of CQ = 0.2 μM). The results of the 
preliminary antiplasmodial tests are presented in the Table 3-2. 
 
Table 3-2. IC50 values against the P. falciparum strain FcB1-Colombia. 
Observing the experimental data, it is interesting to note that the pro-ligand 2 shows modest 
antiplasmodial activities and that the addition of the Ru(bpy)2 moiety seems to deactivate the 
molecule. Furthermore, the transformation of the imidazolium salt in Au-NHC unit reactivates 
the complexes 1RuAu (IC50 = 25.5 µM), 3RuAu  (IC50 = 16.1 µM) and 3RuAu (IC50 = 15.8 
µM). The activity is moderate compared to the reference CQ and to the cationic Au(NHC)2 
complex with NHC corresponding to the derivative of 1 (IC50 = 0.33 µM against the P. 
falciparum strain FcM29).
76
 Thereafter the loss of activity seems to be due to the presence of the 
Ru(bpy)3 unit maybe because of steric hindrance of the bulky Ru(bpy)3 unit, but further 
investigations are necessary to understand this phenomenon. 
3.7.2 Antileishmaniasis investigation 
In collaboration with Prof. Alexis Valentin and Dr. Lucie Paloque from the Laboratoire de 
Pharmacochimie et Pharmacologie pour le Développement (PHARMA-DEV), our compounds 
were screened in vitro against another parasite named Leishmania infantum luciferase.  
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Amphotericin B was chosen as antileishmanial reference-drug, because it is the drug of choice 
for visceral leishmaniasis acquired in India. The results of the preliminary antileishmaniasis tests 
are presented in the Table 3-3.  
 
Table 3-3. IC50 values against L. infantum luciferase promastigotes. 
The tested compounds showed no significant antileishmanial activity. The pro-ligands (1 to 
3), the ruthenium complexes (1Ru to 3Ru) and the complexes 1RuAu and 3RuAu exhibit IC50 
values higher than 50 μM against L. infantum promastigotes. 2RuAu showed similar behavior 
with IC50 = 25 to 50 μM. 
3.7.3  Anticancer investigation 
In order to evaluate the biological activities of our compounds against non-parasitic disease 
we decided to investigate the cytotoxicity of this family of complexes. The investigation on the 
potential anticancer properties of these compounds was performed in collaboration with Dr. 
Maëlle Carraz from the Laboratoire de Pharmacochimie et Pharmacologie pour le 
Développement (PHARMA-DEV), Toulouse.  All compounds were tested for their activity in 
vitro against the human black hepatocyte carcinoma (Hep3B) at 48 h using decreasing 
concentrations. Liver cancer is the fifth most common cancer in men, and the seventh in women, 
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with a very high mortality rate. Amongst the different models of liver cancer cell lines that can 
be used for cytotoxicity evaluation, we retained Hep3B cells as a first choice. Hep3B 
hepatocarcinoma cells are a human HCC cell line containing single copy HBV DNA sequences 
and expressing the viral protein HBx responsible for the enhancement of various virulence 
factors.
162,163
 These cells are susceptible to epithelial-mesenchymal transition (EMT) and induce 
metastasis.
164,165
 Moreover, Hep3B cells are rather chemoresistant to classical antitumor 
therapies such as doxorubicin and cisplatin, making them a model of choice for pharmacological 
studies.
166,167
 
At the best of our knowledge, no example of NHC-gold activity against Hep3B has been still 
reported in literature before to test NHC-gold activity. The results are presented in the Table 3-4. 
 
 
Table 3-4. IC50 values against Hep3B cell line. 
The tested pro-ligands 1 to 3 did not show significant activity with IC50 values higher than 
100 μM. Also the ruthenium complexes private of the gold center (1Ru to 3Ru), were ineffective 
against Hep3B cell line with IC50 values higher than 100 μM. Finally, the bimetallic gold 
containing complexes (1RuAu to 3RuAu) showed interesting antiproliferative effects against 
Hep3B. The cationic Au(NHC)2 complex [Xb] (Figure 3-6) was also tested against Hep3B cells 
showing very similar inhibitory effects of the correspondent mono-NHC heterobimetallic 
complex 1RuAu. Therefore, in this case the ruthenium moiety probably did not influence the 
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antiproliferative effects of the gold center. The 2RuAu complex is the most efficient compound 
(IC50 = 17.1 μM) and 3RuAu exhibited similar activity (IC50 = 18.9 μM), more or less in the 
same range of activity with respect to Sorafenib, the commercial drug currently used in liver 
cancer therapy (IC50 ≈ 7.6 μM).
168
 
Exploiting the luminescence properties of the complexes, we decided to monitor the cellular 
uptake and the intracellular distribution of our molecules by using confocal microscopy. This 
work has been done in collaboration with Dr. Serge Mazères of the Institute de Pharmacologie et 
de Biologie Structurale (IPBS), Toulouse. For the preliminary tests, the most active complex 
2RuAu and the corresponding precursor 2Ru have been selected. It is particularly important to 
understand the subcellular distribution of the bimetallic complexes in order to gain further 
mechanistic insights. Thus, the fluorescence properties of the complexes 2RuAu (λmax = 615 nm) 
and 2Ru (λmax = 630 nm) were investigated in aqueous solution; the absorption and emission 
spectra showed similar patterns but with some small differences that can be exploited in confocal 
fluorescence microscopy. Accordingly, we were able to visualize 2RuAu and 2Ru compounds 
directly in the cells. In detail, cells (Hep-3B) were grown onto a coverslip, were treated with 
2RuAu and 2Ru (luminescent compounds) and the fluorescence of the complexes was evaluated 
using a Zeiss LSM 710 NLO-Meta Confocal microscope. The luminescence of the compounds in 
cells was measured at different times after treatment: T0, T24h, T48h and T72h.  Figure 3-18 shows 
representative images of the cells treated with 10 μM solution of complexes 2RuAu and 2Ru. 
The imaging shows that both complexes enter in cells in few minutes and it is possible to 
observe a large intermembrane distribution due to permeabilization processes. This means that 
there is no problem due to the steric hindrance provokated by the presence of the Ru(bpy)3 unit, 
that alone can present cell uptake problems.
169
  
At T24h the complexes were well localized in specific regions of cells. The complexes 
preferentially accumulated in analogues regions also at T48h and T72h. The distribution of the 
compounds in cells does not change from T24h to T72h and both complexes do not appear to be 
accumulated at the nuclear level, but rather in cytoplasm. These results are in agreement with 
similar examples previously reported by Berners-Price et al. for a dinuclear NHC-gold(I) 
complex and by Mao et al. for a NHC-gold(I) with an anthracene moiety.
129,130
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Figure 3-18.  
Visualization of 
2RuAu (red) and 
2Ru (blue) 
compounds in 
Hep3B cells, using 
confocal microscopy 
in fluorescence 
(column a), in 
transmission 
(column b) and the 
overlap of (a) and 
(b) (column c). 
(a) (b) (c) 
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So, we decided to use a MitoTracker (green) as mitochondrial marker to better understand the 
localization of 2RuAu. 
 
The imaging shows that our complex appeared to be accumulated outside of the mitochondria, 
distributed principally in the cytoplasm, as shown in Figure 3-19. This suggests that neither 
DNA nor mitochondria represents the main target of our molecule. 
Apart from a few exceptions, unlike the known platinum(II) anticancer drugs, DNA is not 
expected to be a target for gold(I)-NHC complexes, but they most likely interact with TrxR 
largely present in the cytoplasmic matrix. 
Furthermore, the difference between the maxima in the emission bands registered for 2RuAu 
(λ = 620 nm) and 2Ru (λ = 640 nm) in culture medium permitted to obtain some interesting 
information about the chemical mutation of the complex 2RuAu in cells at different times. A 
sort of qualitative kinetic study has been realized following the evolution of the emission spectra 
of 2RuAu registered at T0, T24h, T48h and T72h. At T0 we clearly identify a single emission curve 
with a maximum centered at λ = 620 nm. Between T0 and T72h, the emission spectra changed and 
at the end it presents a red-shifted wider band, corresponding probably to a conversion of a part 
of 2RuAu to 2Ru. This conversion correlates with the increment of the antiproliferative effects 
from 24 h to 72 h and consequently with the fact that gold(I) is the major responsible of the 
biological activity against cancer cells (Hep3B in our case). This study also represents a new 
way to observe the chemical evolution of the complex during its biological activity. 
Figure 3-19. Visualization of the 
complex 2RuAu in an isolated 
Hep3B cell using confocal 
microscopy. Boxes: (a) MitoTracker 
green (mitochondria marker 
localization); (b) luminescence of 
the compound;  (c) merge, (d) 
transmission mode. 
(a) (b) 
(c) (d) 
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 Conclusion for NHC-Au(I) complexes containing a 3.8 
Ru(bpy)3-side arm  
In this work we prepared and fully characterized a set of three new luminescent 
heterobimetallic compounds involving NHC-Au(I) complexes with Ru(bpy)3 unit as side arms. 
These compounds have been tested in vitro against Hep3B cell lines (human hepatocarcinoma), 
Leishmania infantum promastigotes and Plasmodium falciparum FcB1-Colombia strain, showing 
antiproliferative effects against Hep3B and moderate activities against P. falciparum. No 
significant activity was observed against L. infantum. Moreover, taking advantage of the 
luminescence properties of the complexes, preliminary studies about the behavior of 2RuAu 
(most active complex) in Hep3B cancer cells were performed by using fluorescence confocal 
microscopy.  
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 NHC complexes containing amine-4.
side arms  
 Introduction 4.1 
In this chapter, the synthesis and the characterization of a family of NHC-gold complexes 
containing amino side arms and the related biological properties will be discussed.  
In the literature, many amino functionalized NHC-gold complexes have been reported, but the 
most of them are mainly related to aromatic or cyclic amines. Catalano and co-workers 
synthetized several complexes based on quinoline and methylbipyridine substituted N-
heterocyclic carbene ligands.
170,60,56,145
 Recently, our group reported the synthesis and the 
biological investigation of a series of gold(I) complexes based on quinoline and bipyridine 
substituted ligands [Xa] and [Xb].
76
 Nevertheless, only few works concerning NHCs complexes 
involving aliphatic amino side-arms can be found in the literature. Monkowius et al. synthesized 
a neutral Au(III)-NHC complex involving an aliphatic amino wing-tip.
171
 
 
Scheme 4-1. NHC-gold complexes reported by Monkowious et al.. 
The NHC-Au(I)Cl complexes ([XIa] and [XIb] in Figure 4-1) have been obtained via the 
transmetalation strategy, by adding [(Me2S)AuCl] to the NHC-Ag precursors. These complexes 
were found to be unstable under ambient conditions, and therefore, the reported characterization 
is not exhaustive. The corresponding Au(III) complexes were obtained by oxidation with Br2 (see 
Scheme 4-1a). The highly basic amine group gives rise to a protonation/deprotonation reaction 
leading to an equilibrium between a square-planar and a square-pyramidal coordination 
environment around the gold atom (Scheme 4-1a).
171
 
Li and collaborators reported a gold(I) complex bearing an amino linked NHC ([XIII] in 
Scheme 4-2) which showed an antiproliferative activity in the human U-87 cancer cells 
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(glioblastoma) and was found to involve the S-phase arrest of the cell cycle (for more details see 
Figure 2-19).
115
 
 
Scheme 4-2. NHC-gold complexes reported by Li et al. and by Cassani et al.. 
Finally, a recent publication by Cassani et al. displayed an example of homoleptic dinuclear 
gold(I) complexes containing a primary amino-functionalized ligand as support for Au(I)···Au(I) 
interactions ([XVb] in Scheme 4-2).
50
 Even in this example, they started forming the silver 
complex, but in this case Ag2CO3 was used instead of the classic Ag2O because it could afford a 
cleaner single product. Subsequently, the transmetalation with a gold precursor allowed to obtain 
the dinuclear gold complex. The X-ray studies showed that pairs of gold(I) centers are linked by 
a pair of bridging ligands with a Au···Au aurophilic contact of 3.233 Å. The complex is 
photoluminescent in solution at room temperature with an emission peak centered at 410 nm 
(λexc = 260 nm) not clearly assigned. However, the aurophilic interaction of the complex seems 
to be responsible of another emission band with a maximum at 367 nm, obtained by excitation of 
the complex at longer wavelengths (at 297 nm and 330 nm).
50
 The same group had previously 
reported the synthesis of t-butyloxylcarbonyl (Boc)-protected and thermally deprotected amino-
functionalized imidazolium cations [NH(R)CH2CH2imMe]I (R = Boc, H; im = imidazole) used 
to form Ag(I)–NHC complexes (not shown).172 
 1-[2-(Diethylamino)ethyl]imidazolydene gold 4.2 
complexes  
As previously discussed, our group recently reported the antifungal and antimalarial screening 
of silver(I), gold(I) and gold(III) mono and dinuclear complexes involving different NHC 
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ligands. The biological results showed a great importance of the presence of NHC ligands with 
N-containing heterocylic side arms (see [Xa] and [Xb] in Figure 3-6) maybe related to the 
lipophilicity or the basicity of compounds.
76
 After these studies, we decided to use heteroditopic 
NHC ligands involving a more flexible aliphatic amino-side arm and to modulate the 
lipophilicity of the compounds by changing the second NHC substituent. Moreover the amino 
wingtip is potentially able to coordinate to other metals next to the gold center. Five 1-[2-
(diethylamino)ethyl]imidazolydene pro-ligands having similar structure and containing five 
different groups (methyl, butyl, mesityl, benzyl and iso-propyl) have been synthesized and 
characterized. 
 
Figure 4-1. NHC pro-ligands 4 to 8. 
Starting from these pro-ligands a series of seven bis-NHC gold complexes, have been 
synthesized and characterized: 
 
Figure 4-2. NHC gold complexes used in this study. 
 Synthesis and characterization 4.3 
The imidazolium salts 4-8 (Figure 4-1) were readily obtained by reaction of 2-bromo-N,N-
diethylethylamine hydrobromide with alkyl- (methyl, butyl or iso-propyl) or arylimidazoles 
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(mesityl or benzyl) in acetonitrile solution under reflux conditions, as hygroscopic white solids 
with high yields (76 - 98%, see Scheme 4-3b).  
In the specific case of pro-ligand 7 the precursor 1-mesityl-1H-imidazole has been 
synthesized by reacting the trimethylphenyl amine with ammonium acetate, glyoxal and 
formaldehyde according to the literature procedure (Scheme 4-3 a)).
173
 
 
 
Scheme 4-3. a) Synthesis of mesitylimidazole precursor; b) Synthesis of the imidazolium  
salts 4-8 (pro-ligands). 
The compounds here reported have been characterized by 
1
H, 
13
C NMR spectroscopy, high 
resolution mass spectrometry and elemental analysis. The main characteristics of the 
imidazolium salts 4-8 in the NMR spectra are the resonances for the imidazolium protons located 
between 9.29 and 9.52 ppm in the 
1
H NMR and the corresponding imidazolium carbons in the 
range of 137.6-138.1 ppm in 
13
C NMR. The resonance of the hydrobromide protons are 
comprised between 9.69 and 11.34 ppm. The HRMS of the pro-ligands exhibit the classical peak 
corresponding to [M – Br – HBr] cations: m/z = 182.1650 for 4, m/z = 182.1650 for 5, m/z = 
224.2129 for 6, m/z = 258.1969 for 7 and m/z = 286.2287 for 8. For the preparation of gold(I) 
complexes we have chosen the convenient transmetalation strategy. Firstly, the silver carbene 
complexes were prepared by deprotonation of the imidazolium salts 4-8, with the mild base 
Ag2O in a suitable dry solvent (dichloromethane or methanol) at room temperature. As reported 
in the literature, in such kind of reactions, the presence of halogen anions can give rise to the 
problem of the formation of AgX2 anions or Ag2X2 clusters.
171,172
 These kind of anions can show 
intermolecular interaction with the NHC-Ag complexes which formation is favored in the solid 
state: a recent study explain that the competition between the neutral form (NHC)AgCl and the 
ionic form [(NHC)2Ag]
+
[AgX2]
-
 is caused by ligand scrambling reactions and determined by the 
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polarity of the solvent.
174
  Because of this, it could be sometimes difficult to identify the 
presence of such anions or clusters in solution. In order to avoid this problem, an ion exchange 
with AgNO3 was performed. Aliquots of the reaction mixtures were taken to control by 
1
H NMR 
the advancement of the reaction. However, the silver(I) transient species were not isolated, due 
to their limited stability both in solution and in the solid state. The carbene transfer reactions 
were thus carried out in situ, by adding one half equivalent of Au(SMe2)Cl, with respect to the 
ligand, either directly to the CH2Cl2/CH3CN medium or dissolved in acetonitrile (when the silver 
reaction was performed in MeOH).  
 
Scheme 4-4. Synthesis of the gold(I) carbene complexes 4Au to 7Au.  
Gold(I) complexes 4Au-7Au were isolated as white powders with good yields (44-96%); all 
the synthesized complexes are highly stable toward air and moisture and soluble in CH3CN, 
MeOH, H2O and DMSO, only 7 showed an evolution after several days in solution. A different 
kind of product was obtained by the complexation reaction of the pro-ligand 8 which was found 
to be a dinuclear gold complex obtained by crystallization witch is not very stable in solution. 
1
H 
NMR spectroscopy unequivocally demonstrated the formation of the gold(I) complexes with the 
absence of the proton resonance of the acidic imidazolium.  
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By way of example, two 
1
H NMR spectra (both recorded in CD3CN), one related to the ligand 
precursor 7 (blue spectum) and one related to the gold complex 7Au (red spectrum), are reported 
in Figure 4-3. 
 
Figure 4-3. 1H NMR spectra of 7 (blue spectum) and 7Au (red spectrum) registered in CD3CN. 
The part of the spectra below 2.5 ppm have been omitted for clarity. H2 proton assignation is 
reported in red. 
From the comparison between the spectra, the good success of the reaction can be easily 
proved. The characteristic signal related to the H2 proton of the imidazolium salt, in fact, is 
absent in the complex spectrum accompanied by a significant shift of the other peaks is 
noticeable (Figure 4-3). These experimental evidences have been observed also for all the other 
compounds. In all cases the integration perfectly fits with the number of protons of the analyzed 
molecules and the clear band structure allowed the assignation of all signals. 
The 
13
C spectra show the resonance for the carbenic carbon atoms at 184.0, 182.8, 183.8, 
183.9 and 182.4 ppm, for 4Au, 5Au, 6Au, 7Au and 8AuAu, respectively. These values are in 
the range of reported values for Au(I)-NHC complexes having C-Au-X (X = halide) or C-Au-C 
motifs.
46
 The HRMS exhibit the classical peaks corresponding to the cationic fragment [M – 
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NO3
-
]
+
 for 4Au (m/z = 559.2827), 5Au (m/z = 643.3768), 6Au (m/z = 711.3461), 7Au (m/z = 
767.4095). 
 Molecular structures 4.4 
The X-ray structures of two key compounds are reported in this section. Crystals of 
compound 4Au, suitable for an X-ray structure analysis, could be obtained by vapor phase 
addition of diethyl-ether to a concentrate acetonitrile solution of the compound. The cationic part 
of the molecule is shown in Figure 4-4.  
 
Figure 4-4. Cationic part of the crystal structure of 4Au. Thermal ellipsoids are depicted at 
50% level. Hydrogen atoms have been omitted for clarity. Selected bond lengths (Å) and 
angles (°): Au1-C1 2.024(3), Au1-C11 2.022(3), C1-Au1-C11 178.8(2). 
Compound 7Au was crystallized by slow evaporation of a concentrated acetonitrile solution. 
The cationic part of the molecule is shown in Figure 4-5. Both structures confirm the presence of 
bis-NHC gold(I) complexes and in both cases the gold atoms are coordinated by two carbenes in 
a classical linear manner with C-Au-C angles of 178.8° (for 4Au) and 174.6° (for 7Au). These 
values are in the range of 170° to 180° found for such compounds in the CCDC (Cambridge 
Crystallographic Data Center) data base. The gold carbon distances are also in good agreement 
with values found for such compounds (CCDC: 1.93 to 2.10 Å). 
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Figure 4-5. Cationic part of the crystal structure of 7Au. Thermal ellipsoids are depicted at 
50% level. Hydrogen atoms have been omitted for clarity. Selected bond lengths (Å) and 
angles (°): Au1-C1 2.012(10), Au1-C19 2.037(10), C1-Au1-C19 174.6(5). 
In 4Au, the two NHC ring systems are nearly in the same plane with an angle of about 2° 
between the two planes, while in 7Au a small distortion of about 28° could be observed, 
probably due to sterical hindrance of the bulky mesityl groups. It is notable that in both 
compounds the amine side arms are on the same side of the planes formed by the NHC-Au-NHC 
units.  
Crystals of compound 8AuAu, suitable for an X-ray structure analysis, could be obtained by 
slow evaporation of an acetonitrile solution of the compound. The cationic part of the molecule 
is shown in Figure 4-6. The structure analysis revealed the presence of two gold(I) atoms in the 
molecule. In this case each gold atom is coordinated on one side to the carbenic carbon of one 
NHC ligand and on the other side to the terminal amino group of the second ligand, with bond 
lengths of 1.983(9) and 2.110(7) Å respectively. The C-Au-N angle is 176.6(3)
◦
, confirming the 
expected linear coordination for the Au(I) atoms. These values are in the range of 170° to 180° 
found for such compounds in literature and in the CCDC (Cambridge Crystallographic Data 
Center) data base.
175–177
 The gold carbon distances are also in good agreement with literature 
values for such compounds (CCDC: 1.93 to 2.10 Å); The Au(I) atoms of the dimeric complex 
are separated by a distance of 4.618 Å, too long to have an aurophilic interaction, that generally 
need Au-Au distances around 3 Å.
49
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Figure 4-6. Cationic part of the crystal structure of 8AuAu. Thermal ellipsoids are depicted at 
50% level. Hydrogen atoms have been omitted for clarity. Selected bond lengths (Å) and 
angles (°): Au-C 1.983(9), Au-N 2.110(7), C-Au-N 176.6(3). 
Concerning the benzyl-substituted gold complex 6Au, all attempts to crystallize the 
compound failed, giving rise to decomposition in solution after 4-5 days. However, the 
decomposition product crystallized by slow evaporation of 6Au an acetonitrile solution gave the 
complex 6AuAu. The cationic part of the molecule is shown in Figure 4-7. 
 
Figure 4-7. Cationic part of the crystal structure of 6AuAu. Thermal ellipsoids are depicted at 
50% level. Hydrogen atoms have been omitted for clarity. Selected bond lengths (Å) and 
angles (°): Au1-C1 1.987(2), Au1-N(3) 2.114(2), C1-Au1-N3 177.91(9). 
The crystal structure of 6AuAu reported in Figure 4-7 consists of a dimeric Au(I) complex as 
seen for 8AuAu with a bond length of 1.987(2) for Au-C and 2.114(2) for Au-N.  The C-Au-N 
angle is 177.91(9)
◦
. These values are in agreement with those found for the compound 8AuAu 
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and with literature values reported for such compounds.
50
 The Au(I) atoms distance is about 
4.778 Å, showing absence of aurophilic interaction also in this case. 
 Photophysical studies 4.5 
Fundamental photophysical studies of these gold compounds have been performed. 4Au and 
7Au complexes have been photophysically investigated in water solution at standard pressure 
and room temperature. The spectrum reported in Figure 4-8 is referred to the characterization of 
the most simple methyl substituted complex 4Au. 
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Figure 4-8. Absorption spectrum of 4Au registered in water at RT. 
The absorption spectrum is characterized by a broad structured absorption band with in the 
200-260 nm range characteristic for such kind of complexes.
17,51,65,178
 The same profile was 
observed for all complexes with two maxima centered around 238 and 255 nm, respectively. 
This high energy band is quite characteristic for gold-NHC complexes and can be considered as 
one vibronic-structured band usually assigned to a metal-perturbed π-π* LC (ligand centered) 
transition.
17,51,178
 However, Messori et al. accredited the absorption of structurally simple (1-
butyl-3-methyl- imidazole-2-ylidene) gold(I) and bis(1-butyl-3-methyl-imidazole-2-ylidene) 
gold(I), with absorbance maxima at ca. 250−260 nm, to a metal-to-ligand charge-transfer 
(MLCT) transition.
65
 As gold(I) has a d
10
 configuration, ligand-to-metal charge-transfer (LMCT) 
transitions and ligand-field (LF) d-d transitions are absent because it is a closed shell metal (MC 
(metal-centered) 3d4s and 3d4p transitions occur only at very high energies).65,179,180 Vogler 
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et al. reported in 2003 that since carbenes are generally stabilized by metals in low oxidation 
states, the M-carbene moiety is characterized by metal-to-ligand charge transfer (MLCT) 
transitions at relatively low energies, but the situation may be quite different for the MNHC 
interaction. NHC ligands are only weak π-acceptor ligands and so, (MNHC) MLCT transitions 
are expected to occur at rather high energies.
6,179
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Figure 4-9. Emission spectrum (red curve, λexc = 260 nm) and excitation spectrum (black 
curve, λem = 410 nm) of 4Au in water at RT. 
The excitation of the dissolved compound 4Au at both absorption maxima generates a 
structureless emission band centered at ca. 410 nm (Figure 4-9); the excitation spectrum (Figure 
4-9) obtained by fixing the emission wavelength at 410 nm is characterized by a band that is very 
similar to the absorption spectra which allows to support that these molecules follow the 
“normal” paths of deactivation according to the Kasha rules.181,182 The rule states that photon 
emission (fluorescence or phosphorescence) occurs in appreciable yield only from the lowest 
excited state of a given multiplicity.
181,182
 However, the calculated quantum yield is relatively 
low, between 1% and 0.5%. Similar results have been reported by Cassani et al. using an amino-
functionalised NHC ligand to prepare a luminescent dinuclear gold(I) complex containing 
aurophilic interactions (see [VIIIb] in Scheme 2-2). The emission spectrum of that complex 
exhibited a featureless band at 410 nm upon irradiation at both the absorption wavelength (236 
nm) and the excitation band (260 nm) in solution.
17,50
 The ligand precursor (similar to 4) is 
characterized by an absorption band centered at ca. 208 nm, and a weak emission band at ca. 316 
nm, blue shifted with respect to the related complex spectra.
50
 So, for complex 4Au, the 
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observed absorption and the emission bands, straightforwardly are probably attributable to LC 
transitions perturbed and red-shifted by the presence of the gold center. 
The dinuclear complexes 6AuAu and 8AuAu were also investigated, showing in acetonitrile 
solution, the photophysical properties than those of the mononuclear complexes. The emission 
spectra do not display any further band attributable to aurophilic effects, confirming the absence 
of significant Au···Au interaction already observed in the crystal structures.50,51,178 
 Biological Studies  4.6 
All compounds presented herein, except dinuclear complexes, have been tested in vitro to 
evaluate their potential anticancer, antileishmaniasis and antimalarial activities. Complexes 
6AuAu and 8AuAu have not been biologically investigated because of their unstable behavior in 
solution. 
4.6.1  Anticancer investigation 
For a first screening, the amino-functionalized imidazolium salts 4 to 7 and the corresponding 
gold(I) complexes 4Au to 7Au were tested for their cytotoxicity in vitro on PC-3 prostate cancer 
cells using decreasing concentrations  (5 µM, 1.0 µM, 500 nM, 250 nM and 100 nM). PC-3 cells 
were seeded (30,000 cells/well) on a 12-well tissue culture plate and allowed to attach overnight. 
Then, cells were treated with our experimental drugs and incubated for different periods of time 
(24 h, 48 h and 72 h). Drug-free solvent controls were also included (not showed) to verify the 
absence of unusual cellular behavior. The values reported in Figure 4-10 represent the mean of at 
least three independent experiments. 
The viability of cells was determined using the colorimetric mitochondrial function-based 
MTT viability assay, as originally described by Mosmann and mofied by Cuvillier et al..
183
 PC-3 
cells were differently sensitive to the different complexes. For the gold complexes 4Au to 7Au, 
cytotoxic activity increases from methyl- to mesityl-substituted systems. As shown in Figure 4-
11, the most active complex is clearly the mesityl-substituted one (7Au). 
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Figure 4-10.  Cell viability of PC-3 at 24 h, 48 h, and 72 h after treatment using concentrations 
of 5 µM, 1.0 µM, 500 nM, 250 nM and 100 nM of gold complexes  4Au, 5Au, 6Au and 7Au. 
 
Figure 4-11. Cell viability of PC-3 at 72h using concentrations of 1.0 µM of gold complexes 4Au 
to 7Au and of pro-ligand 7. 
Furthermore, the ligand precursor (7) of 7Au does not show significant anti-proliferative 
activities, reflecting the key role of the gold cation in the growth inhibition of cancer cells. In 
order to get information about the structure-activity relation, lipophilicity of the gold complexes 
has been determined as follow: solutions of the four compounds (50 μM) were dissolved in water 
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(previously saturated with n-octanol) and aliquots (1 mL) of each of these solutions were then 
added to an equal volume of n-octanol (previously saturated with water); the resultant biphasic 
solutions were mixed for 1 h and then centrifuged; the concentrations of complexes in the 
organic and aqueous phases were then determined using UV absorbance spectroscopy (≈ 260 
nm). Log P was defined as the logarithm of the ratio of the concentrations of the complex in the 
organic and aqueous phases (Log P = Log {[Au(org)]/[Au(aq)]). The obtained results are 
reported in Table 4-1. 
 
Table 4-1. Lipophilicity values for complexes 4Au to 7Au expresses as Log P. 
 
Figure 4-12. Correlation of activity/lipophilicity. The cytotoxic activities of compounds 4Au to 
7Au is defined as “(1 – viability)/100”. 
The Log P values (-0.83 ± 0.07 for 4Au, 0.18 ± 0.07 for 5Au, 0.26 ± 0.14 for 6Au and 1.13 ± 
0.11 for 7Au) show clearly a difference between the mesityl substituted 7Au and the other 
complexes. In this series, the higher lipophilicity found for the system 7Au correlates with the 
higher cytotoxic activities against cancer cells. Furthermore, it is interesting to observe the 
linearity in the correlation between the growth inhibition ability of complexes showed against 
PC-3 and their lipophilicity (see Figure 4-12). The complexes ordered for cytotoxicity are 
4Au<5Au<6Au<7Au and exactly the same order was found for the lipophilicity. The strongly 
[(R-Im(EtNEt2)2Au]
+ Log P
Complex 4Au (R = Me) -0.83 ± 0.07 
Complex 5Au (R = Bu) 0.18 ± 0.07 
Complex 6Au (R = Bn) 0.26 ± 0.14
Complex 7Au (R = Mes) 1.13 ± 0.11
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lipophilic character of complex 7Au can improve the ability of the molecule to pass through the 
lipid bilayer of membranes and this could be a reason for the better cytotoxic activity of this 
compound. 
In order to study the general cytotoxic activities of the most active gold compound, complex 
7Au was tested in vitro against five representative human cancer cell lines: 
 PC-3 (prostate cancer)  
 MCF-7  (breast cancer) 
 U87 (glioblastoma-brain cancer)  
 A549 (lung cancer)  
 Hep3B (liver cancer).  
Prostate cancer is one of the most common cancer among men and PC-3 cells are known to 
have a high metastatic potential, compared to other prostate cancer cell lines as DU145 or 
LNCaP usually selected to evaluate NHC-gold complexes.
184
 Breast cancer is one of the most 
common cancer among women and MCF-7 is one of the most chosen cell line in NHC-gold 
testing.
184
 Glioblastoma is the highest dedifferentiated form of astrocytic brain tumours, and it is 
refractory to chemotherapy in most cases.
184
 Lung cancer is the leading cause of cancer death 
and one of most common cancer among both men and women.
184
 A549 cells are 
adenocarcinomic human alveolar basal epithelial cells and are frequently used to test NHC-gold 
in vitro. Liver cancer is the fifth most common cancer in men, and the seventh in women, with a 
very high mortality rate.
184
 Hep3B is a drug-resistant hepatocellular carcinoma cell line and, for 
our knowledge, it has never been used before to test NHC-gold activity. 
All these cell lines were seeded (A549, MCF-7, U87, Hep3B (50,000 cells/well), PC-3 
(30,000 cells/well) on a 12-well tissue culture plate, allowed to attach overnight and after were 
exposed to 7Au for 24, 48 and 72 hours. The values reported in Figure 4-10 represent the mean 
of at least three independent experiments. The kinetic effects of gold complex 7Au on the cancer 
cell lines are shown in Figure 4-13. 
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Figure 4-13. Cell viability of A549, MCF-7, U87, Hep3B and PC-3 cells at 24, 48 and 72 h after 
treatment with the indicated concentrations of 7Au. 
This set of results show clearly the high growth inhibition ability of 7Au against all the cancer 
cell lines here tested. Furthermore, it is possible to observe a linear decreasing of the cell 
viability over a period of 72 h. It is important to verify this waning trend in order to exclude the 
possibility of a recovery of the cell viability after the first drug impact. With the intent to get a 
first evaluation of 7Au selectivity between non-tumor and tumor cells, we decided to perform a 
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preliminary test by using non-tumorigenic cells. 
MC3T3 osteoblast precursor cell line, derived from 
Mus musculus (mouse) calvaria, was selected for 
this screening.  The advantages in using this cell 
line are that it is easier to manipulate and less 
expensive compared to primary cell culture. 
MC3T3 cells were seeded (50,000 cells/well) on a 
12-well tissue culture plate, allowed to attach 
overnight and then treated with 7Au (1 μΜ) and 
incubated for 72 h. The cell viability values 
obtained by MTT assay are reported in Figure 4-14 
(these values represent the mean of at least three 
independent experiments); the results show a significant different sensitivity to 7Au for the two 
cell lines MC3T3 and PC3. After treatment with complex 7Au the cell viability related to the 
MC3T3 (≈ 75%) cell line was two and a half times higher than the one related to PC3 (≈ 30%)  
cell line suggesting, in this case, the propensity, of our experimental drug, to discriminate cancer 
cells with respect to healthy cells. Once observed this selectivity tendency in mouse derived 
cells, it was important to verify these results in human primary cells; this is a necessary step 
toward in vivo tests. 
Cultures of primary human umbilical vein 
endothelial cells (HUVECs) were seeded 
(60,000 cells/well) on a 12-well tissue culture 
plate, allowed to attach overnight and then 
treated with complex 7Au at different 
concentrations during 72 h (the values reported 
represent the mean of at least three 
independent experiments). As shown in Figure 
4-15, complex 7Au was significantly less 
active in HUVECs than against cancer cell 
lines (see Figure 4-13) supporting the 
previously observed  aptitude of 7Au to be 
prevalently toxic for cancer cells. All the 
viability values, obtained by MTT assay, were used to create log concentration versus percentage 
Figure 4-14. Cell viability of MC3T3 and 
PC-3 cells 72 h after treatment with 7Au 
(1μM) 
Figure 4-15. Cell viability of HUVECs at 72 h 
with the indicated concentrations of 7Au. 
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cell viability curves (Figure 4-16). From these dose-response curves, obtained by nonlinear 
regression analysis the GI50 (growth inhibitory concentration) values were calculated for each 
cell line (Table 4-2). The GI50 parameter corresponds to the concentration of the compound that 
causes 50% decrease in net cells growth.  
 
Figure 4-16. Dose-response curves for the in vitro tested activity of 7Au in human cell lines. 
In literature the reported values for NHC-gold anticancer activity are usually expressed using 
IC50 (concentration causing 50% inhibition of the desired activity) as parameter instead of GI50. 
However, strictly speaking, IC50 in biology applies for inhibition of a specified individual target, 
e.g. inhibition of an isolated enzyme, or reduction in fluorescence for a luciferase reporter assay 
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for an individual protein of interest, etc… For these reasons we consider more correct to present 
the results as GI50 values. Nevertheless, IC50 and GI50 are correlated, and most of the time they 
can be interchanged in this subject. 
 
Table 4-2. GI50 value (growth inhibitory activity) of 7Au after 72 h. 
After 72 h, the GI50 values related to the activity of 7Au are below 1 µM for all cancer cell 
lines (Table 4-2). PC-3 is the most sensitive cell line to the presence of 7Au showing a GI50 = 
400 nM. The mode of action of our compounds have still not been investigated, however the 
presence of cationic charge and the lipophilicity for 7Au are the features for delocalized 
lipophilic cations (DLC). Due to the electric gradient between membranes' inner and outer 
layers, DLCs can penetrate the hydrophobic barrier of the cellular membranes and accumulate in 
mitochondria. Furthermore, a difference of around 60 mV between the mitochondrial membrane 
potentials of cancerous and healthy cells induce a selective accumulation in tumor cell 
mitochondria.
185,186
  
Collectively, these data show that complex 7Au is active against multiple cancer cell lineages 
while having restricted effects on normal human endothelial cells; these promising results make 
this complex a good candidate as anticancer agent with good prerequisites for in vivo tests.  
As previously discussed in the introduction, for such kind of NHC-gold complex, at the 
molecular level, the selenocysteine (Sec) residue in the C-terminal active site of TrxR is 
considered as the ultimate target for gold species, binding convalently the gold ions.
101
 This 
mechanism could be sketched as a two-step reaction that involves the successive substitution of 
the two NHC ligands to form for example a [Au(Sec)2]
-
 complex.
185
 The interaction of Au(I) 
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with Se-free enzyme glutathione reductase (GR) is also well known, due to the Au-S affinity, in 
this case [Au(Cys)2]
-
 should be formed instead of [Au(Sec)2]
-
. In TrxR a mixed interaction with 
the two Sec-Cys has been also taken in consideration (Sec-Au-Cys).
185
  
 
Figure 4-17. General scheme of the possible reaction mechanism previously reported for 
similar complexes, by Berner-Price et al.. 
4.6.2  Antileishmaniasis investigation 
After the anticancer evaluation, we decided to investigate the antiparasitic properties of our 
new family of gold(NHC)2 complexes. In collaboration with Prof. Alexis Valentin and Dr. Lucie 
Paloque from the Laboratoire de Pharmacochimie et Pharmacologie pour le Développement 
(PHARMA-DEV), compounds were first investigated as antileishmaniasis drugs. All 
compounds, except the dinuclear 6AuAu and 8AuAu, were screened in vitro against Leishmania 
infantum luciferase promastigotes by determining their inhibitory concentration 50% (IC50) and, 
in parallel, the J774 mouse macrophage cell line was chosen to assess their cytotoxicity via the 
determination of their cytotoxic concentrations 50% (CC50). Corresponding selectivity indexes 
(SI) were then calculated according to the following formula: SI = CC50/IC50. A molecule starts 
to be considered selective when the related SI is bigger than one. Amphotericin B, pentamidine 
and miltefosine were chosen as antileishmanial reference-drugs (first line drugs currently used 
against leishmaniases) and doxorubicin was used as a positive control for the cytotoxicity 
evaluation. The values reported in Table 4-3 represent the mean of at least three independent 
experiments analyzed 72 h after treatment. While pro-ligands 4 to 7 did not show significant 
activity, with IC50 values higher than 50 μM, complexes 4Au to 7Au showed antiprotozoal 
activities, with IC50 lower than 10 μM for 4Au and lower than 5 μM for the other complexes. 
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This set of results showed a key role of the gold metal center in biological activities of these 
organometallic compounds also against L. infantum luciferase promastigotes. Structure-activity 
relationship can be observed considering that the activity increases from methyl- to mesityl-
substituted systems (from 4Au to 7Au), indeed following the trend found in the anticancer 
investigation, the highest lipophilicity of 7Au correlates with its highest biological activity 
against promastigotes. 
 
Table 4-3. IC50 values against L. infantum promastigotes are reported in μM.  
Compounds 5Au (IC50 = 4.97 μM), 6Au (IC50 = 2.40 μM) and 7Au (IC50 = 1.61 μM), 
exhibited IC50 values lower than the reference drugs Pentamidine (IC50 = 8.2 μM) and 
Miltefosine (IC50 = 11.6 μM). However, our molecules showed low values of CC50, expressing 
aspecific toxicity between the J774 (mouse macrophage cell line) and L. infantum luciferase 
promastigotes, with exception of 6Au that exhibits slight selectivity of action among protozoa 
(SI = 1.31). 6Au is less active and less selective than Amphotericin B, however this reference 
drug is very expensive and it is well known for its severe and potentially lethal side effects.
84
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Furthermore, increasing drug resistance for Amphotherecin B and Pentamidine have been 
reported, making more important the researches on new compounds.
85
 
6Au is one of the few examples of gold complexes and the first example of Au(NHC)2  
showing antileishmanial activity,
80,89,187
  
4.6.3  Antimalaria investigation 
In order to investigate the antiplasmodial properties of this new Au(NHC)2 family, 
compounds were screened in vitro against another parasite named Plasmodium falciparum strain 
FcB1-Colombia. This screening was performed inside the group by Dr. Françoise Benoit Vical. 
The FcB1-Colombia is considered as a chloroquine (CQ) resistant strain (IC50 of CQ = 0.2 μM). 
CQ, the malarial commercial drug most widely used, was chosen as reference in these tests. 
Results of the preliminary antiplasmodial tests are presented in the Table 4-4. 
 
Table 4-4. IC50 values against the P. falciparum strain FcB1 are reported in μM.  
The IC50 values reported represent the mean of at least three independent experiments 
analyzed 48 h after treatment. Also if the drug reference CQ was more effective, the butyl 
substituted complex 5Au, exhibited promising antiplasmodial activity (IC50 = 2.1 μM) against P. 
falciparum, ten times higher than the methyl substituted complex 4Au which showed modest 
effects (IC50 = 22 μM). Once again, a correlation between activity and lipophilicity seems to 
exist, but further results on 6Au and 7Au are necessary to confirm the structure-activity 
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relationship observed in the other effectuated biological studies. Pro-ligands 4 and 5 showed no 
activity with IC50 values higher than 50 μM confirming, also in this case, the key role of the gold 
center as responsible of the antiplasmodial effects. Further studies to exclude hemolytic 
characteristics of compounds and antiplasmodial tests involving 6Au and 7Au are ongoing in our 
group. Previously, Hemmert et al. reported a series of silver and gold compounds involving 
NHC ligands (see example with quinoline and bipyridine group),
76
 where the lipophilicity and 
the basicity of complexes showed a certain importance. Martinez et al. reported in 2009 a series 
of Ru–chloroquine complexes where the activity against resistant Plasmodium falciparum is 
related to lipophilicity and basicity of compounds.
188
 It will be interesting to investigate the 
mechanism of action of these compounds considering that the thioredoxin reductase is the most 
accredited target in cancer cells for such gold complexes and also a crucial redox enzyme of 
plasmodia.
77
 Further experiments are necessary to propose a biological target.  
 Conclusion for gold(I) complexes of 1-[2-4.7 
(diethylamino)ethyl]imidazolydene gold(I) 
 A new series of four gold(I) complexes NHC-Au-NHC containing each two 1-[2-
(diethylamino)ethyl]imidazolydene ligands has been synthesized and characterized. Moreover, 
we have also obtained and characterized (NMR, X-Ray, HRMS, UV-Vis) two homoleptic 
dinuclear gold(I) complexes where metals are coordinated on one side to the NHC and on the 
other side to the terminal amine group. Complexes 4Au to 7Au have been tested in vitro to 
investigate their anticancer, antimalarial and antileishmanial potential. The lipophilic properties 
of these complexes have been calculated and correlated with the found biological activities.  
 1-[2-(diethylamino)ethyl]imidazolydene 4.8 
platinum(II) complexes 
 Motivated by the biological properties of this family of gold compounds and observed the 
interesting selectivity behavior as anticancer agent of the mesityl-gold complex 7Au, we decided 
to synthesize new heterobimetallic compounds by exploiting the coordinating ability of the 
amino side arms. The idea was to add a platinum(II) alongside the gold atom, forming a 
dinuclear complex composed by a linear coordinated cationic gold center and a neutral platinum 
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unit (cisplatin analogue) with a square planar coordination. This approach conceives a dual 
objective:  
i) to obtain a synergic anticancer effect. The presence, in one molecule, of two different 
kinds of potential drugs (Au-NHC and Pt-amino unit) could allow a “double action” 
involving two different kind of targets: mitochondrial TrxR (for the gold(I) entity) 
and DNA (for the Pt(II) moiety);  
ii) to give selectivity to the platinum drug. Exploiting the ability of the gold moiety to 
discriminate cancer and normal cells as DLCs, specific toxicity could be induced to 
the DNA targeting cisplatin analogue, normally unselective. The concept is that the 
cationic gold complex could “drag” the neutral platinum complex in cancer cells, in 
order to have a selective double action drug. 
As first approach, we decided to use Pt(DMSO)2Cl2 as platinum precursor, 1 or 2 
equivalent(s) respect of the gold complex, considering the possibility to obtain a trinuclear or a 
dinuclear system. 
 
Figure 4-18. Synthetic attempts in order to obtain Au-Pt heterobimetallic complexes. 
Different reaction conditions were performed to find the good synthetic way: 
 
Figure 4-19. Synthetic attempts in order to obtain Au-Pt heterobimetallic complexes. 
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The reaction in acetonitrile starting from 4Au or 5Au led to the formation of a mixture that 
seems to be formed by an imidazolium salt and two different complexes. The reaction in MeOH 
at room temperature led to the rapid formation of a red-brown suspension and then, to the 
formation of a gold mirror. However, the 
1
H NMR spectra obtained from the reaction mixtures 
showed the presence of a major product that was different to the starting gold complex: small 
shifts of peaks related to both NHC and amine signals. The absence in the spectra of the 
characteristic signal for the H2 of the imidazolium salt and the presence of the gold mirror 
suggested the possibility of a transmetalation process. Moreover, the 
13
C NMR revealed a big 
shift related to the carbenic carbon from roughly 180 to roughly 170 ppm, value compatible with 
the C2 - Pt(II) signal.
189–191
  
To better understand the reaction, we decided to synthesized a new family of platinum(II) 
complexes containing two 1-[2-(diethylamino)ethyl]imidazolydene ligands. The complexes were 
prepared via direct metalation of the imidazolium salts by using Pt(DMSO)2Cl2 and K2CO3 in 
THF at 70 °C for 24 h. 
 
Figure 4-20. Synthesis of NHC-Pt(II) complexes. 
Starting from the methyl substituted pro-ligand 4 we could obtain the clean complex 4Pt by 
crystallization. The compound 4Pt has been characterized by 
1
H, 
13
C NMR and HRMS. The 
characteristic peak related to the H2 of the imidazolium salt is absent in the complex spectrum. 
The 
13
C spectrum showed the resonance for the carbenic carbon atoms at 166.2 ppm. This value 
is in the range of reported values for Pt(II)-NHC complexes having C-Pt-X (X = halide) or C-Pt-
C motifs.
189–191
 The 
13
C NMR spectrum shows two very close signals for each carbon atom. 
Moreover, a lot of pseudo-coupling could be observed in the 
1
H NMR spectrum. These 
phenomena are probably due to the presence of cis and trans isomers in solution. The HRMS 
exhibits the peak corresponding to the molecule private of a halogen anion [M-Br], m/z = 
767.1246. 
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Crystals of compound 4Pt, suitable for an X-ray structure analysis, could be obtained by slow 
evaporation of an acetonitrile solution of the compound. The cationic part of the molecule is 
shown in Figure 4-21. The structure displays the presence of a bis-NHC platinum(II) complex. 
The C-Pt-C and Br-Pt-Br angles are 180.0°. The platinum atom is in a center of a square planar 
coordination geometry and the carbene ligands are in trans configuration. The NHC rings are 
nearly perpendicular to the coordination plane of the platinum atom. The distances platinum-
carbon (2.025(2) Å; CCDC: 1.93 to 2.10 Å) and platinum-bromine (2.436(1) Å; CCDC: 2.41 to 
2.50 Å) are also in good agreement with literature values for such compounds, more or less the 
same values known for the gold carbon distances.
192
 
 
 
Figure 4-21. Crystal structure of 4Pt. Thermal ellipsoids are depicted at 50% level. Hydrogen 
atoms have been omitted for clarity. Selected bond lengths (Å) and angles (°): Pt-C1 2.025(2), 
Pt-C11 2.025(2), Pt-Br1 2.436(1), Pt-Br2 2.436(1), C1-Pt-C11 180.0, C1-Pt-Br1 91.27(5), C11-
Pt-Br1 88.73(5), C1-Pt-Br2 88.72(5), C11-Pt-Br2 91.27(5), Br1-Pt-Br2 180.0. 
The structure represents trans coordination of the halogen atoms and the amine side arms are 
not on the same side of the planes formed by the NHC-Pt-NHC units as difference with complex 
4Au. 
 
Crystals of compound 6Pt, suitable for an X-ray structure analysis, have been also obtained 
by slow evaporation of an acetonitrile solution of the compound. The cationic part of the 
molecule is shown in Figure 4-22. Also in this case the structure displays the presence of a bis-
NHC platinum(II) complex. The platinum atom is in a center of a square planar coordination 
geometry and the carbene ligands are in trans. Bond lengths and angle values involving the 
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platinum(II) metal center are very similar to those found for 4Au crystals in agreement with 
CCDC and literature values.
192
 
 
 
Figure 4-22. Crystal structure of 6Pt. Thermal ellipsoids are depicted at 50% level. Hydrogen 
atoms have been omitted for clarity. Selected bond lengths (Å) and angles (°): Pt-C1 2.037(9), 
Pt-C17 2.037(9), Pt-Br1 2.431(2), Pt-Br2 2.431(2), C1-Pt-C17 180.0, C1-Pt-Br1 90.2(3), C11-
Pt-Br1 89.8(3), C1-Pt-Br2 89.8(5), C11-Pt-Br2 90.2(3), Br1-Pt-Br2 180.0. 
Our hypothesis of a Au  Pt transmetalation in the reactions involving 4Au, occurred during 
the attempts to synthesized the Pt-Au complexes, seems to be confirmed by the similar C2 
signals in the 
13
C NMR spectra (roughly 170 ppm). Anyway we decided to try again to obtain a 
Pt-Au complex by using different platinum precursors. No reactivity was observed using 
Pt(acac)2 in DMSO at different temperatures in the presence of 4Au or 5Au. The next attempt 
was to react the amino-functionalized NHC-gold complexes with Pt(cod)2Cl2 in acetonitrile at 
room temperature. The 
1
H NMR spectrum of the product showed some small differences respect 
to the starting gold complex, in particular concerning the signals related to the amine chain. 
However the X-ray analysis and mass spectrometry confirmed that the platinum was not present. 
Finally, by employing 4Au as starting product, we tried again the coordination reaction on the 
amine side arms by using K2PtCl4 as platinum precursor. 
 
Figure 4-23. Synthetic attempts in order to obtain Au-Pt heterobimetallic complexes. 
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The formation of a brown-red precipitate was observed again, but the 
1
H NMR showed a 
major product different from gold complex 4Au and from the synthesized platinum complex 
4Pt.  The Figure 4-24 shows clearly that all NMR signals are significantly shifted with respect to 
the starting 4Au and do not correspond to the platinum analogue 4Pt. 
 
Figure 4-24. 1H NMR(CD3CN) spectra related to complexes 4Au (red), 4Pt (blue) and to 
“unknown” new product (green). 
However, the X-ray analysis of the crystallized product showed that once again it was not the 
desired heterobimetallic Au(I)-Pt(II) complex but another interesting neutral NHC-Pt(II) formed 
by another unusual Au  Pt transmetalation. Crystals of compound 4Pt’, suitable for an X-ray 
structure analysis, could be obtained by slow evaporation from an acetonitrile solution of the 
compound. The molecule is shown in Figure 4-25. The solid state structure of 4Pt’ shows that 
the amino functionalized NHC acts as a bidentate chelating ligand coordinated to the metal 
forming a slightly distorted square planar platinum carbene complex. The -CH2-CH2- group 
releases some strain in the molecule resulting as a small perturbation of the C, N, Cl-binding 
motif. The carbenic carbon-Pt bond length 1.964(8) Å is a little shorter than in the bis-NHC 
synthetized complex. All values are found to be in good agreement for such compounds in the 
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CCDC (Cambridge Crystallographic Data Center) data base. The Pt-Cl1 bond distance (2.370(2) 
Å) is slightly longer than the Pt-Cl2 bond distance (2.307(2) Å). 
 
Figure 4-25. Crystal structure of 4Pt’. Thermal ellipsoids are depicted at 50% level. Hydrogen 
atoms have been omitted for clarity. Selected bond lengths (Å) and angles (°): Pt-C 1.964(8), 
Pt-N 2.125(6), Pt-Cl2 2.307(2), Pt-Cl1 2.370 (2), C1-Pt-N 90.9(3), C-Pt-Cl2 90.8(2), N-Pt-Cl2 
174.32(17), C-Pt-Cl1 175.9(3), N-Pt-Cl1 91.81(16), Cl2-Pt1-Cl1 86.76(7). 
From these experimental data we conclude that the carbenic carbon is a stronger σ donor, 
forming a stronger bond with platinum (Pt-C distance = 1.964(8) Å) than the amino-group (Pt-N 
distance 2.125(6). This time the complex presented formed the cis isomer exploiting the 
coordination ability of the amino side arm. In this way, we obtained a neutral cis-coordinated 
Pt(II) complex, with potential anticancer activity as cis-platin analogue.
29
  
 Conclusion for platinum(II) complexes of 1-[2-4.9 
(diethylamino)ethyl]imidazolydene  
 At the moment, the achieving of mixed metal system containing amino-side arms has 
been proved to be still tricky. Using different platinum precursors (Pt(DMSO)2Cl2, Pt(acac)2, 
Pt(cod)2  and K2PtCl4) and different reaction conditions, we always had to face the same 
experimental problem: an unexpected Au  Pt transmetalation. The addition of the platinum 
precursor caused the decomposition of the gold complex, manifested by the formation of the 
gold mirror on the walls of glassware. Nevertheless, these coordination studies led to the 
synthesis of two new NHC-Pt complexes with interesting potential in biological 
applications.
29189190
 Studies of biological activities of these platinum complexes are under 
investigation. 
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 NHC-Au(I) complexes containing a 5.
M(phen)2 moiety  
 Introduction 5.1 
In this chapter, we will discuss our preliminary studies on hetero-polynuclear gold(I)-silver(I) 
and gold(I)-copper(II) complexes containing phenanthroline-NHC pro-ligands. As previously 
described in Chapter 3, only a limited number of heterobimetallic transitions-metal complexes 
with NHC pro-ligands have been reported and just one of them with the aim of biomedical 
applications. In this example, Raubenheimer e al. reported a Au(I)-Fe(II) heterobimetallic 
complex (compound [XV]) exhibiting high growth inhibition potency at lower concentrations 
against three different tumoral cells. However, it is still unclear if the presence of the ferrocene 
fragment can enhance the biological properties or not (see paragraph 2.6.3).
132 
 
Figure 5-1. Heterobimetallic complexes reported by Raubenheimer et al. [XV]  and by Chen et 
al. [XVIa,b]. 
Most targeted applications of NHCs heterobimetallic complexes are in material research or 
catalysis. Recently, Chen et al. achieved to synthesize two hetero-dinuclear compounds 
(complexes [XVIa] and [XVIb] in Figure 5-1) binding two different metal centers (Pd-Cu and 
Pd-Ag) using an asymmetrical 3-(1,10-phenanthrolin-2-yl)-1-pyridin-2-ylmethyl)-
imidazolylidene.
133
 In particular, the palladium(II)-copper(I) complex  exhibited  good catalytic 
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properties for tandem click/Sonogashira reactions of 1-(bromomethyl)-4-iodobenzene, NaN3, 
and alkynes which allows the selective formation of three C–N bonds and one C–C bond.133  
1,10-Phenanthroline (phen) is a chemically versatile module with a fortunate combination of 
structural and chemical properties.
193
 Compared to the more common 2,2'-dipyridyl system, phen 
has a more rigid structure, due to its central ring, that make it an entropically better chelating 
molecule with the two nitrogen atoms always held in juxtaposition.
194
 Among all the various 
aspects of chemical sciences concerned with phenanthrolines and derivatives, we are particularly 
interested on the biological properties. As consequence of the planar nature, indeed, phen is able 
to participate as either an intercalating or groove-binding species with DNA and RNA.
193,195
 
Therefore, it is not surprising that several organometallic compounds containing phen show 
interesting biomedical properties that have been reported in the literature.
196–198
 
The purpose of our work is to synthesize new mixed systems coupling the biomedical 
properties of the NHCs gold(I) compounds to the properties of phen based organometallic 
compounds. Copper complexes of phen and its derivatives are of great interests since they 
exhibit numerous biological activities such as antitumor, anti-Candida, antimycobacterial, and 
antimicrobial activity.
198–204
 It is well known that bis(1,10-phenanthroline) copper(II) shows 
efficient DNA cleavage; it binds to DNA non-covalently in the minor groove and reacts with 
H2O2 to generate active species that leads to DNA strand scission.
199,205,206
 By assembling  
Au(I)(NHC)2 with a Cu(II)(Phen)2 we could obtain a multi target anticancer drug where the 
gold(I) can act as antimitochondrial TrxR moiety and the copper(II) can interact with the DNA 
of cells. Moreover, as noted in the precedent chapter, we could exploit the DLC character of the 
molecule to enhance the selectivity of toxicity for tumor cells. A mixed silver(I)-gold(I) system 
will be presented in this chapter. Silver(I) complexes are also well known since many years for 
their biological activities, especially as antimicrobial agents, and currently found applications as 
antiseptics.
23
 Recently Ag(I)-phen complexes and derivatives have been also investigated for 
their anticancer activity, showing interesting antiproliferative effects by interacting with DNA of 
tumor cells.
201,207
  
 Presentation of compounds 5.2 
In this chapter the synthesis and the characterization of two new imidazolium pro-ligands 
functionalized with a phenanthroline unit it will be presented (see Figure 5-2). 
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Figure 5-2. Imidazolium-phen pro-ligands. 
Three new complexes have been prepared starting from these pro-ligands: a dinuclear 
heterobimetallic complex containing gold(I) and silver(I) metal centers (complex 9AgAu), a 
copper(II) compound (complex 10Cu) and a hetero-trinuclear complex (10CuAuAu). The 
synthetized organometallic compounds are depicted in Figure 5-3. 
 
Figure 5-3. NHC-phen complexes. 
 Synthesis and characterization 5.3 
 Firstly, 3,8-dibromo-1,10-phenanthroline and 3-bromo-1,10-phenanthroline were 
prepared as described in the literature, by treatment of 1,10-phenanthroline monohydrochloride 
monohydrate with bromine in nitrobenzene.
208
 The two multidentate compounds, 3,8-diimidazol-
1,10-phenanthroline and 3-imidazol-1,10-phenanthroline, have been synthesized via the carbon-
nitrogen bond cross-coupling reaction between 3,8-dibromo-1,10-phenanthroline or 3-bromo-
1,10-phenanthroline and an excess of imidazole using Ullmann condensation by modifying the 
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method reported by Wang et al.
209,210
 Subsequently, the reaction of these imidazole-phen 
compounds with MeI (10 equivalent) at 70 °C in acetonitrile or in DMF led to the formation of 
the imidazolium salts 9 and 10 respectively (Scheme 5-1) as white solids with high yields (75 - 
92%). The anion exchange was performed by using NH4PF6 to increase the solubility of these 
compounds and to avoid the I
-
 coordination competition with metals. 
 
Scheme 5-1. Synthesis of the imidazolium salts 9 and 10. 
The pro-ligands have been characterized by NMR spectroscopy, UV-Vis spectroscopy and 
mass spectrometry. The main characteristics of the imidazolium salts 9 and 10 in the 
1
H NMR 
spectra are the resonances for the imidazolium protons located at  9.88 and 9.16 ppm, 
respectively, and the corresponding imidazolium carbons at 137.3 and 138.1 ppm, respectively, 
in the 
13
C NMR. The MS FAB
+
 and the HRMS of the pro-ligands exhibit the classical peaks 
corresponding to [M – PF6
-
]
+
 cations: m/z = 261 (100%) for 9; m/z = 487.1234 for 10.  The 
heterobimetallic complex 9AgAu was obtained by stirring the pro-ligand 9 at 50 °C in the 
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presence of silver oxide (0.5 equivalent) for 12 h and by adding Au(SMe2)Cl (1 equivalent) 
directly in situ. The transmetalation followed by a silver(I) transfer from the carbene to the 
phenanthroline moiety led to the formation of the heterobimetallic Au(NHC)2-Ag(phen)2 
complex (Scheme 5-2). 
 
Scheme 5-2. Synthesis of the heterobiletallic complex 9AgAu. 
The gold(I)-silver(I) complex 9AgAu was isolated from acetonitrile solution as brown-yellow 
crystals (27%) suitable for X-ray analysis; the synthesized complex is highly stable toward air 
and moisture and soluble in CH3CN, DMF and DMSO. 
1
H NMR spectroscopy unequivocally 
demonstrated the formation of the gold(I) complex with the absence of the proton resonance of 
the acidic imidazolium and the QTOF mass spectrometry confirmed the presence of the gold and 
of the silver, showing its characteristic isotopic profile. Furthermore, the mass spectrum exhibits 
the peak corresponding to [M - PF6
-
]
+
 (m/z = 971.2) cation, where M includes a dicationic 
species and 2PF6 anions, confirming the formation of the desired molecule.  
It was not possible to transform the imidazolium compound 10 in a NHC-Au(I) complex by 
using Ag2O. In order to obtain the trinuclear complex 10CuAuAu (Figure 5-3), we decided to 
adopt the same synthetic strategy previously used to obtain the Ru-Au complexes: to prepare the 
copper complex involving the phenanthroline moiety before and, in a second time, to generate 
the NHC-gold(I) units forming the final hetero-trinuclear compound. The copper(II) complex 
10Cu was readily prepared by reaction of pro-ligand 10 with Cu(OTf)2 (5 equivalents) in 
acetonitrile at RT for 30 minutes (see Scheme 5-3). The choice of the Cu(OTf)2 as precursor 
avoid the risk to obtain a mixture of products with different Cu/phen stoichiometry. The triflate 
anion, CF3SO3
-
 is an extremely stable polyatomic ion. The unreacted Cu(OTf)2 was eliminated 
by Sephadex LH-20 column. 
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Scheme 5-3. Synthesis of the copper complex 10Cu. 
The trinuclear heterobimetallic complex 10CuAuAu was obtained by deprotonation of the 
imidazolium salt 10Cu (copper complex) by using nBuLi (4 equivalents) at low temperature (-78 
°C) and following by addition of the gold precursor Au(SMe2)Cl (2 equivalents) that lead to the 
direct metalation of the four free carbenes laterally linked to the copper(II) complex (Cu(phen)2). 
The reaction was then slowly warm up to RT and stirred overnight. The reaction is depicted in 
Scheme 5-4. 
 
Scheme 5-4. Synthesis of the trinuclear heterobimetallic complex 10CuAuAu. 
Compouds 10Cu and 10CuAuAu, have been characterized by ESR (Electron Spin 
Resonance), UV-Vis spectroscopy and mass spectrometry. The hexacationic copper(II) complex 
10Cu is highly sensitive to ESR spectroscopy. The X-band ESR spectrum of a frozen solution 
of 10Cu in acetonitrile is shown in Figure 5-4. 
The spectrum clearly exhibits three discontinuities due to the low field transitions of the 
parallel hyperfine coupling with copper. The small peaks have g// = 2.293 and A// = 160 G and the 
sharp singlet has g⊥= 2.079, values characteristic for such copper ions.
204,211,212
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Figure 5-4. X-band ESR spectrum of a frozen solution of 10Cu in acetonitrile. 
Furthermore, the spectrum indicates an axial symmetry; g//>g⊥>ge suggests a distorted 
tetragonal, square-pyramidal or square-planar geometry. The g// and A// values of 10Cu are found 
in the regions characteristic for Cu-4N or Cu-3N1O chromophores in the g// vs. A// diagram of 
Peisach and Blumberg, where 4N or 3N1O are the equatorial bindings atoms.
213
 Sagakushi and 
Addison showed that the g// / A// ratio can be used as a convenient empirical index of tetrahedral 
distortion in CuN4 units.
214
  In our case g// / A// = 134 cm, conforming to the values range (from 
ca.105 to 135 cm) reported for square-planar structures.  
The MALDI-MS of the complex 10Cu exhibits the peaks corresponding to [CuL2
5+
 + 4PF6
-
] 
(m/z = 1327.1), [CuL2
5+
 + 3PF6
-
 + 1OTf
-
] (m/z = 1331.1), [CuL2
5+
 + 2PF6
-
 + 2 OTf
-
] (m/z = 
1335.1), [CuL2
5+
 + 1PF6
-
 + 3 OTf
-
] (m/z = 1339.1), [CuL2
5+
 + 4 OTf
-
] (m/z = 1343.1) cations. 
The presence of four anions suggests the reduction of Cu(II) to Cu(I) during the mass  
measurement, quite common for these kind of complexes. 
The X-band ESR spectrum of the frozen solution of 10CuAuAu in acetonitrile is shown in 
Figure 5-5 (red curve), overlapped to the spectrum recorded for 10Cu. The spectrum profile of 
the trinuclear 10CuAuAu, appears drastically changed, showing a big distortion respect of the 
geometry observed in the ESR spectrum of the starting copper complex 10Cu. The coordination 
of the two gold(I) centers on the NHCs moieties needs a certain binding linearity that can 
probably force the molecule to pass from a square planar to an unusual tetrahedral geometry, 
losing the axial symmetry. The ESR curve found for 10CuAuAu did not permit to extrapolate in 
a proper way the Hamiltonian parameters g//, A// and g⊥, however it shows clearly that the new 
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species is formed. The MALDI-MS of the complex 10CuAuAu exhibits the peak corresponding 
to [Au2CuL2 + 2PF6]
+
 (m/z 1427.3) cation. The reduction of Cu(II) to Cu(I) during the 
measurements, occurred also in this case. 
 
Figure 5-5. X-band ESR spectrum recorded for a frozen acetonitrile solution of 10CuAuAu 
(red curve) and 10Cu (black curve). 
 Molecular structures 5.4 
The X-ray structures of the pro-ligand 9, the copper complex 10Cu and the heterobimetallic 
compound 9AgAu are reported in this section. 
The asymmetric imidazolium pro-ligand 9 has been crystallized by slow evaporation of a 
concentrated acetonitrile solution of the compound; the yellow crystals have been analyzed by 
X-ray diffraction. The cationic part of the molecule is shown in Figure 5-6. 
 
Figure 5-6. Cationic part of the molecular structure of 3 depicted at a 50% level for the 
ellipsoids. 
 | NHC-Au(I) complexes containing a M(phen)2 moiety 107 
 
 Luca Boselli 
The obtained structure confirms the expected molecule showing the cycle of the aromatic 
methyl imdazolium N-substituted by a phenanthroline functional group. The torsion angle 
between the two aromatic rings is 40°. 
The heterobimetallic complex 9AgAu was crystallized by slow evaporation of a saturated 
solution of the compound in acetonitrile. The cationic part of the molecule is shown in Figure 5-
7. 
 
Figure 5-7. Cationic part of the molecular structure of 9AgAu depicted at a 50% level for the 
ellipsoids. Hydrogen atoms and anions are omitted for clarity. Selected bond lengths (Å) and 
angles (°): Ag-N4 2.251(5), Ag-N8 2.276(5), Ag-N7 2.407(5), Ag-N3 2.427(5), C1-Au 1.990(7), 
C17-Au 2.018(7), C1-Au-C17 173.3(3), N4-Ag-N8 135.07(2), N4-Ag-N7 143.98(2), N8-Ag-N7 
72.51(2), N4-Ag-N3 72.61(2) N8-Ag-N3 146.86(2), N7-Ag-N3 93.31(2). 
The coordination geometry is classical for the gold(I) exhibiting a nearly linear coordination 
of the gold(I) by two NHC with a C-Au-C angles of 173.3°. This value is in the range of 170° to 
180° found for such compounds in the CCDC (Cambridge Crystallographic Data Center) data 
base. The gold carbon distances (C1-Au = 1.990(7) Å; C17-Au = 2.018(7) Å) are also in good 
agreement with values found for such compounds (CCDC: 1.93 to 2.10 Å). The NHC units are 
twisted and present a torsion angle of 37.2°. The silver(I) is tetracoordinated by two planar phen 
units and shows a strongly distorted square planar geometry with a torsion angle of 37.6°. Ag–
N3 and Ag–N7 distances (2.407(5) and 2.427(5) Å, respectively), neighboring to the NHC 
moieties, are remarkably longer than the other two Ag–N bonds (Ag-N4 = 2.251(5) Å and Ag-
N8 = 2.276(5) Å). The values reported in the literature for the Ag–N bond lengths of 
[Ag(Phen)2]
+
 are around  2.31–2.39 Å and the angles from 32 to 40° more or less conforming to 
the results found for 9AgAu.
133,215,216
 
  
 
108 ................... NHC-Au(I) complexes containing a M(phen)2 moiety | 
 
 Synthesis of N-Heterocyclic Carbene Gold(I) Complexes: Towards the Development of new Organometallic Drugs 
The copper(II) complex 10Cu was crystallized by slow vapor diffusion of diethylether in a 
saturated solution of the compound in acetonitrile. Green crystals have been analyzed by X-ray 
diffraction. The cationic part of the molecule is shown in Figure 5-8. 
 
Figure 5-8. Cationic part of the molecular structure of 10Cu depicted at a 50% level for the 
ellipsoids. Hydrogen atoms and anions are omitted for clarity. Selected bond lengths (Å) and 
angles (°): Cu-N4 2.007(4), Cu-N9 2.007(3), Cu-N14 2.033(4), Cu-N3 2.053(4), Cu-N10 
2.280(4), Cu-N13 2.494(5),   N4-Cu-N9 177.2(2), N4-Cu-N14 92.0(2), N4-Cu-N3 81.82(2), N4-
Cu-N10 102.1(1) N4-Cu-N13 86.5(2), N9-Cu-N14 90.8(2), N9-Cu-N3 95.4(1), N9-Cu-N10 
78.5(1), N9-Cu-N13 93.3(2), N14-Cu-N3 161.5(2), N14-Cu-N10 89.9(2), N14-Cu-N13 79.7(2), 
N3-Cu-N10 108.4(2), N3-Cu-N13 82.5(2), N10-Cu-N13 166.7(2).  
The obtained molecular structure shows a hexacoordinated Cu(II), being chelated by two 
phenanthroline units and two molecule of acetonitrile. The coordination geometry of the 
copper(II) is octahedral with a significant distortion provoked by the Jahn-Teller effect, very 
common in six-coordinate copper(II) complexes. The Cu–N bond distances in the equatorial 
plane are comparable in length (Cu-N4 = 2.007(4), Cu-N9 = 2.007(3), Cu-N14 = 2.033(4), Cu-
N3 = 2.053(4) Å), those in the axial positions are significantly longer (Cu-N10 = 2.280(4), Cu-
N13 = 2.494(5) Å). The deviations from the ideal geometry is clearly manifested by the N–Cu–N 
bond angles N4-Cu-N9 177.2(2), N4-Cu-N14 92.0(2), N4-Cu-N3 81.82(2), N4-Cu-N10 102.1(1) 
N4-Cu-N13 86.5(2). Moreover, the molecular structure shows the two acetonitrile molecules 
coordinated in cis position. This is in agreement with the ESR results found for 10Cu (Figure 5-
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4) indicating that the equatorial ligands are in the 4N or 3N1O region, 3N from the 2 pro-ligands 
10 and 1N or 1O from solvent molecules (acetonitrile or H2O). 
Moreover, these experimental results clarify the unexpected loss of axial symmetry noted in 
the ESR spectrum of 10CuAuAu in respect to the spectrum of 10Cu (Figure 5-5). Starting from 
the cis position, the pro-ligands are probably forced by the linear Au(I)-NHCs coordination,  to 
undergo to a change of geometry, in order to form the hetero-trinuclear complex 10CuAuAu. In 
addition, is possible that one Nphen-Cu(II) bond has been broken, permitting the structural 
reorganization. However the X-ray structure of 10CuAuAu is necessary to better understand the 
molecular rearrangement. 
 Photophysical studies 5.5 
Absorption and emission spectra in the UV-Vis range have been performed for all compounds 
presented in this chapter. Furthermore, their fluorescence quantum yield has been calculated. For 
these preliminary studies the photophysical properties of these compounds have been 
investigated in acetonitrile solution at RT. 
 
Figure 5-9. Normalized absorption and emission spectra of the pro-ligand 9 (blue curve) in 
comparison with the phenanthroline (dark pink curve). 
The rigidity of 1,10-phenanthroline is reflected in the structured UV absorption and emission 
spectral features (Figure 5-9, dark pink curve). The maximum of the lowest energy absorption 
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band is centered at 263 nm and the emission spectrum is characterized by a weak fluorescence 
quantum yield (Φ ≈ 0.01) conforming to the results reported in literature.194 
Figure 5-9 shows also the absorption and the emission spectra of pro-ligand 9 (blue curves), in 
comparison with the phen spectra. The spectra have been normalized to better compare the 
profiles. The absorption spectrum of pro-ligand 9, exhibits a broad structured band with two 
maxima centered at 329 nm and at 268 nm with a small shoulder around 287 nm. This high 
structured energy band presents, respect of the absorption spectrum registered for the phen, 
similar maximum and profile at lower energy, some differences at higher energy. The absorption 
band of 9 can be assigned to spin-allowed π-π*, as reported for phen.194 The emission spectrum 
of the pro-ligand 9, assigned to spin-allowed π-π* transitions, shows a broad slightly structured 
high energy emission band centered at 369 nm. The emission maximum of 9, as the absorption 
maxima, is red shifted of just 10 nm in respect to phen (359 nm) and presents a less structured 
but similar band profile. The emission of 9 is significantly more intense of phen with a quantum 
yield of Φ ≈ 0.05, at least five times bigger than the one of phen (Φ ≈ 0.01). This result 
evidences an influence of the methyl-imidazolium substitution on the fluorescence properties of 
phen. 
 
Figure 5-10. Absorption and emission spectra of the complex 9AgAu (dark yellow) 
overlapped to the free pro-ligand 9 (blue). The absorption spectra are normalized. The 
emission spectra are related to the quantum yield. 
Figure 5-10 shows the absorption and the emission spectra of complex 9AgAu in comparison 
with the free pro-ligand 9. The absorption spectrum of the complex 9AgAu exhibits a broad 
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band with two maxima centered at 234 nm and at 273 nm. The band is more structured in respect 
to the one registered for 9, furthermore the peaks are sharper, the distance between the maxima is 
increased and the shoulder around 294 nm is blue shifted and more accentuated respect to phen. 
This high energy absorption band of 9AgAu is due to metal perturbed LC transition. 
Au(I) and Ag(I) have d
10
 closed-shell electronic configurations, therefore d–d metal centered 
transitions are not expected. Furthermore, Ag(I) is hard to oxidize excluding strong MLCT 
transitions.
194
 Exciting in the different absorption maxima, just a very weak and large band has 
been registered for 9AgAu. The metal coordination quenched the fluorescence of the pro-ligand 
9. These results are in agreement with the data reported in the literature for such silver(I) 
compound involving phenanthroline derivatives.
194,217
 Armaroli et al. reported a silver(I) 
complex with phenanthroline substituted ligands that did not show fluorescence at RT, but it is 
phosphorescent at 77K in CH2Cl2. Further studies at low temperature are necessary to investigate 
the nature of the emission band registered for 9AgAu. 
The absorption and the emission spectra of the two pro-ligands (9 and 10) and of the 
unmodified phen are reported in Figure 5.11. From the normalized absorption spectra it can be 
noted that increasing the number of imidazolium substituents on the phen rings, increases the red 
shift of the lower energy band.  
 
Figure 5-11. Absorption and emission spectra of pro-ligands 9 (blue curve), 10 (black curve) 
and phen (dark pink curve). The absorption spectra are normalized. The emission spectra 
are related to the quantum yield. 
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The absorption profile of the bis-imidazolium salt 10 also shows the shoulder at 292 nm more 
accentuated in respect to 9 and phen. The emission spectra of 10 exhibits analogue structured 
profile in respect to the band observed for 9, but with the maximum red shifted to 374 nm. 
Moreover, the fluorescence quantum yields of the compounds, substantially increase with the 
methyl-imidazolium substitution on the phenanthroline. 
Interestingly, the calculated quantum yield of the pro-ligand 10 (Φ ≈ 0.13) is more than two 
times the one found for the mono-substituted pro-ligand 9 (Φ ≈ 0.05) and more than ten times the 
one found for the unsubtituted phen (Φ ≈ 0.01). To understand this enhancement in the 
fluorescence quantum yield of the ligands, further experiment using different solvents and life 
time measurements are necessary.  
The absorption and the emission spectra of complexes 10Cu, 10CuAuAu and related pro-
ligand 10 are reported in Figure 5.12. The UV-Vis spectroscopy is very useful to monitor 
reactions involving paramagnetic species as copper(II) compounds and we used it combined with 
ESR spectroscopy for our compounds.  
 
Figure 5-12. Absorption and emission spectra of pro-ligand 10 (black curve), complex 10Cu 
(green curve) and complex 10CuAuAu (red curve). The absorption spectra are normalized. 
The emission spectra are related to the quantum yield. 
The absorption spectrum of complex 10Cu is very similar to the one observed for the pro-
ligand 10, presenting some small but significant differences. Overlapping the normalized curves 
obtained by the light absorption of 10Cu and 10 in acetonitrile, it is possible to see that the ratio 
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between the two absorption maxima of these compounds is slightly different. Furthermore, the 
curve related to the copper complex cross the one related to the pro-ligand following a different 
profile. The emission spectrum of complex 10Cu is centered at 374 nm as seen for the related 
pro-ligand. The observed electronic bands are assigned to copper perturbed LC transitions. The 
perturbation of the pro-ligand transitions by coordination of copper(II) are highlighted by the 
decrease in the fluorescence quantum yield, reduced of roughly 40% in 10Cu ( Φ ≈ 0.08). 
Chelation with paramagnetic metal ions such as Cu(II) generally tend to promote intersystem 
crossing, quenching fluorescence and sometimes promoting phosphorescence. The absorption 
spectrum of the hetero-trinuclear complex 10CuAuAu (Figure 5-12, red curve), exhibits a broad 
structured band with maxima at 240 and 274 nm. The normalized spectrum shows significant 
differences in respect to the related copper precursor (10Cu) and the related pro-ligand 10; an 
higher ratio between the two absorption band maxima is evident. Furthermore, the absorption 
band of 10CuAuAu cross the curve of 10Cu, and an increment of absorption around 330 nm can 
be noted. The emission spectrum of the complex 10CuAuAu reveals an impressive quenching of 
the fluorescence observed for 10 and 10Cu, in analogy to the observation concerning the 
heterobimetallic complex 9AgAu. The presence of the gold(I) centers coordinated to the NHCs 
seems to have a strong influence on the photophysical properties of the pro-ligands and of the 
phenanthroline copper core. The significant structural distortion observed for 10Cu after the gold 
coordination and the lack of the positive charge on the NHC rings could influence the internal 
and the external coordination sphere of the complex, perturbing the excited state responsible of 
the fluorescence. However, also in this case, further experiments are necessary to understand the 
reasons of this fluorescence quenching. 
The different photophysical properties observed between the two pro-ligands 9 and 10 respect 
of the related polynuclear complexes 9AgAu and 10CuAuAu could be exploited during the 
biological investigation of compounds by using confocal microscopy.  
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A summary of the data obtained by the photophysical characterization of compounds in 
acetonitrile solution are reported in Table 5-1. 
 
 
Table 5-1. Photophysical data obtained by the characterization at RT in acetonitrile solution 
(10-5-10-6 M). 
 Conclusion for NHC-Au(I) complexes containing a 5.6 
M(phen)2 moiety  
Two new NHCs pro-ligands functionalized with a phenthroline unit (9 and 10) have been 
prepared. Moreover, a dinuclear heterobimetallic Au(I)-Ag(I) complex (9AgAu), a hetero  
trinuclear Au-Cu-Au complex (10CuAuAu) and its copper(II) precursor (10Cu) have been 
synthesized for their potential biomedical application. The compounds reported in this chapter 
have been characterized by NMR or ESR, mass spectrometry, UV-Vis spectroscopy and X-ray 
diffraction. 
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 Conclusion and perspectives 6.
In this work, three groups of new NHC-based gold and heterobimetallic complexes involving 
aliphatic or aromatic amino-functionalized NHCs with interesting potential in biomedical 
research have been synthesized and fully characterized.  
The first group represents a family of heterobimetallic complexes of NHC-Au(I) complexes 
containing a luminescent Ru(bpy)3-side arm (1-3RuAu). These compounds have been 
synthesized and biologically investigated showing interesting properties for developing new 
theranostic agents. These Au-Ru complexes are, in fact, bifunctional systems with anticancer 
and luminescent properties that, by making pharmaco-modulations, could be used for both 
therapeutic and imaging applications. One of these complexes (2RuAu) was selected for 
confocal microscopy studies in Hep3B cells, where it showed anticancer activity. The 
intracellular distribution concerns principally the cytoplasm, and not the nuclei or the 
mitochondria. This suggests that probably neither DNA nor mitochondria represents the main 
target of these molecules. The next steps will be to focus on the localization of the complex in 
the cytoplasm by using further markers for specific organelles in order to obtain further 
mechanistic insight. Moreover, other interesting information could be obtained by investigating 
the reactivity of our molecules against TrxR, largely present in the cytoplasm and considered as 
one of the main targets for NHC-Au(I) complexes in cancer cells. Furthermore, other preliminary 
studies on [Xb] indicated greater anticancer potency in different cell lines. Therefore it will be 
interesting to test also these heterobimetallic complexes 1-3RuAu against different tumoral cell 
lines. In order to improve the biological activities of our Au-Ru systems, we could make some 
structural modifications by changing the aliphatic/aromatic group on the NHC or by alkylation or 
arylation on the bpy rings. This will allow a modulation of the lipophilicity of the compounds, 
which could also improve the anticancer activity of the molecules. The addition of methyl groups 
to bpy, next to the nitrogen atoms, generates a strained ruthenium complex, that has been 
recently reported in the literature as a potent light activated anticancer agent.
218
 In this way, two 
drugs in one molecule could be obtained and the specificity of activity could be increased by, for 
example, selective irradiation of the tumoral cells.  
The second family of molecules concerns cationic gold(I) complexes containing two 1-[2-
(diethylamino)ethyl]imidazolydene ligands. The compounds are in the form Au(NHC)2, 
presenting similar structure but different lipophilicity. The complexes have been tested for their 
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antiproliferative effects in human prostate cancer cell line PC-3 showing a linear correlation 
between their lipophilic properties and their biological activities. The most active complex 7Au 
has been tested for the cytotoxic activities in five human cancer cell lines and primary 
endothelial cells demonstrating a potent action and selectivity for cancer cells. The cationic and 
lipophilic 7Au can be considered as a good anticancer agent candidate, with the features of 
delocalized lipophilic cations (DLCs). The mitochondrial TrxR is the most accredited target for 
these kinds of gold complexes, therefore it will be interesting to investigate the inhibition 
properties of 7Au directly on the different TrxR enzymes and try to observe experimentally the 
implication of mitochondria in the mode of action, for example by confocal microscopy. By 
using a fluorescent mitochondrial marker, we could observe the swelling of mitochondria caused 
by MMP. Moreover, 7Au should be tested in vivo in order to provide more conclusive evidence 
and to pursue the development of these kind of organometallic drugs. In addition, antileishmanial 
and antimalarial activities of these compounds have been investigated showing promising 
results. It is interesting to observe one more time the importance of lipophilic modulations. To 
the best of our knowledge, we reported one of the few examples of gold complexes and the first 
example of Au(NHC)2 showing antileishmanial activity. The preliminary studies on 4Au and 
5Au show interesting antimalarial activities and antiplasmodial tests involving 6Au and 7Au are 
ongoing in our laboratory. It will be interesting to investigate the mechanism of action of these 
compounds considering that the thioredoxin reductase is a crucial redox enzyme of plasmodia.   
The third group is formed by a hetero-dinuclear gold(I)-silver(I) and a trinuclear gold(I)-
copper(II) complexes containing phenanthroline-NHC ligands. The compounds are formed by 
two different organometallic units potentially able to act as multi-targeting anticancer drugs. The 
next step will be the screening of the compounds against different cancer cells and against the 
parasites responsible of malarial and leishmaniasis. The tuning of the lipophilicity of these 
compounds employing different alkyl- (or aryl-) substituents on the imidazolium is also 
important. The different photophysical properties observed between the luminescent pro-ligands 
9 and 10 with respect to the related non luminescent polynuclear complexes 9AgAu and 
10CuAuAu could be exploited during the biological investigation of such compounds by using 
confocal microscopy. For example, the complexes, reacting in cells and losing the metal 
cation(s), could “turn on the light” signaling the cell compartment where the drug activity takes 
place. This “switch” behavior could give important insight about the mode of action of these 
compounds. It is also possible to synthetize other mixed metal systems involving Pt(II) or Zn(II) 
(known for their biological properties) on the phen unit and thus forming Au(I)-Pt(II) and Au(I)-
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Zn(II) complexes. Complexes 9AgAu could be used directly as precursor for other mixed metals 
systems by silver transmetalation. 
 
For all the three group of synthesized molecule, it will be very interesting to extend the 
biological investigation by testing the compounds as anti-HIV/AIDS agents. As briefly reported 
in Chapter 2, since some years there is a growing interest in gold containing compounds as 
agents against AIDS, Au(I) in particular (Auranofin, Aurothioglucose, Aurothiomalate) and 
furthermore, some ruthenium polypiridine compounds have been also found to be good 
inhibitors of HIV. 
219
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Experimental section 
General considerations 
All manipulations were performed under an inert atmosphere of dry nitrogen by using 
standard vacuum line and Schlenk tube techniques. Glassware was dried at 120 °C in an oven for 
at least 3 h. Dichloromethane and acetonitrile were dried over CaH2 and subsequently distilled. 
All other reagents were used as received from commercial suppliers. 5-(Bromomethyl)-2,2’-
bipyridine,
1
 3-methyl-1-{[6-pyridin-2-yl)pyridine-3-yl]-methyl-1H-imidazol-3-ium bromide,
2
 1-
mesitylimidazole,
3
 Ru(bpy)2Cl2,
4
 3,8-dibromo-1,10-phenanthroline
5
 and 3-bromo-1,10-
phenanthroline
5
 were prepared as described in the literature. All reactions involving silver 
compounds were performed with exclusion of light. 
1
H (300 or 400 MHz) and 
13
C (75 or 101 
MHz) NMR spectra were recorded at 298 K on Bruker DPX300, Bruker AV300 or Bruker 
AV400 spectrometers in CDCl3, CD3CN, CD3OD, acetone-d6 or DMSO-d6 as solvents. For 
paramagnetic compounds ESR spectra were recorded in CH3CN at 100 K with Elexys E500 
from Bruker. FAB(MNBA) was performed with NERMAG R10-10 spectrometer using a FAB 
ionization, HRMS was performed with a Thermo Finnigan MAT 95 XL spectrometer using 
electrospray ionization (ESI), QTof was performed with a QTof premier spectrometer using 
electrospray ionization (ESI) and Maldi/TOF(DCTB) with a MALDI micro mx Water 
spectrometer by the “Service de Spectrométrie de Masse de l'Institut de Chimie de Toulouse” 
(UPS-CNRS). Microanalyses were performed at the Laboratoire de Chimie de Coordination on a 
Perkin Elmer 2400 Series II Analyzer.  
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 NHC-Au(I) complexes containing a Ru(bpy)3-1.
side arm  
 
Figure. 1-1. General numbering for NMR attribution. 
 Preparation of imidazolium salts 1.1 
1.1.1 3-Butyl-1-{[6-pyridin-2-yl)pyridine-3-yl]-methyl-1H-imidazol-3-ium bromide (2) 
1-Buthylimidazole (1.6 mL, 12.43 mmol) and 5-(bromomethyl)-
2,2’-bipyridine (0.884 g, 3.55 mmol) were stirred in toluene (40 
mL) at 130 °C for 24 h. After cooling to RT, the desired 
white/yellow precipitate was filtered off and dried under vacuum 
(1.020 g, 77%). 
1
H NMR (300 MHz, CDCl3) δ 10.54 (s, 1H, H2), 
8.85 (s, 1H, H16), 8.53 (d, 1H, J = 4.1 Hz, H15), 8.25 (d, 1H,  J = 
8.2 Hz, H12), 8.18 (d, 1H, J = 7.9 Hz, H9), 8.09 (dd, 1H, J = 8.2, 
1.5 Hz, H13), 7.80 (s, 1H, H5), 7.74 – 7.63 (m, 1H, H8), 7.49 (s, 1H, H4), 7.25 – 7.14 (m, 1H, 
H14), 5.80 (s, 2H, H6), 4.20 (t, 2H, J = 7.3 Hz, H17), 1.88 – 1.68 (m, 2H, J = 7.5 Hz,  H18), 1.34 
– 1.12 (m, 2H, H19), 0.81 (t, 3H, J = 7.3 Hz, H20). 13C NMR (75 MHz, CDCl3): δ 156.7 (1C, 
C10), 155.0 (1C, C11), 149.5 (1C, C15), 149.2 (1C, C16), 137.8 (1C, C2), 137.0 (2C, C13), 
136.6 (1C, C8), 129.5 (1C, C7), 124.1 (1C, C14), 122.6 (1C, C5), 122.5 (1C, C4), 121.2 (1C, 
C9), 121.2 (1C, C12), 50.1 (1C, C17), 49.9 (1C, C6), 31.9 (1C, C18), 19.4 (1C, C19), 13.4 (1C, 
C20). MS (FAB
+
): m/z 293 [M-Br
-
]
+
. HRMS (ES+): calcd. For C18H21N4 293.1766; found 
293.1770.  
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1.1.2 3-Benzyl-1-{[6-pyridin-2-yl)pyridine-3-yl]-methyl-1H-imidazol-3-ium bromide 
(3) 
1-Benzylimidazole (0.562 g, 3.55 mmol) and 5-(bromomethyl)-
2,2’-bipyridine (0.884 g, 3.55 mmol) were stirred in toluene (40 mL) 
at 130 °C for 24 h. After cooling to RT, the solvent was removed and 
the solid was dried under vacuum to give a beige paste. The paste was 
dissolved in a small amount of CH2Cl2 and Et2O was added leading to 
the formation of a fine yellow suspension and a brown oily film on 
the glass wall. The suspension was transferred in a round bottom flask, the solvent removed and 
the solid dried under vacuum to give the pure product as a yellow powder (0.986 g, 68%). The 
pro-ligand was crystallized from CH2Cl2/pentane. 
1
H NMR (300 MHz, CDCl3): δ 10.67 (s, 1H, 
H2), 8.84 (d, 1H, J = 1.8 Hz, H16), 8.55 (d, 1H, J = 4.6 Hz, H15), 8.26 (d, 1H, J = 8.2 Hz, H12), 
8.18 (d, 1H, J = 8.0 Hz, H9), 8.07 (dd, 1H, J = 8.2, 2.2 Hz, 1H, H13), 7.74 (s, 1H, H5), 7.72 – 
7.63 (m, 1H, H8), 7.38 (m, 4H, H4, H14, H20), 7.30 – 7.17 (m, 3H, H19, H21), 5.76 (s, 2H, 
H17), 5.48 (s, 2H, H6). 
13
C NMR (75 MHz, CDCl3): δ 156.9 (1C, C10), 155.0 (1C, C11) , 149.5 
(1C, C15), 149.2 (1C, C16), 137.8 (1C, C8), 136.9 (1C, C13), 136.7 (1C, C2), 132.7 (1C, C7), 
129.5 (1C, C21), 129.4 (2C, C19), 129.2 (1C, C18), 128.9 (2C, C20), 124,1 (1C, C14), 122.6 
(1C, C5), 122.2 (1C, C4), 121.3 (1C, C9), 121.2 (1C, C12), 53.4 (1C, C17), 50.3 (1C, C6). MS 
(FAB
+
): m/z 327 [M-PF6
-
]
+
. HRMS (ES+): calcd. For C21H19N4 327.1610; found 327.1612. 
 Preparation of ruthenium(II) complexes 1.2 
1.2.1  Ruthenium(II) 3-methyl-1-{[6-pyridin-2-yl)pyridine-3-yl]-methyl-1H-imidazol-
3-ium-2,2’-bipyridine-tri-hexafluorophosphate (1Ru) 
1 (0.300 g, 0.9 mmol) was dissolved in EtOHaq (95/5) (45 
mL) under N2 and the solution was heated to reflux. 
Ru(bpy)2Cl2 (0.437 g, 0.9 mmol) was added and the mixture 
was heated to reflux for 3 h. After cooling to RT the solution 
was concentrated and cooled in an ice-bath. A saturated 
aqueous solution of NH4PF6 (3-5 mL) was added; the 
formed precipitate was filtered, washed with Et2O and was 
dried under vacuum to give the pure product as a bright orange solid. 1Ru (0.88 g, 88%). 
1
H 
NMR (400 MHz, acetone-d6): δ 8.90 (s, 1H, H2), 8.87 – 8.74 (m, 6H, Harom), 8.29 – 8.15 (m, 6H, 
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Harom), 8.10 – 7.97 (m, 6H, Harom), 7.73 (s, 1H, Harom), 7.64 – 7.52 (m, 6H, Harom), 5.68 – 5.53 
(m, 2H, H6), 4.05 (s, 3H, H17). 
13
C NMR (75 MHz, acetone-d6): δ 157.4 (1C), 157.2 (1C), 157.1 
(1C), 157.1 (1C), 157.0 (1C), 156.7 (1C), 152.1 (1C), 151.9 (1C), 151.8 (1C), 151.7 (1C), 151.7 
(1C), 150.0 (1C), 138.2 (1C), 138.1 (1C), 138.1 (2C), 138.0 (2C), 137.5 (1C), 137.3 (1C), 134.9 
(1C, C2), 128.1 (1C), 128.0 (1C), 127.9 (1C), 127.9 (1C), 127.8 (1C), 124.8 (1C), 124.6 (1C), 
124.5 (1C), 124.4 (1C), 124.3 (2C), 122.7 (1C), 49.4 (1C, C6), 36.0 (1C, C17). MS (FAB
+
): m/z 
955 [M-PF6
-
]
+
 (100%); HRMS (ES+): calcd. For C35H31F12N8P2Ru 955.1008; found 955.1023. 
1.2.2  Ruthenium(II) 3-butyl-1-{[6-pyridin-2-yl)pyridine-3-yl]-methyl-1H-imidazol-3-
ium-2,2’-bipyridine-bromide-dichloride (2Ru) 
2 (0.300 g, 0.8 mmol) was dissolved in 45 mL of 
EtOHaq (95/5) under N2 and the solution heated to 
reflux. Ru(bpy)2Cl2 (0.389 g, 0.8 mmol) was added and 
the mixture was heated to reflux for 3 h. After cooling to 
RT the solvent was removed and the solid was washed 
with Et2O to give a red powder. The crude product was 
dissolved in a minimum volume of acetonitrile and 
precipitated at low temperature (one night in the freezer). This precipitation was done several 
times giving pure 2Ru (0.570 g, 82%). 
1
H NMR (300 MHz, CD3CN): δ 10.14 (s, 1H, H2), 8.76 –  
8.64 (m, 4H, Harom), 8.63 – 8.56 (m, 2H, Harom), 8.25 – 8.16 (m, 1H, Harom), 8.15 – 8.04 (m, 6H, 
Harom), 7.85 – 7.78 (m, 2H, Harom), 7.75 – 7.65 (m, 4H, Harom), 7.61 – 7.46 (m, 2H, Harom), 7.45 – 
7.33 (m, 4H, Harom), 5.70 – 5.49 (m, 2H, H6), 4.23 (t, 2H, J = 7.4 Hz, H17), 1.83 (tt, 2H,  J = 
7.3, 7.4 Hz, H18), 1.42 – 1.29 (tq, 2H, J = 7.3, 7.4 Hz, H19), 0.94 (t, 3H, J = 7.4 Hz, H20). 13C 
NMR (75 MHz, CD3CN): δ 157.2 (1C), 157.1 (1C), 156.9 (1C), 156.8 (1C), 156.7 (2C), 152.9 
(1C), 152.0 (1C), 151.6 (2C), 151.4 (1C), 151.3 (1C), 137.7-137.9 (6C), 137.6 (1C), 134.9 (1C, 
C2), 127.9 (1C), 127.7 (2C), 127.5 (2C), 125.0 (1C), 124.8 (2C), 124.5 (1C), 124.4 (2C), 122.7 
(1C), 122.6 (1C), 49.4 (1C, C6), 48.8 (1C, C17), 31.6 (1C, C18), 19.0 (1C, C19), 12.8 (1C, C20). 
MS (FAB
+
): m/z 823 [M-Cl
-
]
+
 (20%); m/z 583 [Ru(bpy)2(Me-bpy)]
+
 (100%),  HRMS (ES+): 
calcd. For C38H36N8Ru(2+) 353.1058; found 353.1058 (65%), calcd for C34H28N8Ru(2+) [M-
Bu]
2+
 325.0745; found 325.0747. 
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1.2.3 Ruthenium(II) 3-benzyl-1-{[6-pyridin-2-yl)pyridine-3-yl]-methyl-1H-imidazol-3-
ium-2,2’-bipyridine-tri-hexafluorophosphate (3Ru) 
3 (0.300 g, 0.7 mmol) was dissolved in 45 mL of 
EtOHaq (95/5) under N2 and the solution heated to reflux. 
Ru(bpy)2Cl2 (0.339 g, 0.7 mmol) was added and the 
mixture was heated to reflux for 3 h. After cooling to RT 
the solution was concentrated and cooled in an icebath. A 
saturated aqueous solution of NH4PF6 (3-5 mL) was 
added, the formed precipitate was filtered, washed with 
Et2O and dried under vacuum to give the pure product as a bright orange solid 3Ru (0.711 g, 
86%). 
1
H NMR (300 MHz, acetone-d6): δ 9.10 (s, 1H, H2), 8.88 – 8.80 (m, 4H, Harom), 8.79 – 
8.72 (m, 2H, Harom), 8.28 – 8.14 (m, 6H, Harom), 8.13 – 7.99 (m, 5H, Harom), 7.99 – 7.94 (m, 1H, 
Harom), 7.82 (s, 1H, Harom), 7.63 – 7.44 (m, 11H, Harom), 5.66 – 5.60 (m, 2H, H17), 5.59 – 5.54 
(m, 2H, H6). 
13
C NMR (75 MHz MHz, CD3CN): δ 157.4 (1C), 157.0 (2C), 156.9 (3C), 156.4 
(1C), 151.9 (1C), 151.8 (1C), 151.7 (1C), 151.6 (2C), 151.5 (1C), 150.6 (1C), 137.9 (3C), 137.8 
(1C), 137.2 (1C), 136.3 (1C), 133.8 (1C), 133.4 (1C), 129.4 (1C), 129.3 (2C), 128.8 (2C), 127.9 
(1C), 127.6 (3C), 124.8 (1C), 124.4 (1C), 124.3 (2C), 124.2 (2C), 123.0 (2C), 53.1 (1C, C6), 
49.4 (1C, C17). MS (FAB
+
): m/z 1117 [M-PF6
-
]
+
 (100%); HRMS (ES+): calcd. For 
C41H34AuClF6N8Pru 1117.0953; found 1117.0977. 
 Preparation of ruthenium(II)-silver(I) complexes 1.3 
1.3.1 Synthesis of [Ag(MeIm)(CH2bpy)Ru(bpy)2][Cl][PF6]2 (1RuAg)  
1Ru (0.440 g, 0.40 mmol) was dissolved in 20 ml of 
dry acetonitrile under N2. To the solution were added 
0.030 g of KCl and after 5 minutes Ag2O (0.093 g, 0.40 
mmol). The solution was stirred at 40 °C for 24 h. The 
mixture was cooled to RT, filtered on celite, and the 
solvent was removed under reduced pressure to give the 
pure product 1RuAg (0.390 g, 99%). 
1
H NMR (300 MHz, 
acetone-d6): δ 8.85 – 8.67 (m, 6H, Harom), 8.29 – 8.05 (m, 
6H, Harom), 8.05 – 7.93 (m, 5H, Harom), 7.62 – 7.47 (m, 5H, Harom), 7.43 (s, 1H, H8), 7.34 (d, 1H, 
Harom), 7.24 (d, 1H, Harom), 5.55 – 5.33 (m, 2H, H6), 3.79 (s, 3H, H17).  
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1.3.2 Synthesis of [Ag(BuIm)(CH2bpy)Ru(bpy)2][Br][Cl2] (2RuAg)  
2Ru (0.356 g, 0.415 mmol) was dissolved in 
20 ml of dry acetonitrile under N2, Ag2O (0.096 
g, 0.415 mmol) was added and the solution 
stirred at 40 °C for 24 h. After that the mixture 
was cooled to RT, filtered on celite, and the 
solvent was removed under reduced pressure to 
give the pure product 2RuAg (400 mg, 
100%).
1
H NMR (300 MHz, CD3CN-d3) δ 8.87 – 8.60 (m, 6H, Harom), 8.25 – 7.94 (m, 6H, Harom), 
7.93 – 7.65 (m, 5H, Harom), 7.58 – 7.32 (m, 6H, Harom), 7.09 –  6.85 (m, 2H, Harom), 3.97 (t, 2H, J 
= 7.1 Hz, H17), 2.68 (s, 2H, H6), 1.74 (tt, 2H, J = 7.5, 7.1 Hz, H18), 1.29 (tq, 2H, J = 8.1, 7.5 
Hz, H19), 1.02 – 0.85 (t, 3H, J = 8.1 Hz, H20). 
1.3.3 Synthesis of [Ag(BnIm)(CH2bpy)Ru(bpy)2][Cl][PF6]2 (3RuAg)  
3Ru (0.446 g, 0.38 mmol) was dissolved in 20 
ml of dry acetonitrile under N2. To the solution 
were added 0.040 g of KCl and after 5 minutes 
Ag2O (0.088 g, 0.38 mmol). The solution was 
stirred at 40 °C for 24 h. The mixture was cooled 
to RT, filtered on celite, and the solvent was 
removed under reduced pressure and the solid 
dried under vacuum to give the pure product 3RuAg (0.357 g, 80%). 
1
H NMR (300 MHz, 
acetone-d6): δ 8.90 – 8.55 (m, 6H, Harom), 8.28 – 8.09 (m, 5H, Harom), 8.06 – 7.89 (m, 6H, Harom), 
7.64 – 7.43 (m, 7H, Harom), 7.24 (s, 6H, Harom), 5.43 (s, 2H, H17), 5.34 (s, 2H, H6). 
13
C NMR (75 
MHz, acetone-d6) δ 157.1 (1C), 157.0 (2C), 156.9 (1C), 156.7 (1C), 156.6 (1C), 151.8 (2C), 
151.7 (2C), 149.0 (1C), 138.1 (3C), 137.6 (1C), 136.8 (1C), 136.5 (1C), 128.9 (3C), 128.3 (2C), 
128.0 (2C), 127.9 (2C), 127.8 (1C), 127.5 (2C), 124.7 (1C), 124.4 (3C), 124.3 (2C), 124.2 (1C), 
123.3 (1C), 122.7 (1C), 55.0 (1C, C6), 51.6 (1C, C17). 
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 Preparation of ruthenium(II)-gold(I) complexes 1.4 
1.4.1 Synthesis of [Au(MeIm)(CH2bpy)Ru(bpy)2][Cl][PF6]2 (1RuAu) 
1RuAg (0.395 g, 0.36 mmol) was dissolved in 20 ml 
of dry acetonitrile under N2 and under protection of 
light. After addition of Au(SMe2)Cl (0.106 g, 0.36 
mmol) the mixture was stirred at RT overnight. The 
AgCl formed was filtered off on celite and with a PTFE 
(filter membranes, pore size 0.2 µm). The solvent was 
removed under reduced pressure giving the pure product 
1RuAu as an orange/red powder (0.365 g, 92%). 
1
H 
NMR (300 MHz, acetone-d6): δ 8.88 – 8.76 (m, 6H, Harom), 8.34 – 8.14 (m, 6H, Harom), 8.10 – 
7.92 (m, 5H, Harom), 7.65 – 7.49 (m, 6H, Harom), 7.37 (d, J = 1.9 Hz, 1H, Harom), 7.34 (d, J = 1.9 
Hz, 1H, Harom), 5.56 – 5.38 (m, 2H, H6), 3.88 (s, 3H, H17). 
13
C NMR (75 MHz, acetone-d6): δ 
171.3 (1C, C2), 157.1 (1C), 157.0 (1C), 156.9 (1C), 156.8 (1C), 156.7 (1C), 156.6 (1C), 151.8 
(2C), 151.7 (1C), 151.6 (2C), 148.7 (1C), 138.2 (1C), 138.1 (3C), 138.0 (1C), 137.6 (1C), 136.7 
(1C), 128.2 (1C), 128.0 (2C), 127.9 (1C), 127.8 (1C), 124.7 (1C), 124.6 (1C), 124.5 (1C), 124.4 
(1C), 124.3 (1C), 124.1 (1C), 123.1 (1C), 122.1 (1C), 50.8 (1C, C6), 37.9 (1C, C17). MS 
(FAB
+
): m/z 1041 [M-PF6
-
]
+
 (100%); HRMS (ES+): calcd. For C35H30AuClF6N8Pru 1041.0638; 
found 1041.0658. 
1.4.2 Synthesis of [Au(BuIm)(CH2bpy)Ru(bpy)2][Br][Cl]2 (2RuAu) 
2Ru (0.403 g, 0.47 mmol) was dissolved in 20 ml of 
dry acetonitrile under N2 and under protection of light. 
After addition of Ag2O (0.120 g, 0.47 mmol) the 
mixture was stirred at 40 °C for 12 h. After cooling to 
RT Au(SMe2)Cl (0.139 g, 0.47 mmol) was added and 
the mixture was stirred at RT overnight. The AgCl 
formed was filtered off on celite. The solvent was 
evaporated and the solid dried under vacuum to give the pure product as a dark red powder 
(0.403 g, 81%). 
1
H NMR (300 MHz, CD3OD): δ 8.85 – 8.60 (m, 6H, Harom), 8.25 – 8.05 (m, 6H, 
Harom), 7.95 – 7.75 (m, 5H, Harom), 7.62 – 7.45 (m, 6H, Harom), 7.41 – 7.30 (m, 2H, Harom), 5.45 – 
5.27 (m, 2H, H6), 4.19 (t, 2H, J = 7.0 Hz, H17), 1.84 (tt, 2H, J = 7.1 Hz,  H18), 1.45 – 1.25 (m, 
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2H, H19), 0.98 (t, 3H, J = 7.3 Hz, H20). 
13
C NMR (75 MHz, CD3OD): δ 168.7 (1C, C2), 155.6 
(1C), 155.5 (1C), 155.4 (1C), 155.3 (1C), 155.2 (2C), 150.1 (1C), 149.9 (1C), 149.8 (2C), 147.4 
(1C), 136.6 (2C), 136.5 (2C), 136.4 (1C), 136.2 (1C), 135.3 (1C), 126.6 (1C), 126.4 (1C), 126.3 
(2C), 126.1 (1C), 123.2 (1C), 123.1 (2C), 122.9 (2C), 122.7 (1C), 120.8 (1C), 120.1 (1C), 115.4 
(1C), 49.7 (1C, C6), 49.4 (1C, C17), 31.5 (1C, C18), 17.8 (1C, C19), 11.22 (1C, C20). MS 
(FAB
+
): m/z 937 [M-Cl
—
Br
-
]
2+ 
(100%); HRMS (ES+): calcd. For 
C38H36AuClN8Ru(2+) 469.0734; found 469.0738. 
1.4.3  Synthesis of [Au(BnIm)(CH2bpy)Ru(bpy)2][Cl][PF6]2 (3RuAu) 
3RuAg (434 mg, 0.37 mmol) was dissolved in 20 ml of dry acetonitrile under N2 and under 
protection of light. After addition of 
Au(SMe2)Cl (109 mg, 0.37 mmol) the mixture 
was stirred at RT overnight. The AgCl formed 
was filtered off on celite and with a PTFE (0.2 
µm). The solvent was removed under reduced 
pressure to give the pure product 3RuAu as an 
orange/red powder (0.460 g, 98%). 
1
H NMR 
(300 MHz, acetone-d6): δ 8.80 (m, 6H, Harom), 8.38 – 8.14 (m, 6H, Harom), 8.13 – 7.93 (m, 5H, 
Harom), 7.73 – 7.34 (m, 13H, Harom),  5.65 – 5.33 (m, 4H, H6, H17). 
13
C NMR (75 MHz, 
CD3CN): δ 171.1 (1C, C2), 156.9 (3C), 156.8 (1C), 156.6 (1C), 156.5 (1C), 151.8 (1C), 151.7 
(2C), 151.6 (1C), 151.5 (1C), 149.2 (1C), 138.0 (1C), 137.9 (1C), 137.8 (3C), 137.2 (1C), 136.4 
(1C), 136.3 (1C), 129.0 (2C), 128.5 (1C), 127.9 (1C), 127.8 (2C), 127.7 (2C), 127.6 (2C), 124.5 
(2C), 124.4 (1C), 124.3 (2C), 124.0 (1C), 122.7 (1C), 121.8 (1C), 54.7 (1C, C6), 51.0 (1C, C17). 
MS (FAB
+
): m/z 1041 [M-PF6
-
]
+
 (100%); HRMS (ES+): calcd. For 
C41H34AuClN8RuPF6 117.0953; found 117.0977. 
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 NHC complexes containing amine-side arms 2.
 
Figure 2-1. General numbering for NMR attribution. 
 Preparation of imidazolium salts 2.1 
2.1.1 1-[2-(Diethylamino)ethyl]-3-methylimidazolium bromide hydrobromide (4) 
A two neck round bottom flask equipped with a refrigerant was 
charged with solid 2-bromo-N,N-diethylethylamine hydrobromide 
(3.63 g, 13.89 mmol) and 50 mL of dry acetonitrile. The mixture was 
heated at 80 °C and stirred until the solid was completely dissolved. To 
the solution was slowly added 1-methylimidazole (1.1 mL, 13.88 mmol) by syringe. The mixture 
was stirred for 48 h at 150 °C. After cooling to RT, the precipitate formed was filtered, washed 
with diethyl ether and dried under vacuum. 4 was obtained as a highly hygroscopic white 
product (3.81 g, 80% yield).  Anal. Calcd. For C10H21N3Br2: C, 35.01; H, 6.17; N, 12.25. Found: 
C, 35.11; H, 6.08; N, 12.01. 
1
H NMR (400 MHz, DMSO-d6): δ 9.69 (s, 1H, HBr), 9.29 (s, 1H, 
H2), 7.97 (s, 1H, H4), 7.77 (s, 1H, H5), 4.66 (t, 2H, J = 6.6 Hz, H6), 3.88 (s, 3H, H11), 3.71 – 
3.57 (m, 2H, H7), 3.31 – 3.15 (m, 4H, H9), 1.24 (t, 6H, J = 7.1 Hz, H10). 13C NMR (101 MHz, 
DMSO-d6): δ 138.1 (1C, C2), 124.3 (1C, C4), 122.8 (1C, C5), 50.0 (1C, C7), 47.3 (2C, C9), 43.4 
(1C, C6), 36.4 (1C, C11), 8.9 (2C, C10). HRMS (ES+): calcd. for C10H20N3 182.1657; found 
182.1650. 
2.1.2 1-[2-(Diethylamino)ethyl]-3-butylimidazolium bromide hydrobromide (5) 
The pro-ligand 5 was prepared as described for 4, starting 
from 2-bromo-N,N-diethylethylamine hydrobromide (3.63 g, 
13.89 mmol) in 50 mL of dry acetonitrile and 1-butylimidazole 
(1.8 mL, 13.89 mmol). The solvent was removed giving a 
yellow paste that was treated with a small quantity of acetone and stirred for 15 minutes The 
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precipitate formed was filtered and washed with diethyl ether. The solid was dried under vacuum 
to give the pure product as a highly hygroscopic white powder (4.60 g, 85% yield). Anal. Calcd. 
For C13H27N3Br2: C, 40.54; H, 7.07; N, 10.91. Found: C, 40.21; H, 6.93; N, 10.77. 
1
H NMR (400 
MHz, DMSO-d6): δ 9.89 (s, 1H, HBr), 9.46 (s, 1H, H2), 7.98 (s, 1H, H4), 7.87 (s, 1H, H5), 4.69 
(t, 2H, J = 6.4 Hz, H6), 4.19 (t, 2H, J = 7.1 Hz, H11), 3.68 (t, 2H, J = 6.4 Hz, H7), 3.24 (q, 4H, J 
= 6.9 Hz, H9), 1.85 – 1.75 (m, 2H, H12), 1.41 – 1.13 (m, 8H, H10/H13), 0.91 (t, 3H, J = 7.3 Hz, 
H14). 
13
C NMR (75 MHz, DMSO-d6): δ 137.4 (1C, C2), 123.1 (1C, C4), 123.0 (1C, C5), 49.9 
(1C, C7), 49.2 (1C, C11), 47.4 (2C, C9), 43.5 (1C, C6), 31.6 (1C, C12), 19.3 (1C, C13), 13.8 
(1C, C14), 8.9 (2C, C10). HRMS (ES+): calcd. For C13H26N3 224.2127; found 224.2129. 
2.1.3 1-[2-(Diethylamino)ethyl]-3-benzylimidazolium bromide hydrobromide (6)  
The pro-ligand 6 was prepared as described for 4, starting from 
2-bromo-N,N-diethylethylamine hydrobromide (1.65 g, 6.32 
mmol) in 50 mL of dry acetonitrile and 1-benzylimidazole (1.00 g, 
6.32 mmol). The solvent was removed and by addition of a 
mixture of dichloromethane (5-10 mL) and diethyl ether (2 mL), a white solid precipitated. It 
was filtered, washed with diethyl ether and dried under vacuum to give a hygroscopic white 
powder (2.01 g, 76% yield). Anal. Calcd. For C16H25N3Br2: C, 45.84; H, 6.01; N, 10.02. Found: 
C, 45.72; H, 6.11; N, 10.28. 
1
H NMR (300 MHz, DMSO-d6): δ 9.88 (s, 1H, HBr), 9.52 (s, 1H, 
H2), 7.99 (s, 1H, H4), 7.88 (s, 1H, H5), 7.56 – 7.32 (m, 5H, benzyl), 5.48 (s, 2H, C11), 4.69 (t, 
2H, J = 6.7 Hz, H6), 3.75 – 3.60 (m, 2H, H7), 3.32 – 3.07 (m, 4H, H9), 1.24 (t, 6H, J = 7.1 Hz, 
H10). 
13
C NMR (75 MHz, DMSO-d6): δ 137.6 (1C, C2), 135.0 (1C, benzyl), 129.4 (2C, benzyl), 
129.3 (1C, benzyl), 129.0 (2C, benzyl), 123.4 (1C, C4), 123.2 (1C, C5), 52.5 (1C, CH2-benzyl), 
49.8 (1C, C7), 47.4 (2C, C9), 43.7 (1C, C6), 8.9 (2C, C10). HRMS (ES+): calcd. for C16H24N3 
258.1970; found 258.1969. 
2.1.4 1-[2-(Diethylamino)ethyl]-3-mesitylimidazolium bromide hydrobromide (7) 
The pro-ligand 7 was prepared as described for 4, starting 
from 2-bromo-N,N-diethylethylamine hydrobromide (1.40 g, 
5.37 mmol) in 30 mL of dry acetonitrile and 1-
mesitylimidazole (1.00 g, 5.37 mmol). After cooling to RT, 
the desired solid was filtered, washed with diethyl ether and 
dried under vacuum. The pro-ligand 7 was isolated as a white hygroscopic solid (2.36 g, 98% 
yield). Anal. Calcd. For C18H29N3Br2: C, 48.15; H, 6.66; N, 9.51. Found: C, 47.94; H, 6.72; N, 
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9.67. 
1
H NMR (400 MHz, DMSO-d6):  10.05 (s, 1H, HBr), 9.71 (s, 1H, H2), 8.29 (s,1H, H4), 
8.00 (s, 1H, H5), 7.16 (s, 2H, mesityl), 4.84 (t, 2H, J = 6.8 Hz, H6), 3.90 – 3.75 (m, 2H, H7), 
3.33 – 3.21 (m, 4H, H9/H11), 2.34 (s, 3H, p-mesityl), 2.08 (s, 6H, o-mesityl), 1.29 (t, 6H, J = 7.2 
Hz, H10/H12).
13
C NMR (101 MHz, DMSO-d6):  140.8 (1C, mesityl), 138.7 (1C, C2), 134.8 
(2C, mesityl), 131.5 (1C, mesityl), 129.8 (2C, mesityl), 124.4 (1C, C4), 123.9 (1C, C5), 49.8 
(1C, C7), 47.8 (2C, C9/C11), 44.1 (1C, C6), 21.1 (1C, p-mesityl), 17.7 (2C, o-mesityl), 9.1 (2C, 
C10/C12). HRMS (ES+): calcd. for C18H28N3 286.2283; found 286.2287. 
2.1.5 1-[2-(Diethylamino)ethyl]-3-isopropylimidazolium bromide hydrobromide (8) 
The pro-ligand 8 was prepared as described for 4, starting from 
2-bromo-N,N-diethylethylamine hydrobromide (2.37 g, 9.08 mmol) 
in 50 mL of dry acetonitrile and 1-isopropyl  imidazole (1.05 mL, 
9.08 mmol). After cooling to RT, a white solid was formed. Diethyl 
ether was added to precipitate the totality of the product that was filtered, washed with diethyl 
ether and dried under vacuum. The pro-ligand 8 was isolated as a white hygroscopic solid (2.74 
g, 81% yield). 
1
H NMR (400 MHz, DMSO-d6) δ 10.02 (s, 1H, HBr), 9.67 (s, 1H, H2), 8.08 (s, 
1H, H4), 8.03 (s, 1H, H5), 4.73 (t, 2H, J = 6.5 Hz, H6), 4.68 – 4.58 (m, 1H, H11), 3.75 (t, 2H, J 
= 6.5 Hz, H7), 3.26 (q, 4H, J = 7.2 Hz, H9), 1.49 (d, 6H, J = 6.6 Hz, H12), 1.25 (t, 6H, J = 7.2 
Hz, H10). 
13
C NMR (101 MHz, DMSO-d6) δ 136.4 (1C, C2), 123.1 (1C, C4), 121.4 (1C, C5), 
52.9 (1C, C11), 49.9 (1C, C7), 47.5 (2C, C9), 43.4 (1C, C6), 22.7 (2C, C12), 8.9 (2C, C10). 
HRMS (ES+): calcd. for C12H24N3 210.1970; found 210.1967. 
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 Preparation of gold(I) complexes 2.2 
2.2.1 Complex 4Au 
In a Schlenk tube 4 (200 mg, 0.58 mmol) was suspended in 20 
mL of dry dichloromethane and Ag2O (138 mg, 0.60 mmol) was 
added. The mixture was stirred at RT for 3 h. A solution of AgNO3 
(50 mg, 0.30 mmol) in 3 mL of acetonitrile was then added and the 
resulting mixture was stirred for 1 h. Finally, Au(SMe2)Cl (86 mg, 
0.29 mmol) was added and after stirring for 1 h more, the mixture 
was filtered through a pad of celite. The solvent was evaporated 
under reduced pressure to give a white solid (168 mg, 93% yield). Crystals suitable for X-ray 
diffraction analysis were obtained by dissolving in acetonitrile with vapor phase addition of 
diethyl-ether. Anal. Calcd. For C20H38N7AuO3: C, 38.65; H, 6.16; N, 15.78. Found: C, 38.53; H, 
5.98; N, 15.60. 
1
H NMR (300 MHz, CD3CN): δ 7.27 (d, 2H, J = 1.8 Hz, H4), 7.17 (d, 2H, J = 
1.8 Hz, H5), 4.24 (t, 4H, J = 6.3 Hz, H6), 3.87 (s, 6H, H11), 2.86 (t, 4H, J = 6.3 Hz, H7), 2.54 (q, 
8H, J = 7.1 Hz, H9), 0.94 (t, 12H, J = 7.1 Hz, H10). 
13
C NMR (75 MHz, CD3CN): δ 184.0 (2C, 
C2), 122.5 (2C, C4), 122.3 (2C, C5), 53.6 (2C, C6), 49.4 (2C, C7), 47.0 (4C, C9), 37.5 (2C, 
C11), 11.4 (4C, C10). HRMS (ES+): calcd. for C20H38N6Au 559.2823; found 559.2827. 
2.2.2 Complex 5Au 
Complex 5Au was prepared as described for 4Au, starting 
from 5 (300 mg, 0.78 mmol), 25 mL of dry dichloromethane, 
Ag2O (183 mg, 0.79 mmol), AgNO3 (67 mg, 0.395 mmol), 3-
5 mL of acetonitrile and Au(SMe2)Cl (115 mg, 0.39 mmol). 
A white solid was obtained by solvent evaporation (206 mg, 
75% yield). Anal. Calcd. For C26H50N7AuO3: C, 44.25; H, 
7.14; N, 13.89. Found: C, 44.21; H, 6.98; N, 13.69. 
1
H NMR 
(400 MHz, CDCl3): δ 7.27 (s, 2H, H4), 7.18 (s, 2H, H5), 4.23 – 4.12 (m, 8H, H11/H6), 2.82 (t, 
4H, J = 6.1 Hz, H7), 2.50 (q, 8H, J = 7.0 Hz, H9), 1.93 – 1.76 (m, 4H, H13), 1.40 – 1.25 (m, 4H, 
H12), 0.91 (t, 18H, J = 7.1 Hz, H14/H10). 
13
C NMR (101 MHz, CDCl3): δ 182.8 (2C, C2), 122.7 
(2C, C4), 121.3 (2C, C5), 54.0 (2C, C7), 51.1 (2C, C6), 50.1 (2C, C11), 47.4 (4C, C9), 33.5 (2C, 
C12, 19.7 (2C, C13), 13.6 (2C, C14), 12.0 (4C, C10). HRMS (ES+): calcd. for C26H50N6Au 
643.3762; found 643.3768. 
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2.2.3 Complex 6Au 
Complex 6Au was prepared as described for 4Au, starting 
from 6 (285 mg, 0.68 mmol), 20 mL of dry methanol and Ag2O 
(160 mg, 0.69 mmol). The mixture was stirred at RT for 3 h. A 
solution of AgNO3 (58.6 mg, 0.345 mmol) in 10 mL of 
acetonitrile was then added and the resulting mixture was 
stirred for 72 h. After that the mixture was filtered through a 
pad of celite and the solvent was removed under vacuum to give the silver complex (113 mg, 
0.165 mmol). The silver complex was dissolved in acetonitrile (10 mL) and Au(SMe2)Cl (49 mg, 
0.165mmol) was added, and after stirring for 1 h more the mixture was filtered through a pad of 
celite. The solvent was finally evaporated under reduced pressure to give a white solid (115 mg, 
44% yield). Anal. Calcd. For C32H46N7AuO3: C, 49.68; H, 5.99; N, 12.67. Found: C, 49.54; H, 
6.10; N, 12.78. 
1
H NMR (400 MHz, CD3CN): δ 7.43 – 7.17 (m, 14H, benzyl/H4/H5), 5.36 (s, 
4H, CH2-benzyl), 4.18 (t, 4H, J = 6.0 Hz, H6), 2.94 – 2.67 (m, 4H, H7), 2.46 (q, 8H, J = 7.1 Hz, 
H9), 0.87 (t, 12H, J = 7.1 Hz, H10). 
13
C NMR (101 MHz, CD3CN): δ 183.8 (2C, C2), 136.9 (2C, 
benzyl), 128.8 (4C, benzyl), 128.2 (2C, benzyl), 127.2 (4C, benzyl), 123.1 (2C, C4), 121.6 (2C, 
C5), 117.3 (4C, benzyl), 54.08 (2C, CH2-benzyl), 53.6 (2C, C6), 49.8 (2C, C7), 47.0 (4C, C9), 
11.5 (4C, C10). HRMS (ES+): calcd. for C32H46N6Au 711.3449; found 711.3461. 
2.2.4 Complex 7Au 
Complex 7Au was prepared as described for 4Au, starting 
from 7 (303 mg, 0.68 mmol), 20 mL of dry methanol, Ag2O 
(160 mg, 0.69 mmol), AgNO3 (58.6 mg, 0.345 mmol). After 1 
hour stirring, the solvent was removed under vacuum and the 
mixture was dissolved in acetonitrile (10 mL), Au(SMe2)Cl 
(100 mg, 0.34 mmol) was finally added and after 1 h the 
mixture was filtered through a pad of celite. A white solid was obtained by solvent evaporation 
(270 mg, 96% yield). Anal. Calcd. For C36H54N7AuO3: C, 52.11; H, 6.56; N, 11.82. Found: C, 
52.28; H, 6.68; N, 12.01. 
1
H NMR (300 MHz, CD3CN): δ 7.38 (d, 2H, J = 1.9 Hz, H4), 7.05 (d, 
2H, J = 1.9 Hz, H5), 7.02 (s, 4H, mesityl), 4.09 – 4.00 (m, 4H, H6), 2.69 – 2.62 (m, 4H, H7), 
2.44 (q, 8H, J = 7.1 Hz, H9), 2.38 (s, 6H, p-mesityl), 1.83 (s, 12H, o-mesityl), 0.88 (t, 12H, J = 
7.1 Hz, H10). 
13
C NMR (75 MHz, CD3CN): δ 183.9 (2C, C2), 139.4 (4C, mesityl), 135.0 (4C, 
mesityl), 129.0 (4C, mesityl), 123.1 (2C, C4), 122.0 (2C, C5), 53.4 (2C, C6), 49.4 (2C, C7), 47.0 
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(4C, C9), 20.2 (2C, p-mesityl), 16.7 (4C, o-mesityl), 11.7 (4C, C10). Crystals suitable for X-ray 
diffraction analysis were obtained by slow evaporation of acetonitrile. HRMS (ES+): calcd. for 
C36H54N6Au 767.4075; found 767.4095. 
2.2.5 Complex 8AuAu 
Complex 8AuAu was prepared as described for 6Au, starting 
from 8 (252 mg, 0.68 mmol), 20 mL of dry methanol, Ag2O 
(160 mg, 0.69 mmol), AgNO3 (58.6 mg, 0.345 mmol). 
Au(SMe2)Cl (100.1 mg, 0.34 mmol) was finally added and the 
mixture was stirred for 30 minutes A purple oil was obtained by 
solvent evaporation, that was washed with diethyl ether and 
pentane. The oil was dissolved in acetonitrile and recrystallized by slow evaporation (64 mg, 
20% yield). 
1
H NMR (300 MHz, acetonitrile-d3) δ 7.33 (s, 4H, H4/H5), 5.02 – 4.90 (m, 2H, 
H11), 4.25 (t, 4H, J = 6.2 Hz, H6), 2.88 (t, 4H, J = 6.2 Hz, H7), 2.53 (q, 8H, J = 7.0 Hz, H9), 
1.52 (d, 12H, J = 6.8 Hz, H12), 0.92 (t, 12H, J = 7.1 Hz, H10). 
13
C NMR (101 MHz, CD3CN) δ 
182.4 (2C, C2), 122.6 (4C, C4/C5), 53.6 (4C, C6/C7), 53.3 (2C, C11), 47.2 (4C, C9), 22.7 (4C, 
C12), 11.1 (4C, C10).  
2.2.6 Complex 6AuAu  
Complex 6AuAu was obtained from the 
decomposition of 6Au after one week in acetonitrile 
solution. The slow evaporation of this concentrated 
solution led to the formation of the clean compound 
6AuAu as crystals suitable of X-ray analysis. 
1
H 
NMR (400 MHz, acetonitrile-d3) δ 7.46 – 7.11 (m, 
14H, benzyl/H4/ H5), 5.36 (s, 4H, CH2-benzyl), 4.21 
(t, 4H, J = 6.0 Hz,), 2.82 (t, 4H, J = 6.0 Hz, H7), 2.50 (q, 8H J = 7.1 Hz, H9), 0.89 (t, 12H, J = 
7.1 Hz, H10). 
13
C NMR (101 MHz, CD3CN) δ 183.8 (2C, C2), 136.9 (2C, benzyl), 128.9 (4C, 
benzyl), 128.2 (2C, benzyl), 127.3 (4C, benzyl), 123.0 (2C, C4), 121.6 (2C, C5), 54.1 (2C, C6), 
53.5 (2C, C7), 49.7 (2C, CH2-benzyl), 47.0 (4C, C9), 11.4 (4C, C10). 
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 Preparation of Platinum complexes 2.3 
2.3.1 Complex 4Pt 
In a Schlenk tube Pt(DMSO)2Cl2 (62 mg, 0.145 mmol) 
was suspended in 10 mL of dry tetrahydrofuran. K2CO3 
(100 mg, 0.72 mmol) and 4 (100 mg, 0.29 mmol) were 
consecutively added. The mixture was stirred overnight at 
70 °C, cooled to RT and then filtered. The crude product 
was recrystallized in acetonitrile by slow evaporation of 
the solvent and the yellow/green crystals suitable for X-ray diffraction analysis were dried under 
vacuum (32 mg, 31% yield). 
1
H NMR (300 MHz, CD3CN) δ 7.11 – 7.05 (pseudo-t, 2H, H5), 
6.97 (dd, 2H, J = 1.8, 0.9 Hz, H4), 4.53 (dt, 4H, J = 9.5, 6.7 Hz, H6), 4.01 (d, 6H, J = 9.7 Hz, 
H11), 3.02 (dt, 4H, J = 8.3, 6.8 Hz, H7), 2.70 – 2.50 (m, 8H, H9), 1.02 (td, 12H, J = 7.1, 6.0 Hz, 
H10). 
13
C NMR (75 MHz, CD3CN) δ 166.2 (1C, C2), 121.5 (2C, C5), 121.3 (2C, C4), 53.48 (2C, 
C6), 48.13 (2C, C7), 47.01 (2C, C11), 46.8 (2C, C11), 36.5 (2C, C13), 11.6 (2C, C10), 11.5 (2C, 
C12). HRMS (ES+): calcd. for C20H38PtN6Br 715.1230; found 715.1245. 
2.3.2 Complex 4Pt’ 
In a Schlenk tube 4Au (50 mg, 0.08 mmol) was suspended in 10 mL of dry 
dichloromethane, AgNO3 (13.6 mg, 0.08 mmol) was added and the solution was 
stirred for 5 minutes. K2PtCl4 (33.2 mg, 0.08 mmol) was added to the mixture 
that was stirred at RT for 3 h. A brown suspension was immediately formed. 
The solution was filtered on celite and the solvent removed under vacuum. 
1
H 
NMR (400 MHz, CD3CN) δ 7.20 (d, 1H, J = 1.9 Hz, H5), 7.09 (d, 1H,  J = 1.9 Hz, H4), 4.19 (t, 
2H, J = 6.2 Hz, H6), 3.79 (s, 3H, H11), 2.92 – 2.82 (m, 2H, H7), 2.63 – 2.50 (m, 4H, H9), 0.98 
(t, 6H, J = 7.1 Hz, H10).  
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  NHC-Au(I) complexes containing a M(phen)2 3.
moiety 
 
Figure 3-1. General numbering for NMR attribution. 
 Preparation of imidazole precursors 3.1 
3.1.1 Synthesis of 8-(imidazol-1-yl)- phenanthroline 
8-(Imidazole-1yl)-phenanthroline was prepared by a modified 
literature procedure.
6
 3-Bromo-1,10-phenanthroline (0.862 g, 
3.24 mmol), imidazole (0.446 g, 6.48 mmol), K2CO3 (0.448 g, 
3.24 mmol), and anhydrous CuSO4 (0.011 g) were mixed and heated at 180 °C under N2 for 4 h. 
After cooling to RT, the resultant solid was extracted with a mixture of MeOH/CHCl3 (3x50 
mL). The solvent was evaporated and the solid was recrystallized from water and ethanol. The 
white solid was filtered and washed with water and a mixture of THF/Et2O. The solid was finally 
dried under vacuum over P2O5 (0.520 g, 65% yield). 
 1
H NMR (300 MHz, CDCl3) δ 9.31 (d, 1H, 
J = 2.6 Hz, H11), 9.26 (dd, 1H, J = 4.3, 1.6 Hz, H16), 8.32 (dd, 1H, J = 8.1, 1.7 Hz, H14), 8.26 
(d, 1H, J = 2.6 Hz, H12), 8.09 (s, 1H, H2), 7.99 – 7.83 (m, 2H, H7/H9), 7.72 (dd, 1H, J = 8.1, 
4.3 Hz, H15), 7.52 (s, 1H, H4), 7.37 (s, 1H, H5). 
3.1.2 Synthesis of 3,8-di(imidazol-1-yl)-1,10-phenanthroline 
3,8-Di(imidazole-1-yl)-1,10-phenanthroline was prepared 
by modified literature procedure.
6
 3,8-Dibromo-1,10-
phenanthroline (0.600 g, 1.78 mmol), imidazole (0.485 g, 
7.12 mmol), K2CO3 (0.492 g, 3.56 mmol), and anhydrous CuSO4 (0.008 g), were mixed and 
heated at 180 °C under N2 for 4 h. After cooling to RT, the resultant solid mixture was 
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suspended in 50 mL of water. The white suspension was filtered and washed with water and a 
mixture of THF/Et2O. The solid was finally dried under vacuum over P2O5. (0.520 g, 93% yield).  
1
H NMR (500 MHz, CD3OD): δ 9.1 (s, 2H, phen), 8.76 (s, 2H, phen), 8.52 (s, 2H, phen), 8.15 (s, 
2H, H2), 7.93 (s, 2H, H4), and 7.32 (s, 2H, H5). 
 Preparation of imidazolium salts 3.2 
3.2.1 1-(1,10-Phenanthrolin-2-yl)-3-methylimidazolium hexafluoro phosphate (9)  
The pro-ligand 9 was prepared starting from 3-imidazol-1,10-
phenanthroline (0.230 g, 0.99 mmol) in acetonitrile (20 mL); MeI 
(0.6 mL, 10 mmol) was added to the solution and the mixture 
was stirred at 70 °C for 24 h. After that the solution was cooled 
to RT, and the yellow solid was filtered, washed with Et2O and dried under reduced pressure. 
The product was suspended in 5 mL of MeOH and a saturated aqueous solution of NH4PF6 was 
added to the suspension. After 10 minutes at 40 °C the solid became white, it was then filtered at 
RT and dried under vacuum to give the pure product (0.31 g, 75% yield). 
1
H NMR (300 MHz, 
acetone-d6) δ 9.88 (s, 1H, H2), 9.50 (d, 1H, J = 2.7 Hz, H11), 9.22 (dd, 1H, J = 4.3, 1.7 Hz, 
H16), 8.97 (d, 1H, J = 2.7 Hz, H12), 8.58 (dd, 1H, J = 8.2, 1.7 Hz, H14), 8.47 (dd, 1H, J = 8.9, 
1.9 Hz, H7), 8.19 (d, 1H,  J = 8.9 Hz, H4), 8.13 – 8.12 (t, 1H, J = 1.8 Hz, H9), 8.09 (d, 1H, J = 
8.9 Hz, H5), 7.88 (dd, 1H, J = 8.2, 4.3 Hz, H15), 4.32 (s, 3H, H6). 
13
C NMR (75 MHz, DMSO-
d6) δ 151.1 (1C, C16), 145.6 (1C, C19), 145.1 (1C, C13),  143.7 (1C, C11), 137.3 (1C, C14), 
137.2 (1C, C2), 130.8 (2C, C10), 129.5 (1C, C8), 129.4 (2C, C12/C18), 128.4 (1C, C9), 126.7 
(1C, C7), 125.2 (1C, C15), 124.6 (1C, C4), 121.9 (1C, C5), 36.8 (1C, C6). MS (FAB
+
): m/z 261 
[M-PF6
-
]
+
 (100%).  
3.2.2 1,1’-(1,10-Phenanthrolin-2-yl)-3-methylimidazolium dihexafluoro phosphate 
(10) 
The pro-ligand 10 was prepared starting from 
3,8-diimidazol-1,10-phen (0.200 g, 0.64 mmol) in 
DMF (30 mL); MeI (0.8 mL, 12.8 mmol) was added 
to the solution and the mixture was stirred at 70 °C 
for 24 h. After that the solution was cooled to RT, Et2O (20 mL) was added and the precipitate 
filtered and washed with Et2O. The solid was dissolved in hot water and an excess of NH4PF6 
was added leading to the precipitation of a white solid that was filtered, washed with cold 
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MeOH, and finally dried under vacuum (203 mg, 92% yield). 
1
H NMR (400 MHz, CD3CN) δ 
9.36 (d, 2H, J = 2.1 Hz, H9), 9.16 (s, 2H, H2), 8.72 (d, 2H, J = 2.4 Hz, H11), 8.16 (s, 2H, H7), 
8.01 (s, 2H, H5), 7.72 (s, 2H, H5), 4.07 (s, 6H, H6). 
13
C NMR (101 MHz, CD3CN) δ 145.5 (2C, 
phen), 144.3 (2C, phen), 136.0 (2C, C2), 131.0 (2C, phen), 130.1 (2C, phen), 129.1 (2C, phen), 
128.4  (2C, phen), 125.1  (2C, C4), 122.1  (2C, C5), 36.6 (2C, C6). MS (FAB
+
): m/z 487 [M-PF6
-
]
+
 (100%). HRMS (ES+): calcd. for C20H18F6N6P 487.1235; found 487.1234.  
 Preparation of complexes 3.3 
3.3.1 Complex 9AgAu 
9 (0.145 g, 0.357 mmol) was dissolved in 20 ml of dry 
acetonitrile under N2. To the solution was added Ag2O (43 mg, 
0.18 mmol) and the mixture was stirred at 50 °C for 12 h. 
Au(SMe2)Cl (53 mg, 0.18 mmol) was added and after stirring for 
24 h more, the mixture was filtered through a pad of celite. The 
solvent was evaporated under reduced pressure to give a brown 
solid. The crude product was recrystallized in acetonitrile by slow 
evaporation of the solvent and amber crystals suitable for X-ray diffraction analysis were dried 
under vacuum (40 mg, 20% yield). 
1
H NMR (400 MHz, CD3CN) δ 9.41 (dd, 1H, J = 4.6, 1.5 Hz, 
H16), 9.29 (d, 1H, J = 2.4 Hz, H11), 8.81 (d, 1H, J = 2.4 Hz, H12), 8.74 (dd, 1H, J = 8.2, 1.5 Hz, 
H14), 8.30 – 8.18 (m, 2H, H7/H9 ), 8.07 (dd, 1H, J= 8.2, 4.6 Hz, H15), 7.68 (d, 1H, J = 1.9 Hz, 
H4), 7.52 (d, 1H, J = 1.9 Hz, H5), 4.02 (s, 3H, H6). 
13
C NMR (101 MHz, CD3CN) δ 182.7 (2C, 
C2), 153.0 (2C, C16), 145.7 (4C, C11/C19), 142.1 (2C, C13), 139.1 (2C, C14), 135.7 (2C, C10), 
133.0 (4C, C12/C18), 129.9 (2C, C8), 129.2 (2C, C9), 126.8 (2C, C7), 125.4 (2C, C15), 124.9 
(2C, C4), 123.0 (2C, C5), 38.3 (2C, C6). MS-QTOF (ES+): m/z 971.2 [M-PF6
-
]
+
 (100%). 
3.3.2 Complex 10Cu 
10 (150 mg, 0.24 mmol) was dissolved in in 5-10 mL 
of dry acetonitrile and Cu(OTf)2 (0.514 mg, 1.42 mmol) 
was added, after 30 minutes the obtained green solution 
was concentrated under vacuum and filtered on a column 
of Sephadex LH-20 using acetonitrile as eluent 
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(Sephadex was allowed 3 h to swell before filtration). The first green fraction of the column 
contained the product. The solvent was evaporated and the green solid dried under vacuum 
giving a hygroscopic solid 10 (190 mg, 87% yield). Crystals suitable for X-ray diffraction 
analysis were obtained by vapor phase diffusion of Et2O in a saturated acetonitrile solution of 10. 
MS (MALDI
+
): [CuL2
5+
 + 4PF6
-
] (m/z = 1327.1), [CuL2
5+
 + 3PF6
-
 + 1OTf
-
] (m/z = 1331.1), 
[CuL2
5+
 + 2PF6
-
 + 2 OTf
-
] (m/z = 1335.1), [CuL2
5+
 + 1PF6
-
 + 3 OTf
-
] (m/z = 1339.1), [CuL2
5+
 + 
4 OTf
-
] (m/z = 1343.1) cations. ESR (g// = 2.293, A// = 160 G, g⊥= 2.079). 
3.3.3 Complex 10CuAuAu 
10Cu (10 mg, 0.006 mmol) was suspended in 10 
mL of dry THF, the mixture was cooled to -78 °C 
and nBuLi (15 µL, 1.6 M in hexane) was added drop 
wise. The mixture was stirred at -78 °C for 2 h and 
Au(SMe2)Cl (3.4 mg, 0.012 mmol) was added 
followed by  2  mL of acetonitrile. A precipitate was 
formed; the reaction mixture was let to warm up to 
RT and stirred overnight. The solution was filtered 
on PTFE (0.2 µm) and the solvent was evaporated giving 10CuAuAu as pink solid (10 mg, 
96%). MS (MALDI/TOF
+
): m/z 1427.3 [Au2CuL2 + 2PF6]
+ 
(65%), m/z 1219.3 [Au2L2 + PF6]
+ 
 
(100%).  
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Materials and methods 
 X-ray measurements 1.
All crystallographic data were collected at low temperature using oil-coated shock-cooled 
crystals on a Bruker-AXS APEX II diffractometer with MoK radiation ( = 0.71073 Å). The 
structures were solved by direct methods
7
 and all non hydrogen atoms were refined 
anisotropically using the least-squares method on F
2
.
8
 
 Photophysical measurements 2.
UV/Vis absorption spectra were recorded at RT on solutions contained in quartz cuvettes 
(optical pathlength 1 cm, Hellma®) with a Perkin-Elmer λ40 double beam spectrophotometer. 
The estimated experimental error is 2 nm on the band maximum. 
Fluorescence and phosphorescence emission and excitation spectra were obtained with a 
Perkin Elmer LS-50 spectrofluorometer, equipped with Hamamatsu R928 phototube.  
Luminescence quantum yields were measured according to the method of Demas and 
Crosby,
9
 on solution samples at RT. The quantum yield is defined as: 
Φs = Φr (
𝐴s
𝐴r
) (
𝜂s
𝜂r
)
2
 
where Φs is the quantum yield of the sample, Φr is the known quantum yield of the reference 
standard, A the area subtended by the emission band (on a wavelength scale) and η is the 
refractive index of the solvent used for the preparation of the solution. As (related to the sample) 
and Ar (related to the reference) must be relative to the same instrumental conditions and to the 
same solution absorption at the excitation wavelength. 
Different standards were selected depending on the spectral region of interests: Ru(bpy)3 in 
water (Φ = 0.028) naphthalene in ethanol (Φ = 0.21), or quinine sulphate in 0.5 M H2SO4 
aqueous solution (Φ = 0.55).  
Fluorescence lifetime measurements were performed by an Edinburgh FLS920 
spectrofluorimeter equipped with a TCC900 card for data acquisition in time-correlated single-
photon counting experiments (0.5 ns time resolution) with a D2 lamp and an LDH-P-C-405 
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pulsed diode laser. The estimated experimental error is 2 nm on the band maximum. 5% on the 
lifetime, 10% on the fluorescence quantum yield. 
 Measure of lipophilicity 3.
The octanol-water partition coefficients (P) of 4Au to 7Au were determined using a shake-
flask method. Water (100 mL, distilled after milli-Q purification) and n-octanol (100 mL, Sigma-
Aldrich, ACS spectrophotometric grade, ≥ 99%) were shaken together for 24 h to allow 
saturation of both phases. Stock solutions of the four compounds (50 μM) were prepared in the 
aqueous phase and aliquots (1 mL) of each of these stock solutions were then added to an equal 
volume of the n-octanol phase. The resultant biphasic solutions were mixed for 1 h and then 
centrifuged (3000 × g, 5 min) (Eppendorf Centrifuges 5415R and 5804R) to separate the phases. 
The concentrations of the complex in the organic and aqueous phases were then determined 
using UV absorbance spectroscopy (260 nm). Log P was defined as the logarithm of the ratio of 
the concentrations of the complex in the organic and aqueous phases (Log P = Log 
{[Au(org)]/[Au(aq)]}; values reported are the means of at least two separate determinations). 
 Confocal microscopy 4.
Cell imaging was performed on a LSM 710 NLO-Meta confocal microscope with spectral 
detection (Zeiss, Germany). Images were taken through a 40x/1.2W, excitation was provided by 
a 458 nm argon laser line and images were recorded from 501 to 725 nm either in channel mode 
integrating the emitted fluorescence or in spectral mode with 9.8 nm steps. 
 Biology 5.
 Cell lines 5.1 
Human prostate cancer PC-3 and lung carcinoma A549 cell lines were obtained from DSMZ 
(Braunschweig, Germany), human U87 glioblastoma cells, human breast cancer MCF-7 and 
human hepatocarcinoma Hep3B cells were from ATCC-LGC Standards (Molsheim, France). All 
cells were cultured in RPMI 1640 containing 10% fetal bovine serum at 37 °C in 5% CO2 
humidified incubators, except Hep3B cells which were grown in DMEM medium containing 
also 10% fetal bovine serum, non-essential amino acids and 1 mM sodium pyruvate. Cell lines 
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were routinely verified by the following tests: morphology microscopic examination, growth 
curve analysis and mycoplasma detection (MycoAleRTTM, Lonza, Basel, Switzerland). All 
experiments were started with low-passaged cells (<15 times). Early passages (1-4) of HUVECs 
(gift from C. Touriol, CRCT, UMR 1037, Toulouse) were grown in EBM-2 media supplemented 
with bullet kit containing various growth factors (Lonza) and 2% FCS (Lonza) and were 
maintained on gelatin-coated tissue culture dishes. 
 Cell viability assay 5.2 
The MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used 
to determine cell death as originally described by Mosmann
10
 and modified by Cuvillier et al..
11
 
Briefly, cells were seeded (A549, MCF-7, U87, Hep3B (50000 cells/well), PC-3 (30000 
cells/well), HUVECs (60000 cells/well), and allowed to attach overnight. After 24 h, 48 h or 72 
h of treatment, cells (100 μL) were incubated with 25 μL MTT solution (5 mg/mL; Sigma-
Aldrich) in 12-well plates for approximately 4 hours. After solubilization with 100 μL lysis 
buffer (DMSO), formazan was quantified by spectrophotometry with a microplate reader at 560 
nm absorbance. 
The MTT is a colorimetric assay widely used as a rapid and sensitive method for screening 
anticancer drugs as well as for the assessment of cytotoxicity of materials. It is a yellow 
tretrazole that in living cells is reduced, by NADPH dehydrogenase enzymes of the 
mitochondrial respiratory chain, to form purple crystal of formazan. 
 
Figure 5-1. MTT reduction to Formazan by mitochondrial reductase. 
After solubilization of the crystals in DMSO, the absorbance of the obtained solutions were 
recorded at 560 nm with a plate reader (µQuant, Bio-Tek instruments.inc). The outcomes were 
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used to create log concentration versus percentage cell viability curves and the GI50 or IC50 
response parameters were calculated.  
 Antiplasmodial tests 5.3 
The Plasmodium falciparum strain FcB1-Columbia was cultured continuously according to 
the modified Trager and Jensen’s method.12 The antiplasmodial activity was evaluated by the 
radioactive micro-method described by Desjardins et al.
14
 with modifications.
13
  
Compound dilutions were tested 3 to 4 times in triplicate in 96-well plates at 1% parasitaemia 
and 1% hematocrit. For each test, the plates of parasite culture were incubated with compound at 
decreasing concentrations for 48 h. Parasite growth was estimated by [
3
H]-hypoxanthine (Perkin-
Elmer, France) incorporation. Concentrations of compounds inhibiting 50% of the parasite 
growth (IC50) were graphically determined in concentration versus percent inhibition curves. The 
compounds and CQ were dissolved in dimethyl sulfoxide (DMSO, Sigma) (stock solution: 1 
mg/mL) and further diluted in the culture medium so that the final DMSO concentration never 
exceeded 1%. For each experiment, we verified that this 1% concentration of DMSO did not 
affect parasites growth. Parasite growth was estimated by [3H]-hypoxanthine incorporation 
(Perkin Elmer). The control parasite culture (RPMI with 5% of human serum alone or with 1% 
DMSO) was referred to as 100% growth. The chloroquine sensitivity of the strain was routinely 
tested. 
 Antileishmanial activity on promastigotes 5.4 
Leishmania species used in this study were Leishmania infantum MHOM/MA/67/ITMAP-263 
(CNR Leishmania, Montpellier, France) expressing luciferase activity. 
The effects of the tested compounds on the growth of Leishmania infantum promastigotes 
were assessed by Luciferase Assay. Briefly, promastigotes in log-phase in RPMI 1640 medium 
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and antibiotics (100 U/mL 
penicillin, 100 µg/mL streptomycin and 50 µg/mL geneticin), were incubated at an average 
density of 10
6
 parasites/mL in sterile 96-well plates with various concentrations of compounds 
dissolved in DMSO (final concentration less than 0.5% v/v), in duplicate. Appropriate controls 
treated by DMSO and reference drug amphotericin B (purchased from Sigma Aldrich) were 
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added to each set of experiments. Pentamidine and Miltefosine were routinely tested. After a 72 
h incubation period at 24 °C, each plate-well was then microscope-examined for detecting 
possible precipitate formation. To estimate the luciferase activitiy of promastigotes, 80 µl of 
each well are transferred in white 96-well plates, Steady Glow reagent (Promega) was added 
according to manufacter’s instructions, and plates were incubated for 2 minutes The 
luminescence was measured in Microbeta Luminescence Counter (PerkinElmer). Inhibitory 
concentration 50% (IC50) was defined as the concentration of drug required to inhibit by 50% the 
metabolic activity of Leishmania infantum promastigotes compared to the control. IC50 were 
calculated by non-linear regression analysis processed on dose–response curves, using 
TableCurve 2D V5 software. The evaluation of the tested molecules cytotoxicity by MTT assay on 
the J774A.1 cell line (mouse macrophage cell line, Sigma-Aldrich)  was done according to 
Mosmann
10
 with slight modifications. Briefly, cells (5.10
4
 cells/mL) in 100 µL of complete medium, 
[RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and antibiotics 
(100U/mL penicillin and 100 µg/mL streptomycin)] were seeded into each well of 96-well plates and 
incubated at 37 °C in a humidified 6% CO2 with 95% air atmosphere. After 24 h incubation, 100 µL 
of medium with various product concentrations and appropriate controls were added and the plates 
were incubated for 72 h at 37 °C.  Each plate-well was then microscope-examined for detecting 
possible precipitate formation before the medium was aspirated from the wells. 100 µL of MTT 
solution (0.5 mg/mL in RPMI) were then added to each well. Cells were incubated for 2 h at 37 °C. 
After this time, the MTT solution was removed and DMSO (100 µL) was added to dissolve the 
resulting formazan crystals. Plates were shaken vigorously (300 rpm) for 5 minutes The absorbance 
was measured at 570 nm with a microplate spectrophotometer. DMSO or MeOH was used as blank 
and doxorubicin (purchased from Sigma Aldrich) as positive control. CC50 were calculated by non-
linear regression analysis processed on dose–response curves, using TableCurve 2D V5 software. 
CC50 values represent the mean value calculated from three independent experiments. 
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Appendix 1: Crystallographic data 
Compound 2 3 1Ru 3Ru 3RuAu 
Molecular formula C18H21BrN4 C21H19BrN4 C35H31BrCl2N8Ru C45H49F182N8O3P3Ru C41H34AuClF12N8P2Ru 
Molecular weight [g/mol] 373.30 407.31 815.56 12858.90 1262.19 
Temperature [K] 173(2) 180(2) 173(2) 173(2) 173(2) 
Crystal system Triclinic Monoclinic Monoclinic Monoclinic Orthorhombic 
Space group P1 P21/c P21/n P21/n Pbca 
a [Å] 8.105(1) 14.699(1) 15.238(4) 12.179(2) 12.260(6) 
b [Å] 9.198(1) 26.193(2) 13.917(3) 26.720(5) 21.800(13) 
c [Å] 12.909(1) 9.892(1) 17.217(4) 17.866(4) 32.613(18) 
α [°] 70.42(1) - - - - 
β [°] 78.96(1) 102.49(1) 92.49(1) 109.07(3) - 
γ [°] 73.53(1) - - - - 
Volume [Å
3
] 864.45(6) 3718.3(3) 3647.8(14) 5495(2) 8717(8) 
Z 2 8 4 4 8 
Crystal size [mm
3
] 0.40 x 0.30 x 0.10 0.50 x 0.40 x 0.10 0.20 x 0.10 x 0.02 0.50 x 0.20 x 0.20 0.20 x 0.02 x 0.01 
Measured/independent 
reflections 
43122/4107 111649/8805 19916/5142 29646/7440 111442/ 7098 
Data/parameters 4107/209 8805/469 5142/457 7440/775 7098/595 
R1, wR2 (I > 2σ(I)° 0.0291, 0.0746 0.0390, 0.0650 0.0886, 0.1929 0.0468, 0.1220 0.0364, 0.0646 
R1, wR2 (all data) 0.0362, 0.0771 0.0808, 0.0745 0.2254, 0.2560 0.0720, 0.1350 0.0665, 0.0728 
Δρ max [e Å3] 0.976 0.362 0.867 0.481 1.216 
   
Appendix 1: Crystallographic data 
Compound 4Au 7Au 4Pt 6Pt 4Pt’ 
Molecular formula C20H38AuN7O3 C36H56AuN7O4 C20H38Br2N6Pt C32H46Br2N6Pt C10H19Cl2N3Pt 
Molecular weight [g/mol] 621.54 847.84 717.47 869.66 447.27 
Temperature [K] 173(2) 173(2) 173(2) 173(2) 173(2) 
Crystal system Monoclinic Triclinic Monoclinic Triclinic Monoclinic 
Space group P21/n P1 P21/c P1 Pn 
a [Å] 13.244(1) 10.938(1) 7.856(1) 7.323(2) 8.606(1) 
b [Å] 10.299(1) 12.572(1) 11.558(1) 8.333(2) 7.476(1) 
c [Å] 18.288(1) 15.576(2) 14.540(1) 14.757(3) 10.313(1) 
α [°] - 112.16(1) - 101.94(1) - 
β [°] 92.32(1) 92.02(1) 98.54(1) 100.26(1) 94.06(1) 
γ [°] - 91.36(1) - 90.67(1) - 
Volume [Å
3
] 2492.5(2) 1980.7(2) 1305.59(7) 865.8(3) 661.84(6) 
Z 4 2 2 1 2 
Crystal size [mm
3
] 0.50 x 0.50 x 0.40 0.50 x 0.20 x 0.05 0.40 x 0.20 x 0.05 0.30 x 0.20 x 0.20 0.20 x 0.20 x 0.10 
Measured/independent 
reflections 
32871/5256 39255/6536 21793/2431 14064/2431 28354/4433 
Data/parameters 5256/286 6536/480 2431/136 2431/189 4433/148 
R1, wR2 (I > 2σ(I)° 0.0221, 0.0502 0.0676, 0.1686 0.0124, 0.0279 0.0533, 0.0765 0.0334, 0.0859 
R1, wR2 (all data) 0.0275, 0.0527 0.0841, 0.1774 0.0143, 0.0284 0.1203, 0.0905 0.0338, 0.0862 
Δρ max,min [e Å3] 1.398 4.101 0.345 1.833 1.626 
   
Appendix 1: Crystallographic data 
Compound 8AuAu 6AuAu 9AgAu 10Cu 9 
Molecular formula C12H23AuN4O3 C16H23AuN4O3 C32H30AgAuF12N8O3P2 
in work 
Molecular weight [g/mol] 468.31 516.35 1169.41 
Temperature [K] 173(2) 173(2) 173(2) 173(2) 173(2) 
Crystal system Monoclinic Monoclinic Triclinic Monoclinic Orthorhombic 
Space group P21/c P21/c P1 P21/c Pbcn 
a [Å] 9.657(1) 12.123(1) 15.438(1) 16.349(1) 23.003(1) 
b [Å] 10.177(1) 14.729(1) 15.441(1) 25.816(2) 12.432(1) 
c [Å] 16.403(1) 9.831(1) 17.647(1) 20.319(2) 13.369(1) 
α [°] - - 64.90(1) - - 
β [°] 98.30(1) 98.88(1) 83.70(1) 104.88(1) - 
γ [°] - - 80.38(1) - - 
Volume [Å
3
] 1595.35(14) 1734.41(12) 3752.0(4) 8288.25(6) 3823.15(2) 
Z 4 4 4 4 8 
Crystal size [mm
3
] 0.50 x 0.30 x 0.20 0.50 x 0.20 x 0.10 0.40 x 0.10 x 0.10 0.40 x 0.05 x 0.05 0.20 x 0.20 x 0.05 
Measured/independent 
reflections 
25867/2747 17582/4875 60885/18039 178915/21801 28783/3734 
Data/parameters 2747/222 4875/219 18039/1067 21801 3734 
R1, wR2 (I > 2σ(I)° 0.0404, 0.0996 0.0201, 0.0402 0.0497, 0.0687 
in work in work R1, wR2 (all data) 0.0443, 0.1028 0.0265, 0.0421 0.1261, 0.0864 
Δρ max,min [e Å3] 6.452 1.440 1.308 
 
Molecules presented in Chapter 3  
NHC-Au(I) complexes containing a Ru(bpy)3-side arm  
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Molecules presented in Chapter 4  
NHC complexes containing amine-side arms  
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Molecules presented in Chapter 5  
NHC-Au(I) complexes containing a M(phen)2 moiety  
Appendix 2: List of molecules 
